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1 INTRODUCTION 
1.1 Pulmonary arterial hypertension (PAH) 
Pulmonary arterial hypertension is characterized by increased pulmonary vascular 
resistance (PVR) resulting in elevated pulmonary artery pressure (PAP) and leading to right-
heart failure, and ultimately death if untreated [1, 2]. Pulmonary arterial hypertension is no 
longer an orphan disease [3], and 4 classes of drugs have been developed in the last 15 
years [4, 5]. Breathlessness, fatigue, weakness, angina, and syncope are the symptoms of 
PAH [6]. The pathogenesis of PAH is characterized by pulmonary vasoconstriction, 
abnormal pulmonary vascular remodeling, and in-situ thrombosis [7]. 
1.1.1 Definition of PAH  
Pulmonary arterial hypertension is defined by a mean PAP (mPAP) ≥ 25 mmHg at rest with 
a PVR > 3 wood units and an end-expiratory pulmonary artery wedge pressure (PAWP) ≤ 
15 mmHg at the time of right-heart catheterization [8].  
1.1.2 Idiopathic PAH (IPAH) 
The emergence of PAH without a known risk factor or family context is known as IPAH. For 
patients with this sporadic disease, diagnosis is usually late due to the lack of a reliable 
screening program [9-11].  
 
Idiopathic PAH is a progressive, nearly fatal condition with very few treatment options. 
Deregulated proliferation of pulmonary intimal endothelial cells and pulmonary arterial 
smooth muscle cells (PASMCs) results in progressive pulmonary vascular remodeling and 
subsequently elevated PAP during the IPAH progression. Specific targeted therapies have 
been developed using prostacyclin, endothelin-receptor antagonists, and 
phosphodiesterase 5 inhibitors. However, scientists are exploring new therapeutic 
modalities because of the insufficient efficacy and poor tolerability of these agents [12]. 
1.1.3 Epidemiology 
Accurate diagnosis of PAH is difficult, and access to care is limited in many countries, which 
makes the global prevalence of PAH challenging to estimate. The global burden of PAH is 
likely greater than currently recognized, because risk factors, such as HIV, schistosomiasis, 
and sickle cell disease, are more prevalent in the developing world [13]. In developed 
countries, PAH cases will also likely increase as newer associations with PAH emerge, and 
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these include dialysis [14] and metabolic syndrome [15]. In addition, broad access to 
echocardiography results in earlier PAH diagnoses [16]. 
 
The epidemiology of PAH has been described by several registries [17-19]. In Europe, PAH 
occurs in 15 to 60 subjects per million of the population, resulting in 5 to 10 cases per million 
each year [18]. In sum, IPAH, heritable PAH, and drug-induced PAH comprise 
approximately half of registered PAH patients [17].  
1.1.4 Updated clinical classification of PH 
The first classification of pulmonary hypertension (PH) was proposed in 1973 [20]. A clinical 
taxonomy was established at the second World Symposium on PH (Evian, 1998) to 
categorize different classes of PH sharing similar pathological findings, hemodynamic 
characteristics, and management approaches (2).  
 
There are five categories of PH: (1) PAH, (2) PH related to left-heart disease, (3) PH due to 
lung disease/hypoxia, (4) thromboembolic PH, and (5) miscellaneous variants. In the 
consecutive meetings of that global body, a series of changes were carried out. However, 
the general architecture and the philosophy of the clinical classification remained 
unchanged. According to new data published in recent years, certain modifications and 
updates, especially for the first type of PH, were proposed during the Fifth World 
Symposium in 2013 (Table 1) [16, 21]. 
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Table 1. Updated classification of PH (Simonneau, 2013) [22] 
 
1. PAH 
1.1. Idiopathic PAH 
1.2. Heritable PAH 
1.2.1. Bone morphogenetic protein receptor type II (BMPR2) 
1.2.2. Activin receptor-like kinase (ALK-1), Endoglin (ENG), SMAD Family Member 9 
(SMAD9), Caveolin-1 (CAV1), Potassium Two Pore Domain Channel Subfamily K 
Member 3 (KCNK3) 
1.2.3. Unknown 
1.3. Drug- and toxin-induced 
1.4. Associated with: 
1.4.1. Connective tissue disease 
1.4.2. HIV infection 
1.4.3. Portal hypertension 
1.4.4. Congenital heart diseases 
1.4.5. Schistosomiasis 
1′.  Pulmonary veno-occlusive disease and/or pulmonary capillary hemangiomatosis 
1′′. Persistent PH of the newborn (PPHN) 
2. Pulmonary hypertension due to left-heart disease 
2.1. Left ventricular systolic dysfunction 
2.2. Left ventricular diastolic dysfunction 
2.3. Valvular disease 
2.4. Congenital/acquired left-heart inflow/outflow tract obstruction and congenital 
cardiomyopathies 
3. PH due to lung disease and/or hypoxia 
3.1. Chronic obstructive pulmonary disease 
3.2. Interstitial lung disease 
3.3. Other pulmonary diseases with mixed restrictive and obstructive pattern 
3.4. Sleep-disordered breathing 
3.5. Alveolar hypoventilation disorders 
3.6. Chronic exposure to high altitude 
3.7. Developmental lung diseases 
4. Chronic thromboembolic pulmonary hypertension (CTEPH) 
5. Pulmonary hypertension with unclear multifactorial mechanisms 
5.1. Hematologic disorders: chronic hemolytic anemia, myeloproliferative disorders, 
splenectomy 
5.2. Systemic disorders: sarcoidosis, pulmonary histiocytosis, lymphangioleiomyomatosis 
5.3. Metabolic disorders: glycogen storage disease, Gaucher disease, thyroid disorders 
5.4. Others: tumoral obstruction, fibrosing mediastinitis, chronic renal failure, segmental PH 
1.1.5 Histology of PAH 
Intimal hyperplasia, medial hypertrophy, occlusion of small arteries, in-situ thrombosis, 
adventitial proliferation or fibrosis, infiltration of inflammatory or progenitor cells, and angio-
proliferative “plexiform” lesions are the histological features of PAH (Figure 1). In PAH, the 
distribution and prevalence of those histological abnormalities are heterogeneous within the 
lung. Of note, plexiform lesions, which are often located downstream from occluded arteries, 
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are only found in PAH, but not in other PH classes. Plexiform lesions express the 
transcription factors and growth factors (e.g., vascular endothelial growth factor [VEGF] and 
hypoxia inducible factor [HIF-1α]) typically seen in angiogenesis [23].  
 
 
Figure 1. PAH histology. Plexiform lesions on the upper row. Evidence of cell proliferation in upper left-hand 
corner (proliferating cell nuclear antigen [PCNA] in red, smooth muscle [SM] actin in green, 4',6-diamidino-2-
phenylindole (DAPI) nucleus staining in blue. Medial hypertrophy, intimal fibrosis, and adventitial proliferation 
on the bottom row (Archer, 2010) [24].  
1.1.6 Pathogenesis and pathophysiology of PAH 
The unexplained proliferation, migration, and survival of pulmonary vascular cells (i.e., 
smooth muscle cells (SMCs), myofibroblasts, and endothelial cells) within the pulmonary 
arterial wall implicates the complex nature of structural and functional changes in the 
pulmonary vasculature. Important discoveries have been made regarding factors that 
contribute to disease, such as inflammation, pulmonary endothelial dysfunction, aberrant 
cell proliferation in the vascular wall, and several gene mutations. Nonetheless, the causal 
patho-mechanisms of pulmonary vascular remodeling are still unclear [2, 6, 25].  
 
The novel, cancer-like concept for PAH has emerged in recent years and has its roots in 
intriguing in-situ and in-vitro observations [26, 27]. More specifically, compared with 
endothelial cells found in the lungs of patients with congenital heart malformations, a 
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monoclonal expansion of endothelial cells has been found in IPAH [28]. In IPAH, there is 
evidence pointing towards the instability of short DNA microsatellite sequences within 
plexiform lesions [29]. Somatic chromosome abnormalities have been reported in the lungs 
of PAH patients, and in cultured cells from those individuals [30]. Pulmonary endothelial 
cells and vascular SMCs derived from PAH patients maintain their abnormal hyper-
proliferative, apoptosis-resistant phenotype for a longer time than control cells when 
removed from their in-vivo environment [31-33]. More recently, pulmonary vascular cells 
derived from PAH patients exhibited an altered energy metabolism in situ and in vitro [34-
39]. However, there crucial differences between PAH pathogenesis and carcinogenesis 
(Figure 2) [40, 41]. In PAH, neither invasion nor metastasis has been observed. Inspired by 
the cancer-like concept, researchers recently tested certain anti-proliferative and/or 
oncological drugs, typically used in the treatment of cancer, in PAH patients [42-46]. 
Tyrosine kinase inhibitors, such as imatinib, have been demonstrated to have potential 
benefits in PAH patients, but severe side effects raise many concerns regarding their use 
in clinical practice [48, 49]. Therefore, the nature of the similarities and differences between 
PAH pathogenesis and carcinogenesis needs further clarification [7]. 
 
 
Figure 2. Degree of similarity between PAH and cancer. Pulmonary arterial hypertension shares several 
cancer characteristics, although the degree of similarity varies (Guignabert, 2013) [7]. 
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1.1.7 Imbalance of vascular effectors 
1.1.7.1 Prostacyclin and thromboxane A2 
While levels of the potent vasodilator prostacyclin are reduced in PAH patients, 
thromboxane A2, a well-known vasoconstrictor, is elevated [47]. Prostacyclin also exhibits 
anti-proliferative effects on PASMCs [48]. In addition, less prostacyclin synthase was found 
in the small and medium-sized pulmonary arteries of IPAH patients than in healthy 
individuals [49]. 
1.1.7.2 Endothelin-1 
Endothelin-1 is a key player in PAH, and it acts as a vasoconstrictor and as a mitogen [50, 
51]. In PAH patients, plasma levels of endothelin-1 are significantly increased [52-54], and 
hemodynamic changes are directly influenced by this vascular effector. 
1.1.7.3 Nitric oxide 
Nitric oxide, synthesized by nitric oxide synthases (NOSs), inhibits vascular SMC 
proliferation and induces acute vasodilation. Nitric oxide deficiency is recognized because 
of decreased levels of the endothelial isoform of NOS in the pulmonary vasculature of PAH 
patients [55-57]. 
1.1.7.4 Serotonin 
Serotonin (5-hydroxytryptamine [5-HT]) promotes SMC hyperplasia and vasoconstriction 
[58]. In IPAH, elevated plasma levels of serotonin have been reported, potentially due to 
upregulation of 5-HT transporters and 5-HT receptors in the pulmonary vasculature [59, 60].  
1.1.7.5 Vascular endothelial growth factor (VEGF) 
The production of VEGF and its receptors increases in lungs exposed to hypoxia [61]. In 
PAH, the main cause of plexiform lesions is disordered angiogenic responses, one of which 
is an increase in VEGF/VEGF receptor expression followed by activation of hypoxia-
inducible factors in the lesion area [62].  
1.1.7.6 Platelet-derived growth factor (PDGF) 
Platelet-derived growth factor is elevated in PAH patients and has been proven to be a 
predominant inducer of PASMC proliferation and migration [63]. Moreover, increased PDGF 
receptor B expression has been observed in remodeled pulmonary arteries, and imatinib, a 
tyrosine kinase inhibitor [64], demonstrated promising effects in rodent models of PAH by 
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blocking PDGF signaling. Imatinib-treated PAH patients exhibited a significant decrease in 
PVR and cardiac output in a phase 2 study [44].  
1.1.7.7 Transforming growth factor-beta (TGF-β) superfamily  
In heritable PAH, the transforming growth factor-beta receptor family plays an important 
role [65]. The heritable type of PAH is primarily caused by a mutation of Bone 
morphogenetic protein receptor type II (BMPR2), which belongs to the TGF-β receptor 
family [66]. Approximately 45 BMPR2 mutations have been identified [67, 68]. Under normal 
conditions, BMPR2 and type 1 TGF-β receptor heterodimeric complexes are activated by 
their ligands (Bone morphogenetic protein (BMP) 2, 4, and 7) to suppress vascular SMC 
growth. Mutations in the BMPR2 kinase domain lead to dominant negative effects on 
receptor function [69]. Mutations in another member of the TGF-β receptor family, ALK1, 
are found in a rare group of patients with hereditary hemorrhagic telangiectasia and IPAH, 
where they result in Smad-dependent pro-growth signaling [67]. 
1.1.7.8  Role of cytokines and chemokines 
Cytokines and chemokines (soluble cytokines that act as chemoattractant) are significant 
mediators of inflammation. Inflammatory cells of the innate immune system predominantly 
produce these types of mediators. The cellular components of the vascular wall or adventitia 
can also produce cytokines and chemokines [70]. Increased levels of Interleukins (IL-1, IL-
6) [71, 72], CC-chemokine ligand 2/ Monocyte chemotactic protein 1 (CCL2/MCP-1), 
Chemokine C-C motif ligand 5/ Regulated on Activation, Normal T Cell Expressed and 
Secreted (CCL5/RANTES), and chemokine C-X3-C motif ligand 1 (CX3CL1/fractalkine) 
have been found in both the serum and tissue of PAH patients [73-75]. In addition, IL1-β, 
IL-6, and tumor necrosis factor α are predictive of outcome in PAH patients [72, 76].  
1.1.8 Environmental and medical factors 
1.1.8.1 Hypoxia 
Hypoxia induces vasoconstriction in the pulmonary vasculature but stimulates vasodilation 
in systemic vessels. The acute effect of hypoxia is regulated by endothelin and serotonin 
derived from endothelial cells. Hypoxia causes dysfunction of ion-channel activity in SMCs 
[77]. Acute hypoxia leads to PASMC vasoconstriction due to plasma membrane 
depolarization and the accumulation of cytoplasmic calcium [78]. Chronic hypoxia results in 
structural remodeling concomitant with the proliferation and migration of vascular cells and 
extracellular matrix deposition.  
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1.1.8.2 Anorexigen aminorex fumarate 
After the introduction of the anorexigen aminorex fumarate, an epidemic wave of IPAH was 
noted in Europe during the 1960s [79]. Though the prevalence of PAH rises with the period 
of use, an increase in pulmonary pressure can occur after 3 to 4 weeks of anorexigen 
exposure [80, 81]. 
1.1.8.3 Central nervous system stimulants 
The risk of PAH increases with the use of central nervous system stimulants, such as 
methamphetamine and cocaine [82]. Of 20 heavy users of cocaine, the lungs of 4 
individuals displayed medial hypertrophy of the pulmonary arteries, without evidence of 
foreign-body microembolization [83]. However, it is unclear if the stimulants alone can cause 
PAH [62]. 
1.1.9 Therapeutic approaches for PAH 
Effective therapies targeting specific aberrant pathways have been developed for PAH, and 
these rely on an improved understanding of the pathobiological mechanisms of that 
disease. Agents that target prostacyclin, endothelin, and nitric oxide pathways have been 
shown to improve functional status and pulmonary hemodynamics, and possibly, to even 
slow disease progression (Figure 3). Several investigative approaches are in active 
development, and these focus on other potential pathways that have been proven to 
contribute to the pathogenesis of PAH [1]. 
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Figure 3. Therapeutic targets in PASMC. Licensed therapeutic agents (green boxes) and investigational (red 
boxes) treatment approaches for PAH. Arrows represent receptor stimulation, whereas terminated lines indicate 
receptor blockade. Modified from O’Callaghan (2011) [1].  
1.1.9.1 Prostacyclins  
Prostacyclin is a potent vasodilator involved in pulmonary and systemic circulation. 
Prostacyclin analogues in current clinical use include Epoprostenol, Beraprost, Treprostinil, 
and Iloprost. Depending on the individual half-life and mode of absorption, the route of 
administration varies depending on the mode of application (e.g., intravenous, 
subcutaneous, inhalational, or oral) [84]. 
1.1.9.2 Endothelin-receptor blockers 
Endothelin has two receptors Endothelin receptor type A (ETA) and Endothelin receptor 
type B (ETB). Bosentan was the first oral drug to obtain Food and Drug Administration 
(FDA) approval for the treatment of PAH. That agent is a non-selective endothelin 
antagonist blocking both ETA and ETB. Recent studies have found that 1 and 2 year 
courses of bosentan improved survival rate [85, 86]. Ambrisentan, a relatively selective ETA 
antagonist, is also available for PAH treatment. Endothelin-receptor antagonists may be 
hepatotoxic and teratogenic; therefore, liver function tests and pregnancy tests in female 
patients receive regular monitoring. Macitentan is a dual endothelin-receptor antagonist 
with a receptor occupancy half-life 15 times greater than that of other endothelin-receptor 
antagonists. Due to the hydrophobic interaction of macitentan and the ETA receptor, the 
former’s dissociation from the latter is slowed and effectively antagonizes Endothelin 1 (ET-
1). Macitentan has also been associated with a minimized risk of liver enzyme changes (bile 
salt transport) and minimal edema retention [87]. 
1.1.9.3 Phosphodiesterase inhibitors 
Nitric oxide stimulates soluble guanylate cyclase to catalyze guanosine monophosphate 
(GMP) to cyclic guanosine monophosphate (cGMP). This leads to the inhibition of calcium 
channels, thereby reducing intracellular calcium levels and ultimately resulting in 
vasodilation. Phosphodiesterases (PDEs), and especially PDE-5, degrade cGMP, through 
which the effects of nitic oxide are mediated. Moreover, PDE-5 is highly abundant in the 
lung and is upregulated in remodeled pulmonary arteries [88]. Hence, PDE-5 inhibition is 
among the first-line therapies for PAH. Sildenafil, which was initially approved for the 
treatment of erectile dysfunction, is a highly selective inhibitor of PDE–5. As effectual as 
inhaled nitric oxide, oral sildenafil has been demonstrated to improve pulmonary 
hemodynamics [88]. Tadalafil is also a PDE-5 inhibitor with an increased plasma half-life 
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(17.5 hours) as compared to sildenafil. If sildenafil requires 3 daily doses, then tadalafil 
requires 1 dose per day. Therefore, tadalafil is more convenient than sildenafil for the patient 
[89].  
1.1.9.4 Combination therapy 
Combination therapy is likely to be more effective than monotherapy, since it targets more 
than one pathway. The combination of sildenafil and endothelin-receptor antagonists (i.e., 
bosentan), is one of the most commonly used blends [90]. Sildenafil is a phosphodiesterase 
type 5 inhibitor (PDE5 inhibitor), and bosentan is endothelin-receptor antagonist. Their 
combination therapy leads to decreased plasma levels of sildenafil in patients. This might 
be due to the induction of cytochrome P450 3A4 enzyme (CYP3A4), which metabolizes 
sildenafil. However, the pharmacokinetics of these drugs are different. Sildenafil reaches a 
peak plasma level in 1.25 hours, whereas bosentan reaches its peak plasma level after 3 
hours. The combination treatment of sildenafil and bosentan generated only a slight 
decrease in diastolic blood pressure compared to the separate application of each [91].  
1.1.9.5 Soluble guanylate cyclase stimulator (sGC) 
 
Soluble guanylate cyclase is the receptor for nitric oxide (NO). The binding of NO to sGC 
leads to the catalysis of guanosine monophosphate (GMP) to cGMP. In turn, cGMP 
activates protein kinase G and leads to a decrease in intracellular Ca2+ levels, resulting in 
vasodilation [92]. Riociguat is the only sGC stimulator that treats CTEPH and PAH [93]. In-
vitro studies have revealed that Riociguat increases the catalytic rate 73 times and that it 
activates sGC in an NO-independent manner. Moreover, together with nitric oxide, 
Riociguat produces a 122-fold increase in sGC activity [92]. 
1.2 G protein-coupled receptors (GPCRs) 
One of the largest protein super families in mammals is that of GPCRs. They are located in 
the cell membrane, and they sense a large variety of inputs and signals from the 
environment. Based on structural similarities, approximately 1,000 GPCRs are predicted in 
the human genome. Of these, 450 are non-olfactory receptors. Based on their structural 
and functional similarities, GPCRs can be grouped into six classes:  
 
1) Rhodopsin (class A), 
2) Secretin (class B), 
3) Glutamate (class C),  
4) Fungus pheromone (class D), 
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5) Cyclic adenosine monophosphate (cAMP) (class E), 
6) Frizzled/smoothened (class F). 
For many GPCRs, the natural ligand has not been identified, and these are called orphan 
receptors. In the pharmaceutical industry, GPCRs are the most investigated targets [98-
100], since GPCR dysfunction plays role in multiple diseases, including neurological 
disorders, cancer, autoimmune diseases, and diabetes. Furthermore, GPCRs have a wide 
impact on numerous cellular processes, such as cell-cell communication, cell proliferation, 
and gene expression [47, 94-96]. In addition, recent studies have proposed that they 
regulate actin and contribute to other cell processes, such as migration, cell division, and 
membrane trafficking, via both traditional G protein signaling and non-canonical pathways 
[94, 97-99]. 
1.2.1 Canonical signaling of GPCRs 
Also known as 7-transmembrane (TM) receptors, GPCRs have seven cross-membrane 
structures. These GPCRs are coupled to heterotrimeric G proteins, which are located on 
the cytoplasmic side of the plasma membrane (Figure 4). The G proteins are composed of 
Gα, Gβ, and Gγ subunits. When activated by their ligands, GPCRs undergo conformational 
changes and trigger guanosine diphosphate (GDP) to guanosine triphosphate (GTP) 
exchange in Gα, which is then activated and becomes disassociated from Gβγ [100]. In 
addition, GTPase can hydrolyze GTP into GDP, which results in a reversible process with 
Gα re-associated with Gβγ. When disassociated from its complex, Gα can trigger numerous 
signaling cascades via several effectors, such as adenylyl cyclase, protein kinase C 
(PKC),and Rho GTPases [101, 102]. Upon activation, those effectors produce cAMP; 
calcium; GMP; inositol-1,4,5-triphosphate (IP3); diacyl glycerol (DAG); and arachidonic 
acid. These group of cytoplasmic molecules are termed as second messengers. Receiving 
signals from the second messengers, downstream enzymes, intracellular receptors, and 
transcription factors ultimately control gene expression [103-105].  
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Figure 4. GPCR and possible ligand-binding sites. Sites at the outer surface of the receptor, and occasionally 
in the extracellular N-terminus region, are usually orthosteric sites. Sites located in any region of the receptor 
are allosteric sites and are distinct from the orthosteric ones. Finally, GPCRs demonstrate differential signaling 
behaviors when bound to G proteins vs arrestins (Zhang, 2013) [106]. 
 
There are 23 Gα, 5 Gβ, and 12 Gγ subunits in humans, as well as 37 regulators of G protein 
signaling (RGS) proteins [107]. Based on their functions, Gα proteins are classified into four 
categories: Gαs (stimulation), Gαi (inhibition), Gαq/Gα11, and Gα12/13. Each type signals 
through different pathways. In addition to the traditional mode of invoking signaling in the 
cytoplasm upon disassociation from Gβγ, Gαi can translocate into the nucleus in a complex 
with Gβγ and bind to chromatin [108], thereby regulating mitosis but not DNA synthesis 
[109]. Via their respective Gα proteins, GPCRs activate or inhibit several downstream 
effectors [110]: 
 
1) Gαs activates adenylate cyclase and increases cAMP 
2) Gαq/11 activates PLC and increases intracellular Ca2+ levels 
3) Gαi/o inhibits adenylate cyclase  
4) Gα12/13 and Gαq/11 activate Ras homolog gene family, member A 
(RhoA) GTPase 
5) Gβγ activates mitogen-activated protein kinase (ERK) 
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1.2.2  GPCRs and effectors in membrane trafficking 
While GPCRs are mostly localized to the plasma membrane, they also enter the cytoplasm 
through endocytosis, a process called internalization. The GPCR internalization route is 
mainly clathrin-dependent [111], and internalized GPCRs are either degraded in lysosome 
for permanent inactivation of such receptors or recycled back through recycling endosomes 
to the cell membrane for reactivation (Figure 5).  
 
Figure 5. GPCR localizations and trafficking pathways in interphase cells. Two different GPCRs (blue and 
red) illustrate the different membrane trafficking pathways. The blue GPCR goes through the lysosomal 
degradation pathway, and the red GPCR moves through the recycling pathway. The two pathways can coexist 
for a given GPCR. Cells’ responses to GPCRs can happen through external ligand-induced signaling cascades, 
as well as through internalized GPCRs (Zhang, 2013) [106]. 
1.2.3 Non-canonical signaling of GPCRs 
The G protein-coupled receptors are expected to be more complex and diverse than 
predicted. For example, some GPCRs do not need all seven transmembrane domains. In 
addition, the same receptor can be activated by different agonists and cause multiple 
cellular responses [112, 113]. Furthermore, different agonist concentrations can result in 
distinct GPCR-mediated cellular responses [114]. At the same time, GPCR-based 
functional studies and drug designs are highly complex, because many GPCRs exist as 
dimers or oligomers. For G protein coupling, some GPCRs requires dimerization or 
oligomerization, which makes GPCR oligomerization an emerging area of research in need 
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of further investigation [115]. A few studies have indicated that odorant GPCRs are also 
expressed in non-olfactory organs, cells, and tissues. In humans and chimpanzees, many 
olfactory receptors are expressed in liver, heart, testis, lung, myocardial, and erythroid cells, 
as well as in the spleen, brainstem, colon, and prostate [116]. The potential functions of 
olfactory receptors in non-olfactory tissues remain largely unexplored. In light of the 
complex examples mentioned above, it is critical to evaluate and compare GPCR 
expression in different tissues, as well as in divergent cell types, to understand their roles 
in disease.  
 
Independent of G proteins, GPCRs can also activate signaling cascades, for example, c-
Jun N-terminal kinases (JNK), Phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3 kinase), 
alpha serine/threonine-protein kinase (Akt), Ras homolog gene family, member A (RhoA), 
nuclear factor 'kappa-light-chain-enhancer' of activated B-cells (NF-κB) and mitogen-
activated protein kinase (MAPK), via β-arrestins [117, 118]. Upon ligand binding, GPCR 
kinases (GRKs) phosphorylate GPCRs and recruit β-arrestins. That process blocks G 
proteins from further interaction with GPCRs and therefore terminates or reduces 
downstream signaling [119]. Importantly, GPCR desensitization, sequestration, and 
intracellular trafficking are mediated by β-arrestins so that excessive receptor stimulation is 
terminated [120]. 
1.3 GCPRs as a therapeutic target in PAH  
 
Many GPCRs are involved in several aspects of PAH. However, the depth and diversity of 
GPCR signaling requires nuanced study. In addition, the selectivity on pulmonary 
vasculature also poses therapeutic challenges, since in PAH, vascular remodeling is 
restricted to pulmonary circulation, whereas GPCRs are relatively ubiquitously expressed. 
The below figure illustrates GPCRs, their agonists or antagonists, and related therapeutic 
options in PAH.  
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Figure 6. GPCRs and agonists as therapeutic targets studied in PAH. Ligands: ET: Endothelin, 5HT: 5-
hydroxytryptamine (serotonin), ACE: Angiotensin-converting enzyme, Ang-2: Angiopoietin-2, HETEs: 5-
hydroxyicosatetraenoic acid, CX3CL1: C-X3-C motif chemokine ligand 1, CXCL12: C-X-C motif chemokine 
ligand 12, CCL19: C-C motif chemokine ligand 19, CCL21: C-C motif chemokine ligand 21, ETEs:- 
eicosatetraenoate, ACE2: angiotensin I converting enzyme 2, Ang1-7: angiopoietins 1 to 7; Receptors: ETAR: 
endothelin receptor type A, ETBR: endothelin receptor type A, 5HT1B: 5-hydroxytryptamine (serotonin) receptor 
1B, 5HT2A/B: 5-hydroxytryptamine receptor 2A/B, 5HT7: 5-hydroxytryptamine receptor 7, AT1R: angiotensin II 
receptor type 1, TPR: thromboxane receptor, CX3CR1: C-X3-C motif chemokine receptor 1, CXCR4: C-X-C 
motif chemokine receptor 4, CCR7: C-C motif chemokine receptor 7, DPR: prostaglandin D, EP1-4R: 
prostaglandin E2 receptors 1 to 4, FPR: formyl peptide receptor, IPR: prostaglandin I2 receptor, APJ: apelin 
receptor, AT2R: angiotensin type 2 receptor (Paulin, 2012) [121] 
1.3.1 Endothelin signaling pathway 
 
Activation of the ETA receptor mediates PASMC vasoconstriction [122]. ETA receptor is 
coupled to Gαq/11, Gα12/13, and Gαi subunits. By coupling to Gαq/11, ETA subsequently 
activates phospholipase C (PLC) and leads to increased intracellular Ca2+. In contrast, the 
ETB receptor stimulation in pulmonary endothelial cells increases endothelial nitric oxide 
synthase (eNOS) activity via Ca2+ and subsequently produces nitric oxide, which is a 
vasodilator.  
1.3.2 Prostanoid signaling pathway  
 
Prostanoids include prostaglandin D2 (PGD2), prostaglandin E2 (PGE2), prostaglandin F2α  
(PGF2α); prostaglandin I2 (PGI2), and thromboxane A2 (TXA2), they can activate eight 
classical prostanoid receptors: prostaglandin D2 (PGD2) receptor, prostaglandin E2 
receptors (EP 1–4), Prostaglandin F receptor (FP), prostaglandin I2 receptor (IP), 
thromboxane (TPR), prostaglandin D2 receptor 2 (PTGDR2/CRTH2), and peroxisome 
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proliferator-activated receptors (PPAR) [123]. Prostacyclin and its analogues, acting as 
vasodilators via adenylate cyclase activation and cAMP production, have been the first-line 
PAH medication for a decade. However, due to the diversity of ligands and receptors, the 
role of the prostanoid family in PAH is more complicated than what is currently understood. 
For example, mice with IP-receptor deficiency do not develop spontaneous PAH, but they 
are more susceptible to chronic hypoxia exposure and develop more severe pulmonary 
vascular remodeling. Those facts suggest a potential anti-proliferative effect [124]. On the 
other hand, U46619, a TPR antagonist, increases cytosolic Ca2+ and induces a contractile 
response in rat PASMCs [125]. Synthase inhibitor and TXA2-receptor antagonist have also 
been found to reduce monocrotaline-induced PH in rats [126].  
1.3.3 Serotonin (5-HT) signaling pathway 
 
Serotonin causes pulmonary vasoconstriction via its receptors expressed in the lung. These 
are the 5-HT1B (Gαi/o-coupled), 5-HT2A/B (Gαq11-coupled), and 5-HT7 (Gαs-coupled) 
receptors [127-131]. The 5-HT2B receptor antagonist PRX-08066, an antagonist for both 5-
HT2A and 5-HT2B receptors (terguride), and a novel 5-HT2B and 5-HT7 receptor antagonist 
(C-122) have been demonstrated to prevent the progression of PH in the monocrotaline rat 
model [132-134].  
1.3.4 Angiotensin signaling pathway 
 
The renin-angiotensin system (RAS) is an important factor for endothelial dysfunction, as 
well as for the early stages of PAH [135]. The angiotensin-converting enzyme (ACE), 
angiotensin 2, or angiotensin receptor 1 (AT1R) coupled to Gαi/o or Gαq11 leads to 
vasoconstriction, proliferation, and fibrosis [136]. Whereas, ACE2, angiotensin 1-7, or 
angiotensin receptor 2 (AT2R) coupled to Gαi/o2/3, or a Mas receptor coupled to Gαq11, 
induces vasodilatation [137, 138]. Preclinical studies have demonstrated that inhibiting the 
angiotensin 2 AT1R axis or activating the angiotensin 1-7 AT2R axis [121] has beneficial 
effects in PAH animal models. 
1.3.5 Apelin (APJ) signaling pathway 
 
Apelin is the ligand for the GPCR receptor apelin receptor (APJ) [139]. Both apelin and APJ 
are highly expressed in the pulmonary endothelium [140, 141]. Moreover, apelin serum 
levels were significantly lower in PH patients than in healthy controls [142]. Exogenous 
apelin has been demonstrated to have a vasodilatory effect, and the disruption of apelin 
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signaling in mice leads to more severe PAH symptoms than those seen in wildtype mice 
[143].  
1.3.6 β-chemokines (CC chemokines) and the C-C chemokine receptor type 7 
(CCR7) signaling pathway 
 
Inflammatory processes are believed to play a large part in both the initiation and 
progression of pulmonary vascular remodeling. These inflammation events, such as the 
peripheral infiltration of inflammatory cells, are mostly mediated by chemokines and 
cytokines. For example, T cells and antigen-presenting dendritic cells (DCs) are recruited 
to the lymph nodes and interact with each other via the activation of Gαi/o-coupled receptor 
C-C motif chemokine receptor 7 (CCR7), through CCR7 ligands (CCL19 and CCL21). 
Mice deficient in CCR7 develop mild PAH with increased perivascular leukocyte infiltration 
in the lungs [144]. In a subgroup of PAH patients, CCR7 gene expression is reduced in 
circulating mononuclear cells [145]. These findings suggest that CCR7 may play a 
significant role in PAH as an inflammatory mediator.  
1.3.6.1 Fractalkine (CX3CL1), CX3C chemokine receptor 1 (CX3CR1) signaling 
pathway 
 
A Gαi/o- and Gαq11-coupled receptor, CX3CR1 is upregulated in T cells, and an elevation 
of CX3CL1 (a ligand of CX3CR1) in plasma, lung parenchyma, and pulmonary artery 
endothelial cells has been reported in PAH patients [146]. Moreover, patients with 
scleroderma-associated PAH displayed CX3CR1 polymorphisms (249I and 280M), 
indicating a potential role for the CX3CL1/CX3CR1 axis in PAH [147]. In addition, CX3CL1 
and CX3CR1 are upregulated in the PASMCs of a rat model, and CX3CL1 promotes 
PASMC proliferation. These findings suggest that CX3CL1 may also play a direct role in 
pulmonary artery remodeling, in addition to its conventional role in cell recruitment [75]. 
1.3.6.2 Chemoattractant cytokine (CLCX12), C-X-C chemokine receptor type 4 
(CXCR4) signaling pathway 
 
During the embryonic development of the cardiovascular, hemopoietic, and central nervous 
systems, CXCR4 and its ligand CXCL12 play a crucial role in the migration of progenitor 
cells. Furthermore, CXCR4 is involved in neo-intima formation, the mobilization of SM 
progenitor cell, and vascular remodeling [148]. Furthermore, CXCR4 inhibition by its 
antagonist AMD3100 significantly decreases hypoxia-induced PH in animal models [121]. 
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1.4 Purinoceptor 2 (P2Y2) mediated signaling pathways 
 
Purinergic P2Y receptors are heptahelical receptors expressed in eukaryotes. They are 
GPCRs coupled to heterotrimeric G proteins, and they recognize extracellular signaling 
molecules and activate intracellular signaling processes. Adenine nucleotides (adenosine 
triphosphate (ATP) and adenosine diphosphate (ADP)), uridine nucleotides (Uridine-5'-
triphosphate (UTP) and uridine-5'-diphosphate (UDP)), and nucleotide sugars (UDP-
glucose) are the ligands of the purinergic receptors [149]. Due to mechanical stress, 
infections, the activation of apoptosis, or a lack of oxygen, many cells release these 
nucleotides and nucleotide sugars. A purinergic receptor, P2Y2 is activated by ATP or UTP 
ligands. Purinoceptor 2 is coupled to three combinations of heterotrimeric G proteins (G 
with Gq, Go, or G12) [150, 151]. Therefore, the downstream signaling caused by the 
activation of the P2Y2 receptor is based on the activation of G proteins, that is coupled to 
P2Y2 receptor. Activation of Go activates RhoA, Rac. Activation of G12 activates ras-
related C3 botulinum toxin substrate, guanine nucleotide exchange factors (RacGEF). 
Activation of Gα16 activates phospholipase C-β1 (PLCβ) and mobilizes intracellular Ca2+ 
in gastric SMCs [152, 153].  
1.4.1 P2Y2 receptor oligomerization 
 
GPCRs can form homomeric, heteromeric, and oligomeric structures. Co-
immunoprecipitation and fluorescence resonance energy transfer (FRET) analysis have 
provided several examples of P2Y receptor dimerization. In human embryonic kidney 
(HEK293) cells, the A1 adenosine receptor forms a heteromeric complex with P2Y1 and 
P2Y2 68,69. The ligand selectivity of the A1 receptor remains unaffected in the heteromeric 
receptor complex (A1-P2Y2). However, the stimulation of these receptors via their agonist 
interferes with Gi signaling and enhances the Gq signaling pathway [154].  
1.4.2 P2Y2 receptor desensitization and trafficking 
 
Both β-arrestin1 and β-arrestin 2 interact with the P2Y2 receptor. Depending on the ligand 
that activated P2Y2, the β-arrestin coupling differs. If the ATP ligand binds to P2Y2 and 
activate the receptor, the P2Y2 receptor then strongly couples to β-arrestin1 and weakly 
couples to β-arrestin 2. If the receptor is activated by UTP, the P2Y2 receptor strongly 
couples with both β-arrestin1 and β-arrestin2 [155]. 
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1.4.3 P2Y2 receptor coupling to receptor and non-receptor tyrosine kinases 
 
The P2Y2 receptors couple with actin-binding protein and filamin A via proline-rich (PxxP) 
motifs in the C-terminal tail. This is also necessary for transient activation of Proto-oncogene 
tyrosine-protein kinase (Src) [156]. Furthermore, several tyrosine kinase receptors, such as 
PDGF receptor (PDGFR) and epidermal growth factor receptor (EGFR), are activated by 
the P2Y2-dependent activation of Src [156]. In addition, studies of endothelial cells have 
revealed that the VEGF receptor-2 (VEGFR-2) is transactivated by P2Y2 receptors via the 
Src-dependent pathway. The P2Y2-dependent activation of VEGFR-2 leads to the 
increased expression of the vascular cell adhesion molecule VCAM-1, which promotes the 
binding of circulating leukocytes to endothelial cells and the vascular wall [157].
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2 AIM OF STUDY 
As the previous section has demonstrated, GPCRs are centrally involved in the 
pathobiology of PAH. Identifying dysregulated GPCRs in PAH may result in an expanded 
ability to target abnormal pulmonary vasoconstriction and remodeling, thus offering options 
for translational research. Therefore, the main objectives of this study were to: 
 
1) Profile the entirety of GPCR expression in micro-dissected pulmonary vessels from 
donor and IPAH patients, and to identify highly and/or aberrantly expressed GPCR 
candidates for PAH studies. This analysis included cDNA isolation from pulmonary 
vessels. Cryo-sections of human lungs from donors, PAH patients are available from 
the Universities of Giessen and Marburg Lung Center (UGMLC) tissue bank. 
Pulmonary vessels within a diameter of 250µm-500µm were identified by laser-
assisted microdissection. The expression of all GPCRs in the human samples was 
systematically analyzed and quantified using an established quantitative 
polymerase chain reaction (qPCR) array. The validation of GPCR expression and 
determination of GPCRs dysregulated in remodeled pulmonary vessels by 
alternative sets of gene-specific primers and probes. 
2) Determine the functions of the most promising GPCR candidate(s) by applying 
pharmacological agonists, antagonists or respective siRNA, with a focus on the in-
vitro effects of PASMCs. This goal was realized by evaluating intracellular cAMP 
levels, as well as cell proliferation (Bromodeoxyuridine (BrdU) incorporation), and 
migration (transwell), and matrix metalloproteinase (MMP) activity (zymography).  
3) Define the signaling mechanisms of specific candidate(s) involved in the above 
cellular processes by exploring the downstream molecules regulating cell survival 
and motility using polymerase chain reaction (PCR) or immunoblotting. 
 
 
 
 
  
 MATERIALS AND METHODS 
 
28 
 
3 MATERIALS AND METHODS 
 
3.1 Materials 
3.1.1 Chemicals, reagents and kits 
Names        Company 
2-propanol       Sigma- Aldrich, Germany 
Acetic acid       Sigma- Aldrich, Germany  
Acrylamide       Roth, Germany  
Ammonium persulfate (APS)     Sigma- Aldrich, USA  
Bovine serum albumin (2 mg/ml)     Bio-Rad, USA  
Bovine serum albumin powder    Serva, Germany 
Bromophenol blue      Merck, Germany  
Cell Proliferation ELISA, BrdU (colorimetric)  Roche, USA  
Coomassie Brilliant Blue G     Sigma-Aldrich, USA 
Crystal violet solution 2.3% w/v    Sigma-Aldrich, USA  
Crystal Violet Solution     Sigma-Aldrich, USA 
Cyclic AMP EIA Kit      Cayman Europe, Estonia 
DC™Protein Assay      Bio-Rad, USA 
DEPC water        Roth, Germany  
DNeasy Blood & Tissue kit     Qiagen, Germany 
Enhanced chemiluminescence (ECL) kit    Amersham, USA 
Ethanol 70%        SAV LP, Germany  
Ethanol 96%        Otto Fischhar, Germany  
Ethanol 99.9%      Berkel AHK, Germany  
Ethylenediaminetetraacetic acid (EDTA)    Sigma-Aldrich, USA  
SuperSignal™ West Femto Maximum Sensitivity   ThermoFisher Scientific, 
Germany 
Gelatin (porcine skin)      Sigma-Aldrich, USA 
Glycerol       Sigma-Aldrich, USA 
Glycin        Roth, Germany 
iScript cDNA synthesis kit      Bio-Rad, USA 
iTaqSYBR Green Supermix     Bio-Rad, USA 
LightCycler® 480 Probes Master    Roche, Germany 
Methanol       Sigma-Aldrich, USA  
Non-fat milk powder      Roth, German 
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Ovation PicoSL WTA system V2 kit    NuGEN, USA 
Paraformaldehyde (PFA) 3.7%    Sigma-Aldrich, USA 
Positively charged glass slides    Langenbrinck, Germany  
Precision Plus Protein Standards    Bio-Rad, USA 
RIPA buffer       Santa Cruz, USA  
RNAse-Away       Molecular BioProducts 
RNeasy Plus Micro kit     Qiagen, Germany 
RNeasy Plus Mini kit      Qiagen, Germany 
SDS Solution, 20% w/v     AppliChem, Germany  
Sodium chloride (NaCl)      Sigma-Aldrich, USA  
Sodium Orthovanadat (Na3VO4)    Sigma-Aldrich, USA 
Tetramethylethylenediamine (TEMED)    Sigma-Aldrich, USA 
Tissue-Tek® O.C. T™ Compound    Sakura, Japan 
Tris Base       Roth, Germany 
Tris-HCl       Roth, Germany 
Triton-X100       Sigma-Aldrich, USA  
TRIzol® Reagent      Life Technologies, USA  
Tween®20       Sigma-Aldrich, USA  
UltraPure water      Cayman Europe, Estonia 
Universal ProbeLibrary Probes     Roche, Germany 
β-Mercaptoethanol      Sigma-Aldrich, USA 
3.1.2 Cell culture medium and reagents 
Fetal bovine serum       Biowest, Germany 
HBSS (Hank´s buffered saline solution) PBS  PAN, Germany 
Leukotriene D4 (LTD4)     Cyaman, USA 
MRS 2768 tetrasodium salt     Tocris, USA 
ON-TARGETplus siRNA     Dharmacon, USA 
Opti-MEM® I Reduced Serum Medium   ThermoFisher Scientific, 
Germany 
Platelet-activating Factor (PAF) C-16   Cyaman, Germany 
SmBM Smooth Muscle Basal Medium   Lonza, Germany  
SmGM-2 BulletKit (CC-3181 & CC-4149)   Lonza, Germany 
Trypsin/EDTA       PAN, Germany 
X-tremeGENE Transfection Reagent   Roche, Germany 
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3.1.3 Primers used for high-throughput screening of GPCRs  
The primers for screening 408 human non-olfactory GPCRs were all purchased from Sigma, 
Germany. Their respective probes were purchased from Roche, Germany. Primers and 
probes were identified by Roche Universal Probe Library online. The primer sequences and 
probes for profiling and validation are given in appendix (Table 20, 21 App).  
3.1.4 Candidate GPCR primers for quantitative real-time PCR in PASMC 
GPCR primer oligonucleotides were all purchased from Metabion, Germany. The primer 
sequences for quantitative real-time PCR are listed below (Table 2). 
 
Table 2. GPCRs human primer sequences for quantitative real-time PCR 
Human gene Forward primer Reverse primer 
CMKIR1 atc ttc ctg gtg gtg gtc tac aca tgt tgt gga tga gaa gga 
CXCR6 cta tgg gtt cag cag ttt caa cag gct ctg caa ctt atg gta 
CXCR7 acc tca tct tct cca tca acc cgt gac ggt ctt cag gta gta 
CYSTIR1 caa tgg ctt tgt gct cta tgt tgg ctg tca taa aga aga tgc 
DRD1 aag aag ttg gtc acc ttg gac cat ctt act cat tgc cac ctc 
EDNRB aca tcg tca ttg aca tcc cta aga gac cac cca aat caa aac 
GOR 112 cac aat ctg tca gtg tga cca gta tgt cac cac tgc aac tcc 
GPR 112 ctc cat ttttct ggg agt tgc cca ctg cag ctg tga tac aaa c 
GPR 4 ctt tca cca gcc tca act gtg gtt cct ctt gga ggt gag tgg 
GPR109 gcc too aga gga aga taa cag gac aat gtc cct tct tgg aat 
GPR115 ttg ttg ctg tca aca ctc aga cat aat ggt tcc aaa cag cag 
GPR18 aaa agc tgt gaa cgt gct gaa gtg gaa ggg cat aaa gca gac 
GPR18 tca tca tga ttg ggt gct act ccc agg gat tgt aac tgt tct 
GPR21 tgg tcc ctt ctt tat cac tcc cag ggt cga gta tag cca aat 
GPR4 tgg gtt cat ctt cta cac caa gga act tct caa agc aga agg 
GPR97 aca cct act tcg ggc act act aaa gag gaa ggt gat gag gaa 
IGR7 cta tgg cac caa tgg agt atg cag ttg ctg tta tgg cac ttt 
IPAR2 cct ggt caa gac tgt tgt cat gca aga gta cac agc agc att 
LPART 1 atg ctc aca tct ttg gct atg aac aaa acc aat cca gga gtc 
NPY1R atc aat ttc cat cgg act ctc ttt ggt ttc act gga cct gta 
NPY5R cct tct caa gag aac cac tcc tag tgg cat cca act aac agc 
P2RY5 tac att ttcatc tgc gtc ctc tgc ttc cgt aca tgt tgg tat 
P2Y2 cat cct tgt ctg tta cgt gct ggt aac ctt gta ggc cat gtt 
PTAFR ccg att gtt tac agc atc atc aat ttg ggg agt atc cag ttg 
PTAFR4 cat ctt act cat tgc cac ctc ctg agc act gtc ttt ctc agg 
PTGER4 ctg tgc gag tac agcacc ttc gtt gga cgc ata gac tgc aaa 
TAAR8 ggt gtg act gtg atg ctt ttc tag acc agg ggatca gta acc 
VIPR1 tct acc tgt aca ccc tgc ttg cag tga gga gttgat ggt gtc 
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3.1.5 Small interfering RNA (siRNA) 
 
ON-TARGETplus siRNA pools and Non-Targeting control pool (siRNA-scrambled) were 
designed and purchased from Dharmacon, USA. siRNA SMART pool is a mixture of 4 
siRNA provided as a single reagent. The targeting sequences for respective GPCRs are 
provided in Appendix (Table 22 App.) 
3.1.6 Antibodies 
Table 3. Primary antibodies 
Antibody Source Dilution Company 
Phospho- Myosin Light Chain 2 (Thr18/Se19) 
(#3674)  
Rabbit 1:1000 Cell Signaling, USA 
Myosin Light Chain 2 (D18E2) (#8505) Rabbit 1:1000 Cell Signaling, USA 
ROCK1 (C857) Rabbit 1:1000 Cell Signaling, USA 
GAPDH  Mouse 1:5000 Novus Biologicals, UK 
ERK-1 (C16) (sc-93) Rabbit 1:1000 Santa Cruz, USA 
Phospho- ERK (E-4) (sc-7383) Mouse 1:1000 Santa Cruz, USA 
EPAC1 (5D3) (#4155) Mouse 1:1000 Cell Signaling, USA 
 
Table 4. Secondary antibodies: HRP-conjugated 
Antibody Source  Dilution  Company 
anti-mouse IgG Rabbit  1:40000 Sigma-Aldrich, USA 
anti-rabbit IgG Goat 1:50000 Pierce, USA 
3.1.7 Equipment 
 
Names        Company 
Balance 1.0-3000g RP 3000     AugustSauter, Switzerland 
Balance PCB 200-2 Precision     Kern, Germany 
Balance XS205      MettlerToledo, Switzerland 
BioDoc Analyzer      Biometra, USA 
Cell culture incubator, Hera Cell               Heraeus, Germany 
Centrifuge Roranta 460R     Hettich, Germany 
Cytospin™ 4 Cytocentrifuge     Thermo Scientific, USA 
Electrophoresis chamber     Bio-Rad, USA 
Freezer (+4°C, -20 °C, -80 °C)     Bosch, Germany 
Infinite® 200 microplate reader     Tecan, Switzerland 
Inolab PH meter       WTW, Germany 
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Light microscope DM IL      Leica, Germany 
LightCycler® 480 Instrument     Roche, Germany 
Liquidator 96       Steinbrenner, Germany 
Live imaging microscope DMI6000 B    Leica, Germany 
Microtome RM2165      Leica, Germany 
Mounting bath HI1210      Leica, Germany  
Mounting heating plate HI1220     Leica, Germany  
Multifuge centrifuge      Heraeus, Germany  
Mx3000P qPCR System     Stratagene, USA 
Pipetboy and pipettes      Eppendorf, USA  
Power supply        Bio-Rad, USA 
Precellys®24 homogenizer  BertinTech., France 
Rotator Staurt®SB3      Bibby Scientific, U.K. 
Shaker       Bruker, Belgium 
Thermocycler T3000      Biometra, USA 
Vortex machine      VWR, Germany  
Water bath for cell culture     HLC, Germany  
Water bath for tubes      Medingen, Germany 
Western blot unit      Bio-Rad, USA 
3.1.8 Other materials 
Names       Company 
6-well, 24-well, 96-well microplate    Corning, USA  
96er PCR-plate for LC480      Steinbrenner, Germany 
AGFA cronex 5 medical X-ray film    AGFA, Belgium 
Chromatography column     Bio-Rad, USA 
Cover glass 60 x 24 (0.13-0.18 mm)    Langenbrinck, Germany 
Falcon tubes       BD Biosciences, USA  
Film cassettes      Kodak, USA 
Filter tips (10, 100, 1000µl)      Nerbe plus, Germany 
Gel blotting paper       Whatman, USA 
Glass pipettes, cell culture dishes, plates    Sarstedt, Germany 
Glass slides Super Frost® Plus    R.Langenbrinck, Germany  
Needles 26-20G (0.45-0.9mm)     Microlance™ 3 BD, Ireland  
Nitrocellulose membrane     Bio-Rad, USA 
Osmotic minipump (2 mL)     Durect Corparation, USA 
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Precellys bead mill sample tube Berlin Tech., France  
Radiographic films hypersensitive    Amersham, USA  
Radiographic films      Santa Cruz, USA 
Scalpels       Feather, Japan 
Shandon™ Single Cytoslides™    Thermo Scientific, USA 
Syringes 1, 2, 5, 10, 25 ml     B. Braun, Germany 
Tips (10, 100, 1000 µl)     Eppendorf, USA  
Tissue culture chamber slide     BD Falcon, USA  
Transwell permeable support    Corning, USA 
3.1.9 Software 
 
Software       Company 
Excel and Word 2013      Microsoft, USA 
Fluorescence (LAS AF) Microscope Software  Leica, Germany  
i-Control       Tecan, Austria  
Leica Application Suite Advanced     Leica, Germany 
Leica QWin imaging software    Leica, Germany  
LightCycler® 480 Software     Roche, Germany 
Magellan v.6.3      Tecan, Austria MS®  
MxPro™ QPCR software     Agilent Technologies, USA 
Prism® v6.05       GraphPad statistics, USA 
3.2 Methods 
3.2.1 Patients’ characteristics 
 
Human lung tissues were obtained from donors and patients with IPAH undergoing lung 
transplantation. After ex-plantation, lung tissues were formalin fixed and paraffin embedded 
according to common tissue-processing protocols. The study protocol for tissue donation 
was approved by the ethics committee of the University Hospital Giessen, in accordance 
with national law and international guidelines (AZ 31/93). Written informed consent was 
obtained from each individual patient or the patient’s next of kin. 
3.2.2 Microdissection of pulmonary vessels and cDNA synthesis 
 
Laser-assisted microdissection of pulmonary vessels from human lung tissue was 
performed as described below. Human lung tissue cryosections were mounted on glass 
slides. After brief staining with hemalaun and eosin (Table 5), pulmonary vessels (diameter 
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range: 50 – 100 µm), which are placed near the bronchus were microdissected from the 
sections with the use of the Laser Microbeam System (Leica, Germany). Around 100-150 
vessels per donor or per patient were initially collected to 25 µl of RLT lysis buffer (Table 
6), later 275 µl of RLT lysis buffer was added and stored at -80°C. Total cellular RNA from 
microdissected pulmonary vessels were isolated with the micro RNeasy kit according to the 
manufacturer’s instructions (Qiagen, Valencia, CA). The total RNA obtained was reverse 
transcribed and amplified to cDNA by RT-PCR using Ovation PicoSL WTA System V2 kit 
according to the manufacturer’s instructions (NuGEN, USA) (Table 7). The cDNA quality 
and concentration was measured by NanoDrop spectrophotometer. 
 
Table 5. Hematoxylin and eosin staining 
Steps Duration 
3 x Xylol 10 mins 
Ethanol 99.6% (2 times), Ethanol 96%, Ethanol 70% 5 mins (each) 
Distilled water 2 mins 
Haemalaun, acidic 20 mins 
Tap water 5 mins 
Ethanol 96% 1 min 
Eosin-Y alcoholic 4 mins 
Distilled water rinse 
Ethanol 96% (2 times), Ethanol 99.6% 5 mins (each) 
Isopropanol 99.8% 5 mins 
3 x Xylol 5 mins 
 
Table 6. Lysis buffer recipe 
Components  Volume 
Qiagen RLT buffer 1 ml 
ẞ-Mercaptoethanol 10 µl 
 
 
Table 7. NuGEN Reverse transcription – Thermocycler program 
First stand cDNA synthesis 
Primer annealing 65°C – 2 mins, hold at 4°C 
First strand synthesis 4°C – 2mins 
25°C – 30 mins 
42°C – 15 mins 
70°C – 15 mins, hold at 4°C 
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Second stand cDNA synthesis 
Second strand synthesis 4°C – 1 min 
25°C – 10 mins 
50°C – 30 mins 
80°C – 20 mins, hold at 4°C 
SIPA amplification 
SIPA amplification 4°C – 1 min 
47°C – 75 mins 
95°C – 5 mins, hold at 4°C 
 
3.2.3 High-throughput (HT) screening of GPCRs 
 
Gene specific primers for 408 GPCR genes and their corresponding probes were identified 
using the Roche Probe Finder software.  
3.2.3.1 Oligo resuspension and storage 
 
The lyophilized primers were thawed and centrifuged to spin down the lyophilized powder 
from cap. The primers were re-suspended (stock concentration: 100 µM) in respective 
volumes of sterile nuclease-free water as mentioned in the ordering list obtained from 
company (Sigma-Aldrich, Germany). The re-suspended primers were incubated at 37°C in 
shaker for 20 minutes. The primers were diluted to a working concentration ratio of 1:10 
3.2.3.2 Plate preparation and storage 
 
Each well of 96-well plate loaded with gene specific exon spanning primers with their probes 
and stored at -20°C.The daughter plates are prepared from mother plate (10X primer-probe 
mix) by using automated pipetting system (Liquidator 96, Steinbrenner Laborsysteme 
GmbH) and stored at -20°C.  
3.2.3.3 High-throughput (HT) screening procedure 
 
Each plate consists of 48 set of gene specific primers and probes. These plates were 
thawed, centrifuged and loaded with master mix (LightCycler 480 Probe Master, Roche 
Germany) along with 3 ng of cDNA (Table 8). The multiwell plate is sealed with LightCycler® 
480 foil and centrifuged for 2 mins at 1500xg. High-throughput quantitative real-time PCR 
was performed with the LightCycler® 480 Instrument (Table 9). The quality of the RNA is 
tested by Rn 18S primer and the quality test for genomic DNA contamination in cDNA 
samples were tested using intron spanning primer of GPR133. The cDNA levels of each 
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gene were normalized with respective genomic DNA levels and copy number of genes was 
calculated based on absolute quantification. The genomic DNA levels were obtained for 
same set of genes in each plate. From 408 GPCRs around 45 candidates were identified 
and such dysregulated GPCR expression were validated in remodeled pulmonary vessels 
(same set of donors and IPAH patients) by alternative sets of gene-specific primers and 
probes. 
 
Table 8. HT- qPCR reaction components 
Reaction components  Volume per reaction 
Primer-probe mix, 10X conc. 1 µl (Final conc.: primer= 1 µM, probe= 0.2 µM) 
LightCycler 480 Probe Master, 2X conc. 10 µl 
Water PCR grade 4 µl 
cDNA/gDNA (0.6 ng/µl) 5 µl (3 ng) 
Total volume 20 µl 
 
Table 9. HT- qPCR- LightCycler® 480 program 
Program Cycle Temperature Time 
Pre-incubation 1 95°C 5 mins 
 
Amplification 
Denaturation  
45 
95°C 10 secs 
Annealing 60°C 30 secs 
Extension 72°C 1 sec 
Cooling 1 40°C 30 secs 
 
3.2.4 Human pulmonary arterial smooth muscle cells (PASMCs) isolation and cell 
culture 
 
Human pulmonary arterial smooth muscle cells (PASMCs) of donors were purchased from 
Lonza (Basel, Switzerland). PASMCs were isolated from IPAH patients by explant method. 
After removal of pulmonary endothelium and adventitia from distal pulmonary arteries, the 
media layer was cut into 1mm3 pieces. The artery pieces were cultured on cell-culture 
dishes in smooth muscle growth medium (SmGM-2) from Lonza (Basel, Switzerland). Cells 
were incubated in humidified atmosphere of 95% air with 5% CO2 at 37°C and allowed to 
migrate until a monolayer of PASMCs formed.  
3.2.4.1 Cryopreservation 
 
At 80% confluency cells were washed with DPBS buffer. Trypsinization was performed by 
adding pre-warmed Trypsin 1X. FBS was added to stop the trypsin activity. The cells were 
centrifuged at 1000 rpm, 20°C for 5 minutes. The pellet was then resuspended in cooled 
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freezing cryopreservation medium (SmBM medium: FCS: DMSO) and kept in cell-freezing 
container for 24 hours at -80°C, later transferred to liquid nitrogen and stored for future use.  
3.2.4.2 Seeding and splitting 
 
The appropriate volume of medium was pre-incubated at 37°C, 5% CO2 for 30 minutes. The 
cryopreserved cells were thawed and seeded to the plates containing pre-incubated 
medium. The cells were incubated at 37°C, 5% CO2 until the cell confluency reaches to 80-
90%. The cells were trypsinized and cell pellets were re-suspended with fresh SmGM-2 
growth medium. The cell count and viability was determined using hemacytometer and 
trypan blue. The cells were seeded at a seeding density of 1*104 cells/cm2. 
3.2.5 Polymerase chain reaction (PCR) 
3.2.5.1 RNA isolation 
 
The total RNA from PASMCs were isolated by using Qiagen RNeasy Plus Mini/Micro kit. 
The procedures were followed according to the manufacturer’s instructions. Finally, RNA 
was dissolved in DEPC-water and stored at -80°C. The quality and concentration of total 
RNA was measured by NanoDrop spectrophotometer. 
3.2.5.2 Reverse transcription - polymerase chain reaction (RT-PCR) 
 
cDNA was synthesized by RT-PCR using Bio-Rad iScript cDNA synthesis kit according to 
the manufacturer’s instructions. 0.5-1 µg RNA in 20 µl master mix was used per reaction 
(Table 10). The reverse transcription was performed in thermocycler and the program is 
shown in Table 11.  
 
Table 10. RT-PCR components 
Components Volume per reaction 
RNA (0.06 µg/µl) 15 µl 
5x iScript reaction mix  4 µl 
iScript reverse transcriptase 1 µl 
Total Volume 20 µl 
 
Table 11. RT-PCR thermocycler program 
Program Temperature Time 
Annealing  25°C 5 mins 
Incubation  42°C 30 mins 
Thermal inactivation of reverse transcriptase  85°C 5 mins 
Hold at 4°C 
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3.2.5.3 Quantitative realtime- polymerase chain reaction (qPCR) 
 
The exon-spanning primer pairs for human GPCR genes were designed using the Primer3 
software tool and are shown in Table 2. Nucleotide blast was used to cross check primers 
for specificity and homology. The product size is within the range of 150 bp - 200 bp. qPCR 
was performed on a Mx3000P® QPCR system machine using iTaqTM SYBR® Green 
Supermix kit and procedures were followed according to manufacturer’s instructions (Table 
12, 13). The nuclease free water instead of cDNA was used as negative control.  
 
Table 12. Quantitative PCR reaction components 
qRT- PCR reaction component Volume per reaction Final concentration 
cDNA template Variable 0.2 µg 
Forward primer 10 µM 0.5 µl 0.2 µM 
Reverse primer 10 µM 0.5 µl 0.2 µM 
iTaq SYBR Green supermix (2X) 10 µl  1X 
Nuclease-free water  Variable  - 
Total volume 20 µl - 
 
Table 13. Quantitative PCR program 
qPCR program Temperature Time Cycle 
Polymerase Activation & DNA denaturation 95°C 10 mins 1 
 
Amplification 
Denaturation 95°C 30 secs   
40 
  
Annealing 58°C 30 secs 
Extension 72°C 30 secs 
Denaturation  95°C 1 min   
Melt-Curve analysis 55-95°C (0.5°C 
increment) 
2-5 secs/step 1 
Hold 4°C Indefinite  - 
 
The dissociation curve was generated by MxPro™ QPCR software, and used to ensure a 
single product amplification. Threshold cycle (Ct values) was determined for each gene. 
Hypoxanthin phosphoribosyl transferase (HPRT) was used as housekeeping gene, all Ct 
values of target genes were normalized to HPRT by using the formula, 
∆Ct = Ct reference gene - Ct target gene 
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The mRNA levels were compared between donor and IPAH patients or between siRNA-
scrambled and siRNA-target gene. Each reaction was run in duplicate and repeated three 
times independently. 
3.2.6 RNA interference by siRNA (GPCRs) 
 
Transient transfection of siRNAs (Table 22 App.) was performed with X-tremeGENE siRNA 
transfection reagent according to the manufacturer’s instruction.  
3.2.6.1 siRNA re-suspension and storage 
 
siRNA vials were briefly centrifuged to ensure the siRNA pellet was collected at the bottom 
of the tube. 5 nmol of siRNA was re-suspended in 100 µl of RNase free water to obtain a 
stock concentration of 50 µM. The siRNAs were aliquoted and stored at -20°C. 
3.2.6.2 Transient transfection of siRNA in PASMC 
 
Donor PASMCs were cultured to 30-50% confluency in antibiotic-free SmGM-2 medium. 
The cells were pre-incubated with opti-MEM medium at 37°C, 5% CO2 for 30 minutes. In 
mean time siRNA and transfection reagent were diluted in opti-MEM medium and mixed 
within 5 min after dilution. 3:1 ratio of X-tremeGENE siRNA transfection reagent (µl) to 
siRNA (µg) was used. The mixture of siRNA and transfection reagent were incubated at 
room temperature (RT) for 20 mins. After incubation 50 nM siRNA was transfected to 
PASMCs in opti-MEM medium for 4 hours at 37°C, 5% CO2. Later the opti-MEM medium 
was replaced by fresh SmGM-2 growth medium and cultured for 48 hours. The RNA 
interference was well established and repeated at least three times. The knockdown 
efficacy was checked by quantitative PCR. The siRNA knockdown of GPCRs were used to 
study the proliferation and migration of PASMCs. 
3.2.7 BrdU cell proliferation assay 
 
PASMCs proliferation was determined using Cell Proliferation ELISA, BrdU (colorimetric) 
assay based on manufacture instructions (Roche, Germany). The cellular proliferation 
detection of this kit is based on the BrdU incorporation into the genomic DNA of proliferating 
cells. Cells were grown in 96-well tissue-culture microplates (initial seeding density 1×104 
cells / well). After 24 hours of 50 nM siRNA transfection followed by 24 hours’ starvation 
and 24 hours’ stimulation (FCS/PDGF/ligands), the cells were incorporated with BrdU 
labelling for 4 hours. Labelling medium is removed by flicking off and tapping the plate, and 
the cells were fixed with 200µl of FixDenat solution for 0.5 hrs. FixDenat was removed by 
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flicking off and tapping the plate, 100µl of anti-BrdU-POD antibody working solution (1:100) 
was added and incubated in RT for 90 mins. The anti-BrdU-POD antibody then bound to 
the BrdU incorporated into the newly synthesized cellular DNA. After 3 times washing with 
1XPBS washing buffer, the immune complexes were detected by addition of 100 µl of 
substrate. The reaction product was quantified by measuring the absorbance at 370nm with 
the reference at 492 nm using TECAN spectrophotometer (ELISA reader). 
3.2.8 Wound healing - in vitro scratch assay 
 
PASMC were seeded on 24-well plates. Transfected cells were serum-starved for 24 hours 
and scratches were made using a p10 pipette tips in the center of each well. At this stage 
cells were at complete confluency. After scratch cells were carefully washed with 1X PBS 
twice and freshly prepared basal medium (SmBM) with or without stimulators (FCS, PDGF), 
with or without ligands (MRS2768, PAF, LTD4). The closure of the scratch was monitored 
by live cell imaging and the images were captured every 1 hour until 24 hours by Leica real-
time microscope system. The distances of migration from the scratch to the growing edges 
were measured at five different points by Leica Application Suite Advanced Fluorescence 
(LAS AF) Microscope software and percentage of closure was calculated. 
3.2.9 Transwell migration assay 
 
PASMCs were transfected with 50 nM of siRNA-scrambled or siRNA-P2Y2 for 24 hours 
and serum-starved for 24 hours. Cells were trypsinized and 1×104 cells were plated in 100 
µl of SmBM medium with or without P2Y2 ligand 10µM MRS2768, in the 6.5-mm transwell 
inserts with 8.0-µm pore size polycarbonate membrane. The lower chambers were filled 
with 600 µl of SmBM medium with or without stimulator (5% FCS or 30 ng/ml PDGF) and 
with or without P2Y2 ligand 10 µM MRS2768. The migration of cells through the membrane 
was analyzed after 10 hours of incubation at 37°C, and 5% CO2. PASMCs on the upper 
side of the insert were removed by using cotton swab. Migrated PASMCs on the lower side 
of the insert were fixed for 10 mins with 3.7% PFA. Cells were washed by merging the insert 
in water. Then cells were stained for 30 mins with 0.1% crystal violet in 20% methanol. The 
cells were washed 2 times with tap water and the inserts were dried in RT. The percentage 
of migrated cells were calculated by counting the cells under 20-fold magnification using 
Leica DM6000 B microscope.  
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3.2.10 cAMP enzyme immunoassay (EIA) 
 
Intracellular adenosine 3’,5’ cyclic monophosphate (cAMP) content of PASMCs were 
determined by a competitive non-acetylated EIA. The assay procedures were followed 
according to the manufacturer's instructions of cAMP EIA Kit (Cyaman, Europe, Estonia). 
PASMCs (1.6 x 105 / well of 6-well plate) were transfected with siRNA-scrambled and 
siRNA-P2Y2 for 24 hours followed by serum-starvation for 24 hours. Then the cells 
stimulated for 24 hours with P2Y2 ligand (MRS 2768). At this stage cells were 80% 
confluent. 
3.2.10.1 Sample preparation 
 
Cells were washed with 1XPBS twice and lysed with 0.1 M HCL at RT for 20 mins on a 
shaker. Cells were scraped with a cell scraper and the cell mixture was dissociated with 24 
g needle and 1 ml syringe by pipetting up and down. The cell suspension was further 
centrifuged at 1000 x g for 10 mins at 4°C. The supernatants were collected to clean 
Eppendorf tubes and stored at -80°C. All samples were diluted with equal volume of 
UltraPure water (50 µl sample in 50 µl water).  
3.2.10.2 Assay procedure 
 
The standards (S1 to S8) range from 750 pmol/ml to 0.3 pmol/ml, were prepared by 
manufacturer’s instructions. 50 µl of diluted protein samples and standard solutions were 
incubated with 50 µl of tracer and 50µl of antibody at 4°C for 18 hours. Then the plate was 
washed 5 times with washing buffer and 200 ml of Ellman’s solution was added to each well 
using a multi pipette. The plates were incubated in the dark at room temperature for 90 to 
120 mins on an orbital shaker. 
3.2.10.3 Reading the plate and calculation 
 
The absorbance was read at between 405 - 420 nm using TECAN spectrophotometer 
(ELISA reader). The cAMP concentrations were calculated by the online available Cayman 
EIA Double workbook. The cAMP concentration of the samples was provided as pmol/mL 
protein. The standard curve was made as a plot of %B/B0 (%Bound/Maximum Bound) for 
standards (S1-S8) versus cAMP concentrations using a linear (y) and a log (x) axes. Each 
sample were performed in duplicate and repeated twice. 
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3.2.11 Western blotting 
3.2.11.1 Protein isolation 
 
Cells were washed with 1XPBS and lysed with RIPA buffer. The RIPA buffer composed of 
PMSF, proteinase inhibitor cocktail and sodium orthovanadate and was freshly prepared 
before use. 2×106 PASMCs in 250 µl RIPA was centrifuged under 12000 rpm for 30 min at 
4°C and the supernatants were collected and stored at -80°C. 
 
 
Table 14. RIPA buffer recipe 
Components of RIPA buffer Final concentration 
RIPA buffer 1x 
Protease inhibitor cocktail 1x 
Sodium orthovanadate 1% 
PMSF 1% 
 
3.2.11.2 Protein concentration analysis 
 
Bio-Rad DC protein assay was used to determine the protein concentration. The procedures 
were followed according to manufacturer’s instructions. It is based on Lowry assay with 
slight modifications. Bovine serum albumin (BSA) was used as standard (0.25, 0.5, 1, 2 
mg/ml). The protein samples were pre-diluted to fall in the range of standards. The protein 
concentrations of each sample were estimated in duplicates. Protein concentrations were 
determined by measuring absorbance at 750 nm using TECAN spectrophotometer (ELISA 
reader). Final protein concentrations were calculated using Magellan™ software. The 
protein samples were stored at -80°C 
3.2.11.3 SDS-PAGE gel electrophoresis 
 
Protein samples were equalized to fixed concentration. The protein samples were 
denatured by adding 5X SDS loading buffer (Table 15) at a ratio of 4:1 (v/v) and by 
incubating at 100°C for 10 mins. The denatured protein samples were stored at -20°C.  
 
Table 15. 5×SDS loading buffer recipe 
Components  Final concentration 
Tris-HCl (2 M, pH 6.8) 375 mM 
SDS 10% (w/v) 
 MATERIALS AND METHODS 
 
43 
 
Glycerol 50% (v/v) 
β-Mercaptoethanol 12.5% (v/v) 
Bromophenol blue 0.02% (w/v) 
 
Polyacrylamide gels were prepared by filling the space between glass plates with 10% of 
resolving gel mixture (Table 16) and gel was solidified for 30 mins. Later 6% of stacking gel 
mixture (Table 17) was added and comb was inserted. The gel was allowed to polymerize 
for 1 hour. Protein samples and rainbow marker were loaded in the wells of the gel. The 
gel electrophoresis was carried out in running buffer (Table 18) at 100-130 v for 2-3 hours 
for protein to separate well based on their molecular size. 
Table 16. Resolving gel (10%) components 
Resolving gel (10%) component Volume Final concentration 
Tris-Cl (1.5 M, pH 8.9) 1.875 ml 375 mM 
Acrylamid 30% (w/v) 1.5 ml 10% (w/v) 
SDS 10% (w/v) 75 µl 0.1% (w/v) 
APS 10% (w/v) 37.5 µl 0.05% (w/v) 
TEMED 7.5 µl 0.1% (w/v) 
H2O 3.5 ml - 
 
Table 17. Stacking gel (6%) components 
Stacking gel (6%) component Volume Final concentration 
Tris-Cl (0.5 M, pH 6.8) 0.625 ml 375 mM 
Acrylamid 30% (w/v) 0.5 ml 10% (w/v) 
SDS 10% (w/v) 25 µl 0.1% (w/v) 
APS 10% (w/v) 12.5 µl 0.05% (w/v) 
TEMED 2.5 µl 0.1% 
H2O 1.34 ml - 
 
Table 18. Running buffer components 
Running buffer component Final concentration 
Tris-HCl 25 mM 
Glycine 192 mM 
SDS 10% (w/v) 0.1% (w/v) 
 
3.2.11.4 Immunoblotting 
 
Immunoblotting was performed by wet transfer method and the proteins on the SDS-PAGE 
were transferred to nitrocellulose membrane at 100V for 1 hour in blotting buffer (Table 19). 
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The membranes were removed from the blotting chamber and blocked with 5% non-fat milk 
or 5% BSA at RT for 1 hour. The membranes were washed with 1XTBS and incubated 
overnight at 4°C with primary antibodies, that were diluted in 1XTBST (Table 20) with 5% 
BSA. After overnight incubation, the membranes were washed with 1XTBST for 15 mins (3 
times, 5 mins each). The membranes were incubated for 1 hour at RT with horse radish 
peroxidase (HRP) conjugated secondary antibodies (diluted in TBST with 5% BSA). After 
secondary antibody incubation, membranes were washed 3 times for 5 mins with 1XTBST.  
 
 
 
Table 19. Blotting buffer recipe 
Blotting buffer Final concentration 
Tris-HCl 50 mM 
Glycine 40 mM 
Methanol 20% (v/v) 
 
Table 20. TBST buffer recipe 
TBST buffer (pH 7.6) component Final concentration 
Tris-HCl 20 mM 
NaCl 150 mM 
Tween 0.1% (v/v) 
 
3.2.11.5 Developing and densitometry analysis  
 
The membranes were developed using substrates such as, enhanced chemiluminescence 
(ECL) kit or SuperSignal™ West Femto Maximum Sensitivity and by X-ray films. The protein 
band density was measured using BioDoc densitometry analyzer. The protein expression 
levels of target proteins were normalized to loading control GAPDH. 
3.2.12 Zymography 
3.2.12.1 Sample preparation from medium 
 
Cell culture medium (400 µl) was centrifuged shortly (to remove cell debris) and supernatant 
was collected. To this supernatant 100 µl of 5X SDS buffer (without ẞ-mercaptoethanol) 
was added. The protein samples were stored in -20°C. 
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Table 21. Preparation of 5X SDS 
Reagents For 10 ml 
Tris-Cl 3.75 ml 
SDS 1 g 
Glycerol 5 ml 
PMSF 0.5 ml 
H2O 0.75 ml 
Bromophenol blue spatula 
 
 
3.2.12.2 Sample preparation from cells 
 
Cells were washed with PBS and 500 µl of 1X SDS buffer (without ẞ-mercaptoethanol) was 
added. The cell culture plates were kept on ice for 5 mins. Cell lysates were collected by 
cell scrapper and transferred to fresh Eppendorf tube. 100 µl of this cell lysate was 
transferred to a new Eppendorf tube (this was used for running loading control GAPDH) 
together with 25 µl of ẞ-mercaptoethanol and boiled for 10 mins at 100°C. The remaining 
samples were stored at -20°C. 
3.2.12.3 Loading and running gel electrophoresis 
 
The protein samples were loaded in the gel. The gel electrophoresis was carried out in 
running buffer (Table 18) at 100-130 v for 2-3 hours for protein to separate well based on 
their molecular size. The gel was carefully removed from the glass plated. Gel was washed 
2 times for 30 mins with wash buffer (2.5% triton X-100, 0.02% NaN3 mixed in water) and 
one time with incubation buffer (50mM Tris-HCl of pH7.6, 5mM CaCl2, 0.02% NaN3) for 20 
mins. After washing the gel was incubated with fresh incubation buffer for 48 hours at 37°C. 
Then buffer was removed and gel was fixed and stained with coomassie blue solution (0.1% 
m/v coomassie, 30% methanol, 10% acetic acid, 60% H2O) for 1.5 hours.  
 
Afterwards the gel was distained with 1st wash buffer (30% methanol, 10% acetic acid, 60% 
H2O) for 30 mins, followed by 2nd wash buffer (20% methanol, 10% acetic acid, 70% H2O) 
for 1 hour and finally with 3rd wash buffer (10% methanol, 5% acetic acid, 85% H2O) for 2 
hours. The MMPs protein bands were viewed under BioDoc analyzer and photographed. 
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Table 22. Zymography gel recipe 
Components Stacking gel (2.5 ml) Separating gel (6 ml) 
30 % Acrylamide 500 µl 2 ml 
1.5M Tris pH 8.9 - 1.5 ml 
1M Tris pH 6.8 625 µl - 
H2O 1.34 ml 1.8 ml 
10% SDS 25 µl 60 µl 
10% ammonium persulfate (APS) 12.5 µl 30 µl 
TEMED 2,5 µl 6 µl 
1% Gelatin - 0.6 ml 
 
3.2.13 P2Y2 ligand 
 
MRS2768 is selective ligand/agonist for P2Y2 (EC50 = 1.89 μM). Displays no affinity for 
human P2Y4 or P2Y6 receptors. MRS2768 chemical name is Uridine-5'-tetraphosphate δ-
phenyl ester tetrasodium salt. In vitro experiments were carried out using MRS2768 agonist. 
MRS2768 aliquots were stored at -80°C for long storage and -20°C for one month. 
3.2.14 Statistical analysis 
 
GraphPad Prism® v6.05 was used for all statistical analysis. Data are expressed as mean 
±SEM. Significance was calculated using unpaired t-test to compare between two test 
groups or one-way ANOVA Dunnett test to analyze multiple test groups. The significance 
was considered when P value was < 0.05. Graphs are represented in column, grouped or 
contingency method of GraphPad Priam tool. 
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4 RESULTS 
4.1 Gene expression profiling of GPCRs in human pulmonary vessels 
4.1.1 High-throughput screening of 408 GPCRs with first set of primers 
 
The expression of 408 GPCRs in laser micro-dissected human pulmonary vessels from 
donors (n-5) and IPAH patients (n=7) was investigated via a customized high-throughput 
PCR array. The mRNA expression level was represented as the absolute number of copies, 
which was normalized with genomic DNA from the respective GPCR gene. Initially, 40 
candidates were identified from among 408 GPCRs (Figure 7). 
4.1.1.1 Upregulated GPCRs in pulmonary vessels from IPAH patients versus donors 
 
The high-throughput screening revealed 32 GPCRs that were upregulated in the pulmonary 
vessels from the IPAH patients compared to donors (Figure 7A). These included the 
leukotriene receptor (CYSLTR1), vasoactive intestinal peptide receptor (VIPR1), 
chemokine receptors (CMKLR1, CXCR7, CXCR3, CXCR6), adrenoceptors (ADRA2C, 
ADRB1), neuropeptide Y receptors (NPY1R, NPY5R), endothelin receptors (EDNRA, 
EDNRB), adenylate cyclase-activating polypeptide receptor (PACAP), platelet-activating 
factor receptor (PTAFR), lysophosphatidic acid receptors (LPAR1, LPAR2), leucine-rich 
repeat (LGR7), adenosine receptor (ADORA2A), angiotensin II receptor (AGTR1), 
purinergic receptor (P2Y12), trace amine receptor (TAAR8), and 10 orphan receptors 
(GPR137B, GPR18, GPR82, GPR21, GPR4, GPR112, GPR20, GPR109B, GPR97, 
GPR115). Of note, GPR109B has recently been deorphanized and is also known as niacin 
receptor 1 [158-160].  
4.1.1.2 Downregulated GPCRs in pulmonary vessels from IPAH patients versus 
donors 
The high-throughput screening revealed 8 GPCRs were downregulated in the pulmonary 
vessels of IPAH patients compared to donors (Figure 7B), and these included a 
prostaglandin E receptor (PTGER4), frizzled receptor (FZD1), serotonin receptor (HTR2B), 
sphingosine receptors (S1PR3, S1PR1), purinergic receptor (P2Y2), dopamine receptor 
(DRD1), and one orphan receptor (GPR110). 
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Figure 7. High-throughput screening of GPCRs in laser micro-dissected pulmonary vessels from IPAH 
patients and donors. The mRNA levels of GPCRs in the laser micro-dissected pulmonary arteries (diameter 
range: 50-100µm) from donors (black bars) and IPAH patients (grey bars) were acquired by high-throughput 
PCR array. The high-throughput screening data are represented in copies per ng of DNA after normalization to 
genomic DNA levels of the respective GPCR genes. (A) Upregulated GPCR gene expression (upper panel) in 
pulmonary arteries from IPAH patients compared to donors. Abbreviations for upregulated genes in IPAH 
patients: leukotriene receptor (CYSLTR1), vasoactive intestinal peptide receptor (VIPR1), chemokine receptors 
(CMKLR1, CXCR7, CXCR3, CXCR6), adrenoceptors (ADRA2C, ADRB1), neuropeptide Y receptors (NPY1R, 
NPY5R), endothelin receptors (EDNRA, EDNRB), adenylate cyclase-activating polypeptide receptor (PACAP), 
platelet-activating factor receptor (PTAFR), lysophosphatidic acid receptors (LPAR1, LPAR2), leucine-rich 
repeat (LGR7), adenosine receptor (ADORA2A), angiotensin II receptor (AGTR1), purinergic receptor (P2Y12), 
trace amine receptor (TAAR8), and 10 orphan receptors (GPR137B, GPR18, GPR82, GPR21, GPR4, GPR112, 
GPR20, GPR109B, GPR97, GPR115). (B) Downregulated GPCR gene expression (lower panel) in the 
pulmonary arteries of IPAH patients compared to donors. Abbreviations for downregulated genes in IPAH 
patients: prostaglandin E receptor (PTGER4), frizzled receptor (FZD1), serotonin receptor (HTR2B), 
sphingosine receptors (S1PR3, S1PR1), purinergic receptor (P2Y2), dopamine receptor (DRD1), and one 
orphan receptor (GPR110). All values are expressed as the mean ± SEM of n=5 in the donor group and n=7 in 
the IPAH patient group. *P < 0.05, **P < 0.01, ***P < 0.001 versus donors.  
4.1.2 Validation of dysregulated GPCR expression by alternative sets of primers  
 
The expression of the 40 candidate GPCRs was validated with different primer sets using 
the same PCR array system employed for screening. Only 22 GPCRs demonstrated an 
expression pattern consistent with that seen for the previous array of IPAH patients versus 
donors. More specifically, there were 19 upregulated GPCRs (including 5 orphan receptors) 
and 3 downregulated candidates (Figure 8). The data confirmed the known dysregulation 
of certain GPCRs in PAH, which are marked with black boxes in Figure 8. Examples 
included VIPR1 and EDNRB. However, most of the candidates have not been previously 
reported in the field of PAH, and so they deserve further investigation.  
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4.1.2.1 Validation of upregulated GPCRs in the pulmonary vessels of IPAH patients 
 
The consistently and significantly upregulated GPCR mRNA expression level in the IPAH 
patients (Figure 8A) involved the following GPCRs: vasoactive intestinal peptide receptor 
VIPR1, chemokine receptors (CMKLR1, CXCR7), platelet-activating factor receptor 
PTAFR, leukotriene receptor CYSLTR1, neuropeptide Y receptors (NPY1R, NPY5R), 
lysophosphatidic acid receptors (LPAR1, LPAR2), endothelin receptor EDNRB, trace amine 
receptor TAAR8, leucine-rich repeat LGR7, niacin receptor GPR109B, and 5 orphan 
receptors (GPR18, GPR21, GPR97 GPR112, GPR115). 
4.1.2.2 Validation of downregulated GPCRs in the pulmonary arteries of IPAH 
patients 
 
The downregulated GPCR mRNA expression level in the IPAH patients (Figure 8B) involved 
the following GPCRs: prostaglandin E receptor PTGER4, purinergic receptor P2Y2, and 
dopamine receptor DRD1.  
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Figure 8. Validation of GPCRs with different primer sets in laser micro-dissected pulmonary vessels 
from IPAH patients and donors. The mRNA levels of the candidate GPCRs were validated using different sets 
of primers, and the mRNA levels were determined via a high-throughput PCR array in laser micro-dissected 
pulmonary arteries (diameter range: 50-100µm) from donors (black bars) and IPAH patients (grey bars). The 
validation data are represented in copies per ng of DNA after normalization to genomic DNA levels of the 
respective GPCR genes. The GPCRs already known in the PAH field are marked with black boxes. (A) 
Upregulated GPCR gene expression (upper panel) in the pulmonary arteries of IPAH patients compared to 
donors. Abbreviations for upregulated genes in IPAH patients: vasoactive intestinal peptide receptor VIPR1, 
chemokine receptors (CMKLR1, CXCR7), platelet-activating factor receptor PTAFR, leukotriene receptor 
CYSLTR1, neuropeptide Y receptors (NPY1R, NPY5R), lysophosphatidic acid receptors (LPAR1, LPAR2), 
endothelin receptor EDNRB, trace amine receptor TAAR8, leucine-rich repeat LGR7, niacin receptor GPR109B, 
and 5 orphan receptors (GPR18, GPR21, GPR97 GPR112, GPR115). (B) Downregulated GPCR gene 
expression (lower panel) in the pulmonary arteries of IPAH patients compared to donors. Abbreviations for 
downregulated genes in IPAH patients: prostaglandin E receptor PTGER4, purinergic receptor P2Y2, and 
dopamine receptor DRD1. All values are expressed as the mean ± SEM of n=5 in the donor group and n=7 in 
the IPAH patient group. *P < 0.05, **P < 0.01 versus donors.  
4.2 Screening for candidate GPCRs in the PASMCs of donors and IPAH patients 
via real-time PCR 
The abnormal proliferation, migration, and survival of PASMCs within the pulmonary arterial 
wall is a key pathological feature of vascular remodeling in IPAH. Therefore, it was important 
to investigate the expression patterns of the GPCR candidates identified by high-throughput 
array in the human PASMCs. The relative mRNA expressions of 22 candidate GPCRs were 
examined in cultured PASMCs from donors and IPAH patients using quantitative PCR.  
4.2.1 Expression of the upregulated candidate GPCRs in the PASMCs of donors 
and IPAH patients 
The qPCR results revealed upregulation of VIPR1 and LGR7 mRNA expression in the 
PASMCs of IPAH patients compared to the donor PASMCs. However, CYSLTR1, which 
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exhibited upregulation in the pulmonary vessels from IPAH patients (high-throughput array), 
was found to be downregulated in the PASMCs from IPAH patients relative to those of the 
donors. No significant differences between the PASMCs from the IPAH patients and the 
donors were noted for the 16 remaining GPCRs (Figure 9). 
 
Figure 9. Expression of upregulated candidate GPCRs in the PASMCs of IPAH patients and donors as 
identified by quantitative PCR. The relative mRNA expressions of the candidate GPCRs in cultured PASMCs 
from IPAH patients (grey bars) and donors (black bars) were analyzed using quantitative PCR (qRT-PCR). The 
mRNA expression of each GPCR is represented as the delta Ct value after normalization with house-keeping 
gene hypoxanthine-guanine phosphoribosyl transferase (HPRT). Vasoactive intestinal peptide receptor (VIPR1) 
and leucine-rich repeat (LGR7) were significantly upregulated in the cultured PASMCs from the IPAH patients. 
A leukotriene receptor (CYSLTR1) was significantly downregulated in the cultured PASMCs from the IPAH 
patients. All values are expressed as the mean ± SEM of n=5 in the donor PASMCs and n=6 in the IPAH 
PASMCs. *P < 0.05, **P < 0.01 versus donor PASMC. 
4.2.2 Expression of the downregulated candidate GPCRs in the PASMCs of donors 
and IPAH patients 
The qPCR results revealed downregulation of the purinergic receptor (P2Y2) and dopamine 
receptor (DRD1) in the PASMCs of the IPAH patients compared to those from the donors 
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(Figure 10). In contrast, mRNA expression of the prostaglandin E receptor (PTGER4) was 
not detected in the PASMCs from either the IPAH patients or the donors, indicating that the 
PTGER4 might only be expressed in other vasculature compartment cell types. 
 
 
Figure 10. Expression of downregulated candidate GPCRs in PASMCs from IPAH patients and donors 
as identified by quantitative PCR. The relative mRNA expressions of the candidate GPCRs in cultured 
PASMCs from IPAH patients (grey bars) and donors (black bars) were analyzed using quantitative PCR (qRT-
PCR). The mRNA expression of each GPCR is represented as the delta Ct value after normalization with house-
keeping gene hypoxanthine-guanine phosphoribosyl transferase (HPRT). The purinergic receptor (P2Y2) and 
dopamine receptor (DRD1) were significantly downregulated in the cultured PASMCs from the IPAH patients. 
All values are expressed as the mean ± SEM of n=5 in the donor group and n=6 in the IPAH patient group. *P 
< 0.05, ***P < 0.001 versus donor PASMCs. 
4.3 si-RNA knockdown of GPCRs in PASMCs  
Six GPCRs that have not been well studied in PAH were selected and further examined in 
terms of their functional role in human PASMCs. To that end, the transient knockdown of 
GPCRs (GPR 21, P2Y2, PTAFR, CYSLTR1, LGR7, GPR115) was established in cultured 
PASMCs from donors. All 6 selected GPCRs were successfully knockdown by 50 nM 
siRNA. Around 83-96% knockdown of GPCR mRNA is achieved, and no changes occurred 
when the cells were treated with scramble siRNA (Figure 11).  
 RESULTS 
 
54 
 
 
Figure 11. Knockdown of GPCRs by specific siRNAs. Human PASMCs from donors were transiently 
transfected with 50nM of si-GPCRs for 48 hours. Human PASMCs treated with si-scramble served as a negative 
control. Relative mRNA levels of GPCRs in human PASMCs after 48 hours of transfection were determined by 
quantitative PCR (qRT-PCR). The mRNA expression of each GPCR is indicated as a percentage of si-scramble 
after normalization to HPRT. mRNA expression of respective GPCRs after si-scramble transfection are 
represented in black bars. mRNA expression of respective GPCRs after respective si-GPCRs transfection are 
represented in grey bars. The knockdown efficiency of the respective GPCR gene expressions were as follows: 
si-GPR21= 83.32%, si-P2Y2= 88.50%, si-GPR115= 96.45%, si-CYSLTR1= 96.43%, si-LGR7= 96.43%, and si-
PTAFR= 92.83%. All values are expressed as the mean ± SEM of n=4 in each group. ***P <0.001 versus si-
scramble. Abbreviations: orphan GPCRs (GPR21, GPR115), purinergic receptor (P2Y2), leukotriene receptor 
(CYSLTR1), leucine-rich repeat (LGR7), platelet activating factor receptor (PTAFR), and small (or short) 
interfering RNA (si-RNA). 
4.4 Proliferation of PASMCs after the siRNA knockdown of GPCRs 
 
To examine the functional role of GPCRs in the proliferation of PASMCs, specific GPCRs 
were knocked down using siRNA transfection. The proliferation of PASMCs was determined 
after serum stimulation. No differences in PASMC proliferation occurred between the non-
transfected (mock) and scrambled siRNA. The serum-stimulated (+FCS) proliferation of 
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PASMCs was slightly inhibited after the siRNA knockdown of GPR115, LGR7, and PTAFR 
(Figure 12). Knockdown of the P2Y2 receptor, which was downregulated in both the 
pulmonary vessels and PASMCs from the IPAH patients, did not produce any differences 
in the proliferation of the donor PASMCs (Figure 12). Under the serum-starved condition, 
PASMC proliferation was constant and at a basal level in both all siRNA knockdown 
scenarios and mock controls. 
 
 
Figure 12. Effect of GPCR siRNA knockdown on human PASMC proliferation. Human PASMCs from 
donors were serum-starved for 24 hours and stimulated with 10% fatal calf serum (FCS) to induce cellular 
proliferation. The black bars indicate serum starvation (-FCS), the grey bars indicate serum stimulation (10% 
FCS). The siRNA for P2Y2, GPR21, GPR115, CYSLTR1, LGR7, and PTAFR was transfected for 24 hours to 
knockdown the respective GPCR gene expression. Before the end of stimulation, BrdU incorporation was 
performed for 4 hours to determine the rate of human PASMC proliferation. Knockdown of GPR115, LGR7, and 
PTAFR gene expression led to significant inhibition of serum-stimulated (10% FCS) human PASMC 
proliferation. All values are expressed as the mean ± SEM of n=6 in each group. *P < 0.05, **P < 0.01 versus 
si-scrambled. Abbreviations: orphan G protein-coupled receptor (GPR115), leucine-rich repeat (LGR7), platelet-
activating factor receptor (PTAFR), small (or short) interfering RNA (si-RNA). 
4.5 Functional role of the purinergic receptor (P2Y2) in human PASMCs 
Purinergic receptor P2Y2 was the most downregulated in the pulmonary vessels and 
PASMCs from IPAH patients. Hence, P2Y2 was further studied using human PASMCs to 
better understand its functional role in IPAH and pulmonary vascular remodeling. 
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4.5.1 Effect of a P2Y2 agonist (MRS2768) on the basal proliferation of PASMCs  
The knockdown of the P2Y2 receptor did not influence PASMC proliferation under serum-
starved or serum-stimulated conditions as compared to the scrambled siRNA (Figure 12). 
Therefore, it was necessary to investigate whether the activation of the P2Y2 receptor by 
its ligand influences PASMCs proliferation. To that end, the PASMCs were serum-starved 
for 24 hours and treated with increasing concentrations of P2Y2 receptor-specific agonist 
MRS2768 (uridine-5'-tetraphosphate δ-phenyl ester tetrasodium salt) for 24 hours. The 
basal proliferation of the PASMCs is decreased when treated with 5, 10, and 50µM of 
MRS2768 compared with the non-treated control (Figure 13). However, at higher dosages 
(100 µM and 200 µM), MRS2768 had no effect on PASMC proliferation. This might be due 
to P2Y2 receptor desensitization triggered by exposure to an excess amount of the agonist.  
 
Figure 13. Anti-proliferative effect of selective P2Y2 agonist MRS2768 in human PASMCs. Human 
PASMCs from donors were serum-starved for 24 hours and treated for 24 hours with increasing concentrations 
of MRS2768. During the last 4 hours of stimulation, BrdU incorporation was performed to determine the rate of 
human PASMC proliferation. Human PASMC proliferation was inhibited by 34.65%, 37.71%, and 33.91% when 
treated with different concentrations of MRS2768 (5µM, 10µM, and 50µM) respectively. All values are expressed 
as the mean ± SEM of n = 4 in each group *P < 0.05, **P < 0.01 versus non-treated cells (NTC). 
4.5.2 The P2Y2 ligand MRS2768 inhibited PASMC proliferation induced by serum 
and PDGF 
Uncontrolled PASMCs proliferation is a pathological feature of progressive pulmonary 
vascular remodeling, and so the effect of MRS2768 on donor PASMC proliferation induced 
by serum or PDGF was determined. The results indicated that MRS2768 (10 µM) inhibited 
serum- and PDGF-induced PASMC proliferation by 28% and 25%, respectively, as 
compared with the NTCs (Figure 14 A and B). 
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Figure 14. MRS2768 (10 µM) attenuated FCS- and PDGF-induced proliferation of human PASMCs. 
Proliferation of donor PASMCs induced by A) 10% fatal calf serum (FCS) and B) 30ng/ml platelet-derived growth 
factor (PDGF). The PASMCs underwent serum starvation for 24 hours and were subsequently stimulated with 
10% FCS or PDGF for 24 hours in the presence or absence of 10 µM of MRS2768. In the last 4 hours of 
stimulation/treatment, BrdU incorporation was performed. The BrdU proliferation results indicated a 473% 
increase in serum-induced (10% FCS) PASMC proliferation and a 292% increase in PDGF-induced PASMC 
proliferation relative to the serum-starved (-FCS) PASMCs. Moreover, MRS2768 (10µM) significantly attenuated 
serum-induced (10%FCS) and PDGF-induced (30ng/ml) PASMC proliferation, resulting in boosts of 10% and 
25%, respectively. All values are expressed as the mean ± SEM of n = 3 in each group, ***P < 0.001 versus 
serum-starved (-FCS); ++P < 0.01 versus serum-stimulated (+FCS)/PDGF-stimulated. 
4.5.3 The P2Y2 ligand MRS2768 inhibited PASMC migration induced by serum and 
PDGF 
 
Uncontrolled PASMC migration is another pathological feature of progressive pulmonary 
vascular remodeling. The effect of PASMC migration was determined by scratch wound 
healing assay, with human PASMCs from donors treated with 10µM of MRS2768 (ligand 
activates P2Y2 receptor) after the transfection of si-P2Y2 (P2Y2 receptor gene knockdown) 
and si-scrambled (presence of P2Y2 receptor). Real-time microscopy monitoring revealed 
that the knockdown of the P2Y2 receptor increased wound closure by 50% and 35% relative 
to the si-scrambled control in serum-starved (-FCS; Figure 15 A and B) and PDGF-
stimulated (Figure 15 E and F) PASMCs, respectively. While MRS2768 via P2Y2 inhibited 
PASMC wound closure by 20% under the basal condition (-FCS; Figure 15 A and B) 
compared with MRS2768 non-treated si-scr PASMCs. MRS2768 via P2Y2 significantly 
inhibited serum-induced (+FCS) by 65% (Figure 15 C and D) or PDGF-induced PASMC 
wound closure by 50% (Figure 15 E and F). In addition, MRS2768 failed to attenuate basal, 
or serum- or PDGF-induced, PASMC wound closure after the knockdown of P2Y2 receptor 
as compared to MRS2768-treated si-scrambled PASMCs (Figure 15 A-F). 
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Figure 15. MRS2768 inhibited human PASMC wound healing induced by FCS and PDGF. Human donor 
PASMCs were transfected by si-scr (scrambled) and si-P2Y2 receptor. They were then serum-starved for 24 
hours and a scratch was made in the center of each well. Following the scratch, the PASMCs were either (A, 
B) serum-starved (-FCS), (C, D) stimulated with 5% fetal calf serum (FCS), or (E, F) stimulated with 30ng/ml 
platelet-derived growth factor (PDGF) for 10 hours. Wound healing was monitored from the 0 hour to 10 hours 
using a live-cell imaging microscope, and images of each scratch were captured every hour, with the wound in 
the same position. Wound closure after 10 hours is expressed as a percentage of closure at the 0 hour. 
Representative live-cell images (A, C, E) at 0 hours (dotted line) and 10 hours are shown. Graphical 
representations are given in B, D, and F, respectively. When the P2Y2 receptor gene expression was knocked 
down, the migration of donor PASMCs increased in the serum-starved condition (A, B) and the PDG stimulation 
condition (E, F) (si-scr versus si-P2Y2). The MRS2768 (10µM) attenuated serum-induced (C, D) and PDGF-
induced (E, F) migration in the presence of endogenous P2Y2 receptor expression (si-scr versus si-scr 
MRS2768 10µM). In contrast, MRS2768 (10µM) failed to attenuate basal, or serum- or PDGF-induced, PASMC 
migration when the P2Y2 receptor gene expression was knocked down (si-scr MRS2768 10µM versus si-P2Y2 
MRS2768 10µM). All values are given as the mean ± SEM of n= 5 per group. *P < 0.05, **P < 0.01, ***P < 0.001 
versus si-scrambled; +P < 0.05, +++P < 0.001 versus si-scrambled treated with MRS2768 (10µM). 
Abbreviations: non-significant (ns), purinergic receptor (P2Y2), small (or short) interfering RNA (si-RNA), and 
siRNA scrambled (si-scr). 
 
Additionally, cell migration was validated by transwell migration assay, and the results 
demonstrated a 45% and 25% increase in serum-starved (-FCS) and PDGF-induced 
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migration, respectively, after P2Y2 knockdown in the PASMCs relative to the si-scrambled 
transfected PASMCs. In contrast, MRS2768 inhibited FCS- and PDGF-induced migration 
by 25% and 35%, respectively (Figure 16), and it failed to attenuate basal (-FCS), serum-
induced (+FCS), or PDGF-induced PASMC migration when P2Y2 was knocked down. 
(Figure 16). The transwell migration assay presented results consistent with the scratch 
wound closure results. These data strongly suggest that MRS2768 suppresses FCS- and 
PDGF-induced PASMC migration through the P2Y2 receptor. 
 
 
Figure 16. MRS2768 inhibited human PASMC migration induced by FCS and PDGF. Transwell migration 
of donor PASMCs under serum-starved (-FCS) conditions was induced by 5% fetal calf serum (FCS) and 
30ng/ml platelet-derived growth factor (PDGF). The migration rate after 10 hours is expressed in terms of the 
number of migrated cells. Representative images of cells on transwell membranes were taken using light 
microscopy (20X). The graphical representation of each group is depicted below. When the P2Y2 receptor gene 
expression was knocked down, the migration of donor PASMCs increased in serum-starved condition. The 
MRS2768 (10µM) attenuated serum-induced or PDGF-induced migration in the presence of endogenous P2Y2 
receptor expression (si-scr versus si-scr MRS2768 10µM). In contrast, MRS2768(10µM) failed to attenuate 
basal or PDGF-induced PASMC migration when the P2Y2 receptor gene expression was knocked down (si-scr 
MRS2768 10µM versus si-P2Y2 MRS2768 10µM). All values are given as the mean ± SEM of n= 5 per group. 
*P < 0.05, **P < 0.01 versus MRS 2768 untreated si-scrambled; +P < 0.05, +++P < 0.001 versus si-scrambled 
 RESULTS 
 
61 
 
treated with MRS2768. Abbreviations: non-significant (ns), purinergic receptor (P2Y2), small (or short) 
interfering RNA (si-RNA), and siRNA scrambled (si-scr). 
4.5.4 P2Y2 ligand MRS2768 inhibited matrix metalloproteinases 2 (MMP-2) in 
PASMCs 
In addition, MMP-2 is involved in PASMC migration [161]. The MMP activity was examined 
by gelatin zymography. The zymography results did not reveal any changes in active MMP-
2s (62 kDa) in the PASMCs after P2Y2 knockdown (si-P2Y2) as compared with the control 
(si-scrambled). When treated with the P2Y2 ligand (MRS2768) in the presence of its 
receptor, active MMP-2 levels decreased compared to the non-MRS2768 treated condition, 
although the difference was not significant. In contrast, MRS2768 failed to reduce active 
MMP-2 levels and significantly increased the amount of active MMP-2 in the knockdown of 
the P2Y2 receptor (Figure 17). Taken together, the data revealed that MRS2768 slightly 
reduced MMP2 activity in the presence of P2Y2. Furthermore, in the case of P2Y2 receptor 
knockdown, MRS2768 failed to attenuate MMP2 activity in the PASMCs. Therefore, 
MRS2768 and P2Y2 might play a role in migration involving MMP2 activity. 
 
Figure 17. Matrix metalloproteinases 2 (MMP-2) activity in human PASMCs analyzed using gelatin 
zymography. The level of active MMP-2 is determined in human donor PASMCs culture medium either in the 
presence of P2Y2 receptor or knockdown-induced absence of the P2Y2 receptor both with or without MRS2768. 
(A) Gelatin zymography gels representing MMP2 (above) protein expression from the PASMC culture medium 
and a western blot representing GAPDH (below) protein expression in the PASMCs. (B) Densitometry and 
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quantification of MMP2 zymography with GAPDH serving as the loading control. Zymography analysis revealed 
that MRS2768 slightly reduced MMP2 activity in the presence of P2Y2 (si-scr versus si-scr MRS2768 10µM) 
and failed to reduce MMP2 activity when the P2Y2 receptor expression was knocked down (si-scr MRS2768 
10µM versus si-P2Y2 MRS2768 10µM). The enzyme activities of MMP-2 are expressed as the mean ± SEM of 
n= 3 per group. +P < 0.05 versus si-scrambled treated with MRS2768 10µM. Abbreviations: non-significant (ns), 
purinergic receptor (P2Y2), small (or short) interfering RNA (si-RNA), and siRNA scrambled (si-scr). 
4.5.5 P2Y2 ligand MRS2768 increased intracellular cAMP in PASMCs 
Cyclic adenosine monophosphate plays a significant role in vascular SMC relaxation and 
proliferation. Hence, the intracellular cAMP level was analyzed by enzyme immunoassay 
(EIA). The human donor PASMCs were transfected with either si-scrambled or si-P2Y2 and 
treated with or without MRS2768 (10µM). The results demonstrated a basal intracellular 
cAMP level of 2.99 (pmol/mL protein) in the si-scrambled transfected PASMCs and 25.23 
(pmol/mL protein) in the MRS2768-treated (10µM) si-scrambled transfected PASMCs. 
When the P2Y2 receptor gene expression was knocked down (si-P2Y2), MRS2768 failed 
to increase the cAMP levels in the PASMCs (Figure 18). These results confirmed that 
MRS2768 activates cAMP production via the P2Y2 receptor. 
 
Figure 18. The P2Y2 ligand MRS2768 resulted in the accumulation of intracellular cAMP in human 
PASMCs. Donor PASMCs were transfected with si-scr or si-P2Y2, starved for 24 hours, and treated with 
MRS2768 (10µM) for 24 hours to perform cAMP EIA assay. The cAMP contents of the PASMCs’ lysates are 
given as pmol/mL protein. The MRS2768 (10µM) activated cAMP production via the P2Y2 receptor (si-scr 
versus si-scr MRS2768 10µM). The MRS2768 (10µM) failed to increase cAMP production when the P2Y2 
receptor expression was knocked down (si-scr MRS2768 10µM versus si-P2Y2 MRS2768 10µM). All values 
are given as the mean ± SEM of n= 3 per group. **P < 0.01 versus si-scrambled untreated; +P < 0.05, +++P < 
0.001 versus si-scrambled treated with MRS2768 10µM. Abbreviations: non-significant (ns), purinergic receptor 
(P2Y2), small (or short) interfering RNA (si-RNA), and siRNA scrambled (si-scr). 
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4.6 Downstream signaling pathways of P2Y2 
4.6.1 MRS2768 increased exchange protein directly activated by cAMP (EPAC) in 
PASMCs 
The EPAC group is a newly described class of guanine nucleotide exchange factors (GEFs) 
that contain a cAMP-binding domain(s). Cyclic adenosine monophosphate was 
demonstrated to inhibit the rho-associated coiled-coil-containing protein kinase 1 (ROCK1) 
pathway through EPAC [162]. Western blot analysis from cultured human PASMCs from 
donors revealed that MRS2768 (10µM) increased EPAC protein expression both in serum-
starved (-FCS) and serum-stimulated (+FCS) conditions (Figure 19). 
 
Figure 19. MRS2768 (10µM) increased EPAC protein expression in human PASMCs. Protein expression 
of EPAC is determined using western blot. GAPDH expression is used as the loading control. (A) Representative 
western blot of EPAC and GAPDH. (B) Densitometry analysis of EPAC protein expression. The experiment was 
performed after 24 hours of serum-starvation, followed by FCS stimulation (10%FCS) for 24 hours, in the 
absence or presence of MRS2768 (10µM). The MRS2768 increased EPAC protein expression in both serum-
starved (-FCS) and serum-stimulated (+FCS 10%) conditions, although the results were only significant in the 
latter case. All values are given as the mean ± SEM of n = 3 per group. ++P < 0.01 versus NTCs. Abbreviations: 
non-significant (ns), exchange protein directly activated by cAMP (EPAC), glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH), fatal calf serum (FCS), and serum starvation (-FCS).  
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4.6.2  MRS2768 attenuated ROCK1 and myosin light chain 1 (MLC1) 
phosphorylation in PASMCs 
Activation of the RhoA and ROCK1 pathway led to MLC phosphorylation, resulting in 
vascular SMC contraction and migration. Previous studies have reported that ROCK1 is 
inhibited by cAMP via EPAC [163]. It is already known from our previous results, that 10µM 
of MRS2768 activates cAMP (Figure 18) and increases EPAC protein expression (Figure 
19). Western blot analysis from the cultured human donor PASMCs revealed that MRS2768 
(10µM) significantly reduced ROCK protein expression (Figure 20 A and B) and serum-
induced (+FCS) MLC phosphorylation (Figure 20 C and D). In contrast, no significant 
differences regarding the protein expression of ROCK1 and MLC phosphorylation in serum-
starved (-FCS) PASMCs (Figure 20) were found. Taken together, these results suggest that 
MRS2768 activates the EPAC/cAMP cascade and block ROCK/MLC activation which 
reduces vascular SMC migration. 
 
Figure 20. MRS2768 attenuated ROCK1 expression and MLC1 phosphorylation in human PASMCs. (A, 
B) Western blot analysis of ROCK1 protein expression, with GAPDH serving as the loading control. (C, D) 
Western blot analysis of phospho-MLC1 expression, with MLC1 serving as total protein. (B, D) Densitometry 
analysis of ROCK1 and p-MLC1 protein expression. The experiment was performed on donor PASMCs 
stimulated with or without 10% FCS for 24 hours in the absence or presence of MRS2768 (10µM). The 
MRS2768 significantly reduced ROCK protein expression and MLC phosphorylation induced by serum (+FCS 
10%) in the PASMCs. All values are given as the mean ± SEM of n = 3 per group. *P < 0.05 serum stimulated 
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versus serum starved, +P < 0.05, ++P < 0.01 versus NTCs. Abbreviations: non-significant (ns), glyceraldehyde 
3-phosphate dehydrogenase (GAPDH), rho-associated, coiled-coil-containing protein kinase 1 (ROCK1), 
myosin light chain 1 (MLC1), fatal calf serum (FCS), and serum starvation (-FCS).  
 DISCUSSION  
 
66 
 
5 DISCUSSION 
 
This study provided evidence that GPCRs play a pathological role in PAH. Purinoceptor 2 
receptor gene expression was downregulated in the pulmonary arteries of PAH patients 
and highly expressed in pulmonary arteries from donors. MRS2768 was the ligand for the 
P2Y2 receptor by which P2Y2 was activated, and it mediated several downstream signaling 
pathways. Via the P2Y2 receptor, MRS2768 mediated anti-proliferative and anti-migration 
effects in human donor PASMCs stimulated by serum or PDGF. Furthermore, this study 
defined the downstream signaling of the P2Y2 receptor and found that that receptor and its 
ligand MRS2768 increased cAMP production. By elevating cAMP, MRS2768 activated the 
cAMP direct downstream effector, EPAC. Via cAMP and EPAC, MRS2768 decreased 
ROCK1 protein expression, resulting in the reduced phosphorylation of pMLC. This 
reduction in the phosphorylation pMLC might explain the decreased PASMC migration. 
5.1 GPCR expression profile in the pulmonary vasculature of IPAH patients 
 
Depending on the cell type and organ, GPCRs have a broad spectrum of pathophysiological 
functions. They have been intensively studied in many diseases, including obesity, 
cardiovascular disease, inflammation, cancer, diabetes, and Alzheimer’s disease. The 
human genome contains approximately 800 GPCR genes, of which roughly 450 are non-
olfactory receptors. Approximately 50% of GPCRs are orphan receptors with unknown 
agonists and modes of action.  
 
Figure 21. Classification of GPCRs based on orphan receptors and known receptors. The rhodopsin 
(class A) receptor family comprises 76% of all GPCR receptors. Around 10% of GPCRs belong to secretin (class 
Class A 
knowns; 
39%
Class B 
orphans; 
6%
Class B 
knowns; 
5%
Class C 
orphans; 
1%
Class C 
knowns; 
2%
Other 
orphans; 
6%
Other 
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 DISCUSSION 
 
67 
 
B) receptor family. A further 3% of GPCRs belong to the glutamate (Class C) receptor family, among which 1% 
are orphans. In addition, 10% of GPCRs belong to other families, such as cAMP receptors, fungus pheromone 
receptors, and frizzled receptors. This class represents 6% of orphan receptors (Murray, 2011) [110]. 
About several aspects of PAH etiology, convincing evidence supports the involvement of 
several GPCRs. However, in terms of their depth and breadth, cellular functions, and 
signaling pathways, those GPCRs are not yet completely understood. That is also why 
ongoing therapeutic strategies targeting such GPCRs have being facing challenges. 
Moreover, in PAH, the potential role of many orphan GPCRs, as well as those of their 
agonists and antagonists, remains to be discovered [121]. Given the increasing interest in 
targeting GPCRs to treat PAH and other diseases, this study provided initial profiles of all 
non-olfactory receptors in the pulmonary vasculature by performing a GPCR array. Dozens 
of GPCRs were expressed differentially in the pulmonary vessels of IPAH patients versus 
donors.  
5.1.1 Micro-dissection of pulmonary arteries from donors and IPAH patients 
 
Human tissue from IPAH patients’ lungs and non-tumorous donor lungs were cut into small 
pieces and cryopreserved. Following cryopreservation, a thin layer of tissue was cut and 
mounted on glass slides. The tissue slides were briefly stained with hematoxylin and eosin. 
After staining, the pulmonary arteries of diameter ranging between 50-100 µm were micro-
dissected using the laser microbeam system (Leica, Germany). Pulmonary arteries from 
IPAH patients exhibited plexiform lesions (PLs) in some cases, and they also revealed a 
thickening in the intima, medial hypertrophy, and a reduced lumen diameter. 
5.1.2 Upregulated GPCRs in the pulmonary vasculature of IPAH patients 
 
Data from the high-throughput screening showed that VIPR1, chemokine receptors 
(CMKLR1, CXCR7, CXCR6), platelet-activating factor receptor PTAFR, leukotriene 
receptor CYSLTR1, neuropeptide Y receptors (NPY1R, NPY5R), lysophosphatidic acid 
receptors (LPAR1, LPAR2), endothelin receptor EDNRB, trace amine receptor TAAR8, 
leucine-rich repeat LGR7, niacin receptor GPR109B, and 5 orphan receptors (GPR18, 
GPR21, GPR97 GPR112, and GPR115) were highly expressed in the remodeled 
pulmonary vasculatures of the IPAH patients.  
5.1.2.1 Vasoactive Intestinal Peptide Receptor 
 
The agonist of VIPR1 is the vasoactive intestinal peptide (VIP), and its role has been well 
studied in the treatment of PAH. Specifically, VIP is an agonist for both VIPR1 and VIPR2, 
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also known as pituitary adenylate cyclase-activating peptide receptor type1 (VPAC1) and 
type 2 (VPAC2), respectively. While VIPR1 is widely expressed in the central nervous 
system, liver, lung, intestine, and T-lymphocytes, VIPR2 is widely expressed in the CNS, 
pancreas, skeletal muscle, heart, kidney, adipose tissue, testis, and stomach [164]. 
Decreased VIP levels and increased VIP receptor expression in the pulmonary vasculature 
have been reported in clinical settings [165].  
 
Consistent with previous analyses, this study found that VIPR1 was significantly 
upregulated in pulmonary vessels and PASMCs from IPAH patients. Hilarie et al. also 
demonstrated that VIP receptors are expressed in rat tissue sections from pulmonary 
arteries and cultured SMCs from those arteries. Moreover, they also found that antagonists 
of VIP receptors restored PASMC proliferation and reduced cAMP levels mainly by blocking 
VIPR2 [164]. Kort et al. found that VIP knockout mice developed severe PAH [166]. Those 
researchers also found that when VIP knockout mice were treated with VIP, vascular and 
right ventricular remodeling were attenuated [166]. Despite all the encouraging preclinical 
studies demonstrating the vasodilative and anti-proliferative effects of VIP, VIP inhalation 
did not prove effective in a recent phase 2 clinical trial [167]. The role of VIP and VIP 
receptors in PAH requires further clarification, and thus, further investigation.  
5.1.2.2 Chemokine receptors 
 
An accumulating body of evidence suggests that inflammation plays a significant role in the 
pathogenesis of PAH. In IPAH patients, increased perivascular infiltration of inflammatory 
cells, such as T and B cells, and macrophages was found [168]. A mononuclear 
inflammatory infiltrate that primarily included T cells, macrophages, and B cells was found 
around the remodeled vessels and plexiform lesions in PAH patients [76, 169-172]. In IPAH 
patients, perivascular mast cells [173] and DCs were also present [174]. Cytokines, such 
as interleukin (IL-1-β, IL-6, and IL-8) [72, 175], and chemokines (CCL2/MCP-1, 
CCL5/RANTES, and CX3CL1/fractalkine) were elevated in serum from IPAH patients [76]. 
 
The high-throughput screening revealed the elevated expression of CXCR7 in the 
pulmonary vessels of IPAH patients relative to those of donors, and that finding agrees with 
previous studies pointing to increased CXCR7 expression in the pulmonary vasculatures of 
chronic hypoxia-induced PH mice. Newly deorphanized, CXCR7 is a receptor for SDF-1, 
CXCL11, and CXCL12. Studies from Karen C. Young et al. have also suggested that the 
antagonist (CC-X771) of CXCR7 attenuates chronic hypoxia–induced PH in mice [176]. 
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However, no significant difference in cultured PASMCs was noted between IPAH patients 
and donors. Costello et al. found CXCR7 elevation in the pulmonary endothelium of IPAH 
patients, and its agonist, CXCL12, promotes pulmonary endothelial cell proliferation [177]. 
Thus, it is reasonable to speculate that increased CXCR7 expression in pulmonary vessels, 
as observed in this study, may be primarily attributed to endothelial cells, and not to 
PASMCs.  
 
Other chemokine receptors were also upregulated in the pulmonary vessels of IPAH 
patients, and these included CMKLR1 and CXCR6. The former is well known for its 
multifunctional effects in reducing immune responses and enhancing adipogenesis and 
angiogenesis [178]. In addition, CXCR6 expression has been studied in non-small cell lung 
carcinoma. Via metalloproteinases, CXCR6 supports metastatic processes [179]. It also 
plays a critical role in renal injuries and fibrosis through regulating macrophages, T-cell 
infiltration, and the bone marrow-derived accumulation of fibroblasts [180]. However, the 
mRNA analysis found no significant differences concerning CMKLR1 and CXCR6 in the 
PASMCs of IPAH patients and donors. The roles of CMKLR1 and CXCR6 in PAH remains 
unclear.  
 
5.1.2.3 Leukotriene receptor CYSLTR1 
 
In previous studies, cysteinyl leukotrienes (CysLTs) were recognized as causing hypoxic 
pulmonary vasoconstriction, bronchoconstriction, decreased lung compliance, and 
pulmonary edema [181-183]. The role of leukotrienes remains poorly understood in PAH, 
but it has been well studied in pulmonary airway diseases. Elevated levels of leukotrienes 
in neonates with hypoxemia and PH were first reported in 1983 [184]. An increase in 
leukotriene receptor agonists, such as LTB4, LTC4, and LTE4, has also been reported in 
the bronchoalveolar lavage fluid (BALF) and blood of infants with persistent PH. Studies on 
CysLTs in airways might lead to further insights concerning the role of leukotrienes in the 
development of PH and PAH [185]. 
 
This study revealed an upregulation of CYSLTR1 in pulmonary vessels from IPAH patients. 
In contrast, CYSLTR1 was downregulated in PASMCs from IPAH patients as compared 
with donors. Therefore, expression of CYSLTR1 must be studied in other pulmonary 
vasculature cell types (e.g., endothelial cells, fibroblasts, and immune cells). The 
involvement of leukotriene receptors has yet to be determined. 
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5.1.2.4 Neuropeptide Y receptors  
 
Recent findings from Kwapiszewska et al. revealed an increase in the expression of the 
NPY1 receptor within the pulmonary arterial wall of IPAH patients as compared with donors, 
but no changes in NPY1 were observed in the serum or pulmonary arteries [186]. In 
addition, the study also identified the upregulation of the NPY1 receptor in different PAH 
animal models.  
 
Correlating to those findings, our study’s high-throughput screening showed an 
upregulation of NPY1R and NPY5R in pulmonary vessels from IPAH patients compared to 
donors. However, no significant difference in NPY1R and NPY5R mRNA expression in 
cultured PASMCs was observed between IPAH patients and donors. Kwapiszewska’s study 
also indicated that activating the NPY/Y1 axis leads to vasoconstriction, and more 
importantly, pulmonary vascular remodeling [186]. Therefore, neuropeptide Y receptors 
may present a promising target for PAH, and so they are worth further investigation. 
5.1.2.5 Lysophosphatidic acid receptors 
 
Lysophosphatidic acid, the ligand for lysophosphatidic acid receptors, is a bioactive lipid 
molecule synthesized by plasma. In rodents, the local administration of LPA promotes 
systemic arterial remodeling [187-189]. Smyth et al. found that when LPA is absent, the 
endothelin system takes over and supports vascular remodeling [190]. The same 
vasoconstrictive and phenotypic changes are stimulated in cultured SMC by LPA and ET-1 
[191].  
 
This high-throughput screening study found increased expression of LPAR1 and LPAR2 in 
laser micro-dissected pulmonary arteries from IPAH patients. However, no significant 
upregulation of LPAR1 and LPAR2 was noted in the cultured PASMCs from the IPAH 
patients. The LPAR1 and LPAR2 gene expression was equal in the cultured PASMCs from 
the IPAH patients and donors. 
5.1.2.6  Endothelin receptors 
 
Endothelin receptors are the best known GPCRs in PAH. Endothelin is the ligand for both 
the ETA and ETB receptors. Endothelin (ET1) is a vasoconstrictor expressed by endothelial 
cells and SMCs, and it plays an important role in the pathobiology of PAH [52]. The protein 
levels of ET1 are elevated in the plasma of IPAH patients [192]. Endothelin binding to ETA 
receptor leads to Gq activation. Gq activates PLC, leads to the formation of IP3, and finally, 
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an increase in intracellular Ca2+ levels in the SMC [195]. The persistently elevated 
intracellular Ca2+ levels lead to vasoconstriction, even after removing ET1 (the ligand 
required for ETA receptor activation) [196]. In chronic hypoxia-induced rats, ET-1 and ET 
receptors levels are increased. Monocrotaline induced in ETB-deficient transgenic rats 
demonstrates higher PVR levels and increased neo-intimal lesions similar to those of PAH 
patients [193]. Muller et al. found that when ET1 receptors (ETA and ETB) were blocked, 
inflammatory signaling was inactivated [194]. Bosentan is a potent antagonist/blocker for 
ETA and ETB receptors, and it inhibits NF-kappaB and AP1 activation. The genes that are 
regulated by NF-kappaB and AP1, such as intercellular adhesion molecule 1(ICAM-1), 
VCAM-1, and transferrin (TF), are also further blocked by bosentan. 
 
The high-throughput screening confirmed the increase in ETA and ETB (also known as 
EDNRA and EDNRB, respectively) in a remodeled pulmonary vasculature. However, 
pulmonary vasculature is differentially regulated by ET-1 depending on the receptors and 
cell types. Many studies have indicated that in PASMCs, ETA mediates vasoconstriction 
and vascular remodeling, whereas ETB promotes vasodilatation in endothelial cells by 
increasing nitric oxide production. In addition, ETB mediates endothelial cells’ reuptake of 
ET-1, thereby clearing circulating ET-1 [195, 196]. Therefore, in a clinical setting, an ETA-
specific antagonist, such as ambrisentan, may be a better option than a dual-receptor 
antagonist.  
5.1.2.7 Leucine-Rich repeat LGR7 
 
Well studied in airway diseases, LGR7 is relaxin family peptide receptor-1 that shares the 
ligand, relaxin, with LGR8 [197]. Tang et al. have demonstrated that LGR7 protects against 
airway fibrosis during homeostasis but fails to protect against fibrosis associated with 
chronic allergic airway disease [198].  
 
Our high-throughput screening study found the upregulation of LGR7 in both pulmonary 
vessels and PASMCs from IPAH patients as compared to donors. The receptor itself has 
not previously been implicated in PAH. However, highly elevated relaxin levels have been 
reported in serum from PAH patients, although not in diastolic heart failure-induced PH 
patients [199]. Interestingly, an earlier study found a therapeutic effect of recombinant 
relaxin on hypoxia-induced PAH in rats [200]. These controversial observations encourage 
further studies addressing the potential role of LGR7 and relaxin in PAH.  
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5.1.2.8 Other candidate GPCRs 
 
The recently deorphanized niacin receptor GPR109B [159, 201] and several orphan 
receptors (trace amine receptor TAAR8, GPR18, GPR21, GPR97 GPR112, and 
GPR115) were also upregulated in the pulmonary vessels from the IPAH patients, 
according to this study’s screen data. However, none of these receptors exhibited 
differential expression in the cultured PASMCs of IPAH patients versus donors. Defining 
the role of these dysregulated orphan receptors in PAH may prove rather challenging until 
their ligands are discovered.  
5.1.3 Downregulated GPCRs in the pulmonary vasculature of IPAH patients  
 
High-throughput screening by means of GPCR arrays revealed 3 significantly 
downregulated GPCRs, namely, PTGER4, P2Y2, and DRD1. 
5.1.3.1 Prostaglandin E receptor  
 
One of the earliest and most effective treatments for PH is iloprost. It activates prostacyclin 
receptors (IP receptor) and increases cAMP, resulting in vasodilation and less remodeling 
of the pulmonary arteries [48]. Prostacyclin signaling is altered in PAH. Prostaglandin I2 
(prostacyclin) receptor (IP) protein expression is low in IPAH lung tissues [202]. In addition, 
prostacyclin is a potent vasodilator and exhibits anti-inflammatory properties via the IP 
receptor [203].  
 
Our previous studies have indicated that the prostacyclin analog iloprost reverses vascular 
remodeling in monocrotaline-induced PH rats [204, 205]. Our previous findings clarified that 
other prostanoid receptors, such as prostaglandin E2 receptor 2 (EP2/PTGER2) and 
prostaglandin E2 receptor 4 (EP4/PTGER4) are stably expressed in lung tissue from IPAH 
patients and monocrotaline-induced PH rats [48]. Moreover, EP2 and EP4 receptors are 
coupled to the Gαs protein, and therefore, receptor activation leads to both an increase in 
cAMP levels in SMCs and relaxation [206]. Iloprost, in the absence of its receptor 
prostaglandin I2 (prostacyclin) receptor (IP), acts via EP4/PTGER4 and mediates 
vasodilation in PH [48]. 
 
Building on our previous findings that IP receptor expression is reduced in remodeled 
PASMCs and lung homogenates from IPAH patients [48], our high-throughput GPCR array 
revealed decreased PTGER4 mRNA expression in the laser micro-dissected pulmonary 
arteries of IPAH patients versus donors.  
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5.1.3.2 Dopamine receptors  
 
Dopamine receptors are expressed in the vascular wall. Activation of a dopamine receptor 
by its ligand (dopamine) results in vasodilation [207]. Dopamine plays an important role in 
epithelial sodium transport, and it interacts with vasoactive hormones, thereby playing a 
crucial role in the pathogenesis of systemic hypertension [208]. Kummer et al. demonstrated 
that pulmonary arterial endothelial cells and VSMCs produce a substantial pool of dopamine 
[209]. 
 
Our current findings from our high-throughput GPCR array revealed reduced DRD1 (a 
dopamine receptor subtype) levels, in laser micro-dissected pulmonary arteries and 
cultured PASMCs from IPAH patients, suggesting a vasoconstrictive potential of the 
pulmonary arteries in PAH patients.  
 
5.1.3.3 Purinergic receptor P2Y2 
 
Vasodilatory mediators, such as nitric oxide, that are released from the endothelium 
determine the blood pressure. Offermanns et al. evaluated human and bovine endothelial 
cells and found that the purinergic receptor P2Y2 mediated activation of [Ca2+] transients, 
activation of the eNOS, phosphorylation of PECAM-1 and VEGFR-2, and activation of SRC 
and AKT. A lack of P2Y2 in endothelial cells reduced eNOS activation, deceased 
vasodilation, and resulted in hypertension in those mice [210].  
 
Our current findings from the high-throughput GPCR array revealed the reduced expression 
of purinergic receptor P2Y2 in laser micro-dissected pulmonary arteries and cultured 
PASMCs from IPAH patients. 
5.2 Effect of GPCRs on human PASMC proliferation 
G protein-coupled receptors play several roles in cellular functions, among which SMC 
proliferation is essential to PAH pathogenesis. Histological lung biopsy studies have 
revealed that medial vascular wall remodeling is mainly due to PASMC proliferation [211]. 
Therefore, we were interested in the role of GPCRs in PASMC proliferation. Loss-of-
function experiments employing siRNA targeting GPR115, LGR7, and PTAFR found a mild 
inhibitory effect on serum-induced PASMC proliferation.  
 
 DISCUSSION 
 
74 
 
Previous findings have noted that the ligand of LGR7 (relaxin) regulates 
fibroblast proliferation, differentiation, and collagen deposition in cardiac fibrosis. Relaxin is 
known to reduce fibroblast proliferation mediated by angiotensin II and TGF-beta [212]. 
Studies on Sertoli cells have indicated that relaxin increases cell numbers and the 
expression of PCNA [213]. In our current study, we found that the knockdown of LGR7 gene 
expression resulted in the inhibition of serum-induced human donor PASMC proliferation. 
However, determining the exact mechanism and role of relaxin/LGR7 in PASMC 
proliferation requires further investigation.  
 
Platelet-activating factor, a potent phospholipid mediator, and its receptor (PTAFR) have 
been well studied in cardiovascular diseases. Platelet-activating factor, released by either 
inflammatory cells or the endothelium, has been shown to promote atherosclerosis by 
activating MMPs [214], while PTAFR is present in vascular SMCs. Moreover, PTAFR has 
been reported in the pathogenesis of PPHN. Ibe et al. have stated that hypoxia and 
hyperoxia increase proliferation via PTAFR signaling in PASMCs from newborn ovine [215]. 
In our current study, we found that the knockdown of PTAFR gene expression resulted in 
the inhibition of serum-induced human donor PASMC proliferation. The downstream 
mechanisms through which PTAFR regulates PASMC proliferation have yet to be 
investigated.  
 
Our BrdU proliferation assay also revealed an orphan receptor (GPR115) with a role in 
PASMC proliferation. The knockdown of GPR115 gene expression reduced serum-induced 
donor PASMC proliferation. Since GPR115 is an orphan receptor, further investigation of 
its functional role in PAH could be possible after deorphanization. 
 
Although the knockdown of P2Y2, CYSLTR1, and GPR21 did not have any effect on serum-
induced PASMC proliferation, that finding does not rule out the possibility that activation of 
CYSLTR1 and GPR21 by their specific ligands contributes to the pro-proliferative and anti-
apoptotic effects of other vascular cell types. Therefore, further studies are necessary to 
address the potential role of dysregulated GPCRs.  
5.3 Role of purinergic receptor P2Y2 in PAH 
 
Activation of P2Y receptors by ATP and UTP has been repeatedly reported in 
carcinogenesis, endothelial regulation, and blood flow regulation [216]. However, evidence 
on its role in vascular remodeling is very limited. In our study, expression profiling of GPCRs 
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suggested a remarkable dysregulation of P2Y2 in pulmonary vessels and PASMCs from 
PAH patients. The role of P2Y2 is completely unknown in PAH, and its part in vascular cell 
functioning has yet to be investigated.  
5.3.1 Effect of P2Y2 agonist MRS2768 on PASMC proliferation  
 
In PAH, PASMCs play an important role in pulmonary vascular remodeling mediated by 
strong proliferation and migration [217]. Several growth factors and tyrosine kinase 
receptors (PDGF receptor) are involved in the process of SMC proliferation [217].  
 
In this study, we observed that MRS2768 reduced PASMC proliferation at lower doses (5µM 
to 50µM). However, higher doses of MRS2768 failed to influence PASMC proliferation, 
perhaps due to the desensitization of the P2Y2 receptor when exposed to excessive amount 
of its ligand, MRS2768.  
 
Earlier studies have indicated that via Raf1 (serine/threonine kinase) and MAPK, PDGF 
leads to an increase in smooth muscle proliferation [218, 219], which could be inhibited by 
a cAMP-mediated PKA mechanism [220]. The PDGF-β receptor is activated by the PDGF 
ligand, which results in Ras-Raf mediated ERK1/2 activation [221]. In turn, ERK1/2 
activation leads to the transcription of protooncogenes (c-fos, c-myc) and matrix 
metalloproteinases (MMP2 and MMP9), which result in cell proliferation [221]. Previous 
studies from our team have demonstrated the degradation of the extracellular matrix by 
MMPs and elastase, followed by vascular SMC proliferation [64]. Lung homogenates from 
monocrotaline rat models exhibited a significant increase in MMP2 and MMP9 expression 
[64]. The effects of PDGF receptor activation and increased MMP levels were reversed after 
PDGF receptor inhibition by STI571 [64].  
 
More interestingly, we also observed that MRS2768 could moderately attenuate the PDGF- 
and serum-induced proliferation of donor PASMCs. This brings raises the question of 
whether the P2Y2 receptor engages in crosstalk with other receptor families that interfere 
in PASMC proliferation. In particular, P2Y2 is known to transactivate non-tyrosine kinase 
receptors, as well as several receptor tyrosine kinases [149]. The crosstalk may explain 
why MRS2768 partially inhibits PASMC proliferation induced by both PDGF and serum.  
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5.3.2 Effect of P2Y2 agonist MRS2768 on PASMC migration  
 
Increased PASMC migration into the media and the intima is another pathological feature 
of PASMCs in PAH [222, 223]. Several growth factors, including PDGF, activate the MAPK 
pathway, which then leads to an increase in MMP expression and cell migration [224]. In 
contrast, the MAPK mechanism is inhibited by c-AMP via PKA [220].  
 
In atherosclerosis, the role of PDGF in SMC proliferation and migration has received 
substantial attention [225]. Endothelial cell and PASMC migration result in plexiform lesions 
and neointima formation [172, 226, 227]. Perros et al. revealed the overexpression of PDGF 
and PDGF receptors in the pulmonary arterial walls of PAH patients [63]. They also found 
phosphorylated PDGFR-β (activated PDGF receptors) in vascular lesions and cellular 
proliferation in the lung tissues of PAH patients [63]. Specifically, the PDGFR-β receptor 
was overexpressed in hyperproliferating PASMCs [63]. Perros et al. found increased 
PASMC migration upon the activation of PDGF signaling [63].  
 
In turn, PDGFR activation results in the activation of several pathways such (e.g., PI3K, 
Ras-MAPK, and PLC) that result in the proliferation, differentiation, and migration of VSMCs 
[228]. In hypoxia-induced PH in rats, elevated mRNA expression of PDGF-B and PDGF-A 
was noticed [229]. Rosenkranz et al. found that under hypoxic conditions, normal human 
PASMCs displayed an increased expression of PDGF-B and heightened PASMC 
proliferation and migration [230]. 
 
Therefore, we were interested in studying the role of P2Y2 receptors in PDGF- and serum-
induced human PASMC migration. Initially, we studied the role of P2Y2 in donor PASMC 
migration by performing a scratch wound healing assay to monitor the wound closure rate. 
We later validated our results on PASMC migration by conducting a transwell migration 
assay. These experiments on the migration of donor PASMCs demonstrated that P2Y2’s 
loss of function due to siRNA knockdown promoted spontaneous cell migration without 
growth factors (when the PASMCs were serum-starved). In contrast, MRS2768 could 
attenuate the PDGF- or serum-induced migration of donor PASMCs via the P2Y2 receptor. 
In the case of P2Y2 receptor knockdown, MRS2768 failed to attenuate the PDGF- or serum-
induced migration of donor PASMCs. Our data implied that MRS2768, via P2Y2, is a 
potential agent that acts against the PDGF- or other growth factor- (serum-) mediated 
migration of human donor PASMCs.  
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In line with our discovery, studies from Lehmann et al. have stated that P2Y2 activation by 
ATP delays the growth factor-induced wound healing of keratinocyte monolayers [231]. 
They also suggested that the anti-migration effect of P2Y2 on keratinocytes is mediated by 
blocking growth factor-induced ERK and AKT phosphorylation. On the other hand, other 
study has suggested that uridine adenosine tetraphosphate (Up4A) induces VSMC 
migration by directly activating its receptor, P2Y2, and transactivating the PDGF receptor 
[232]. These controversial findings are not surprising, since the cellular functions of GPCRs 
are highly dependent on the cell type and ligand type.  
5.3.3 MRS2768 regulates MMP2 in human PASMCs via the P2Y2 receptor 
 
An MMP imbalance is involved in extracellular matrix turnover, which in turn affects cell 
migration and proliferation in the vascular wall [233, 234]. Studies from Lafuma et al. have 
demonstrated an overexpression of MMP2 total protein and elevated MMP2 activity in 
SMCs from IPAH patients. They also found that tissue inhibitor of metalloproteinase (TIMP) 
was dysregulated in cultured PASMCs from IPAH patients [235]. Elevated MMP2 activity is 
responsible for the migrative and proliferative phenotype of PASMCs from IPAH patients 
[235]. Studies of adult respiratory distress syndrome (ARDS) have indicated that the active 
MMPs in the epithelial lining fluid degrade the extracellular matrix (ECM) [236]. Specifically, 
MMPs cleave elastin, and elastin fragments have been observed in patients with congenital 
heart defects and PAH [237, 238].  
 
Studies on IPAH associated with human herpesvirus 8 (HHV8) infection have indicated that 
a viral GPCR (vGPCR) activated Src and focal adhesion kinase (FAK) and promoted the 
angiogenesis of human pulmonary arterial endothelial cells (HPAECs) [239]. In addition, 
MMP2 activation is inhibited or blocked by membrane type 1 MMP (MT1-MMP) neutralizing 
antibody and TIMP2 [239]. Shan et al. found that Scr activation by vGPCR led to pro-MMP2 
activation by regulating MT1-MMP and TIMP2 expression [239]. 
 
Studies from Ravindra et al. revealed the crosstalk between EGFR (tyrosine kinase 
receptor) and chemokine receptors (GPCRs: CCR3 and CXCR4) [240]. Activation of CCR3 
and CXCR4 chemokine receptors by their respective ligands, eotaxin-1 (CCL11) and 
stromal cell-derived cell factor (CXCL12), leads to the phosphorylation or activation of the 
EGFR receptor and increases the synthesis of pro-MMP2/active MMP2 in arterial SMCs 
[240]. 
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It is known that MMPs play a significant role in the migration of PASMCs and that GPCRs 
are involved in the regulation and activation of MMPs. Our findings indicated that the P2Y2 
receptor (a GPCR receptor) is involved in regulating the migration of PASMCs. Thus, we 
were interested in studying the role of P2Y2 and its ligand, MRS2768, in regulating MMP 
activation. The zymography experiment revealed that MRS2768 diminished MMP2 activity 
in human donor PASMCs in culture medium. 
5.3.4 P2Y2 agonist MRS2768 increases cAMP production in human PASMCs 
 
Prostacyclins, prostaglandins, and thromboxanes are pulmonary vasoactive mediators 
[241]. Prostacyclins activate GPCRs that bound to Gαs proteins, resulting in the 
hydrolyzation of GTP to GDP [241]. Later, GTP activates adenylate cyclases (ACs) and 
converts ATP to cAMP [241]. Prostanoids (prostacyclin analogues), such as epoprostenol, 
treprostinil, and iloprost, are used for the treatment of IPAH [242].  
 
Cyclic adenosine monophosphate is a universal second messenger that regulates various 
biological processes, such as vascular cell differentiation, proliferation, migration, and 
apoptosis, and so it governs vascular toning and remodeling. It is degraded by the PDE 
enzymes superfamily [243]. According to our previous findings, PDE1 is upregulated in 
PASMCs and lung homogenates from IPAH patients and PAH animal models (hypoxic mice 
and monocrotaline rats) [244]. Our studies from 2011 revealed that PDE10 A expression 
was upregulated in PASMCs from PAH induced by monocrotaline (MCT) in rats. Upon 
PDE10A knockdown, the intracellular cAMP levels increased, which resulted in decreased 
PASMC proliferation [245]. 
 
Our current findings revealed that the P2Y2 receptor and its ligand, MRS2768, regulate the 
proliferation and migration of human PASMCs. Moreover, cAMP is the second messenger 
of GPCR, which regulates PASMC proliferation. Thus, we wanted to examine the effect of 
MRS2768 on intracellular cAMP levels. The results of our cAMP-EIA assay revealed that 
MRS2768 elevated intracellular cAMP levels in human donor PASMCs, whereas it failed to 
increase cAMP levels when P2Y2 receptor expression was knocked down by siRNA. These 
findings suggest that via P2Y2, MRS2768 increases cAMP levels in human PASMCs. 
5.3.5 MRS2768 increases EPAC expression in human PASMCs 
 
The direct downstream effectors of cAMP are PKA and EPAC [246]. In pulmonary artery 
SMCs, cAMP activates PKA and suppress PASMC proliferation [241]. Murray et al. found 
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decreased EPAC1 gene and protein expression in PASMCs isolated from IPAH patients 
[247]. Murray et al. also showed that overexpression of EPAC1 by adenovirus transfection 
decreased serum-induced proliferation of PASMCs isolated from IPAH patients [247].  
 
It was recently demonstrated that beraprost (prostacyclin analogue), increases cAMP levels 
and decreases PDGF-induced human VSMC migration via EPAC [248]. Fluorescence 
resonance energy transfer studies by McKean et al. found that beraprost activates EPAC 
but not PKA. In addition, EPAC inhibits VSMC migration by activating Ras-related protein 1 
(Rap1) and by inhibiting Ras homolog gene family member A (RhoA) [248]. Compared with 
the well-studied cAMP/PKA pathway, the functions and downstream targets of the more 
recently identified cAMP/EPAC pathway are not yet fully understood [246].  
 
Based on the above-mentioned studies, EPAC is a direct downstream effector of cAMP, 
and it regulates VSMC proliferation and migration. In our study, MRS2768 increases cAMP 
levels in human PASMCs. Furthermore, MRS2768 regulated the proliferation and migration 
of human PASMCs. Therefore, we studied the effect of the P2Y2 receptor and its ligand, 
MRS2768, on EPAC protein expression in human PASMCs. Western blot analysis revealed 
that MRS2768 significantly increased EPAC protein expression in serum-starved and 
serum-stimulated human donor PASMCs. Hence, we believe that the MRS2768-mediated 
regulation of PASMC proliferation and migration may function via activation of cAMP and 
its downstream protein, EPAC. 
5.3.6 MRS2768 inhibits ROCK and decreases MLC phosphorylation in human 
PASMCs 
 
In SMCs, the activation of GPCR coupled to Gq/11 or G12/13 converts RhoA-GDP to RhoA-
GTP. Activated Rho-GTP binds to ROCK at the Ras-binding domain (RBD-domain). This 
leads to the stimulation of ROCK1 activity. The phosphorylation of MLC is known to promote 
cell migration and increased cell contractility [249]. Myosin light chain is regulated by two 
enzymes, MLC kinase (MLCK) and MLC phosphatase (MLCP). A ligand binding to a GPCR 
coupled to Gq/11 or G12/13 G-proteins results in the activation of phosphoinositide 
phospholipase C- beta (PLC-β). Phosphoinositide phospholipase β increases intracellular 
Ca2+ and MLCK activity, which in-turn increases the phosphorylation of MLC [249]. 
Furthermore, the activation of the RhoA/ROCK1 cascade leads to the inactivation of MLCP, 
which is responsible for MLC dephosphorylation [250, 251]. Decreased MLCP activity and 
increased MLCK activity lead to a surge in MLC phosphorylation, which results in SMC 
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contraction and migration [252]. Studies from Oldenburger et al. have demonstrated that 
EPAC can inhibit RhoA and ROCK1 cascades [253]. Rho-kinases (ROCK-1 and ROCK-2) 
play a key role in vascular cell proliferation and vasoconstriction [254]. In the lung 
homogenates of IPAH patients, Guilluy et al. found an increase in Rho kinase expression 
and RhoA activity [255]. Therefore, it was essential to study the effects of MRS2768 and 
the P2Y2 receptor on ROCK protein expression and MLC phosphorylation. 
 
Expression analysis revealed that MRS2768 significantly increased EPAC protein 
expression and led to a simultaneous reduction in ROCK protein expression. The decrease 
in ROCK protein levels led to an increase in MLCP, which boosted MLC levels and 
decreased the MLC phosphorylation level. Based on these results, we believe that P2Y2 
receptor signaling inhibits ROCK activity via EPAC and further decreases MLC 
phosphorylation and PASMC migration. 
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6 CONCLUSION 
 
The data from our screening experiment demonstrated a clear difference in GPCR gene 
expression in the pulmonary vasculature of IPAH patients versus donors. However, of the 
dysregulated genes from the array data, only a few are regulated in the same direction in 
the PASMCs of IPAH patients, with VIPR1, LPAR1, and LGR7 being upregulated, and P2Y2 
and DRD1 being downregulated. The selective knockdown of candidate GPCRs. including 
GPCR115, LGR7, and PTAFR, had a significant but mild inhibitory effect on PASMC 
proliferation. However, further studies are needed for each dysregulated GPCR candidate 
to understand their importance in PAH.  
 
Further, P2Y2 receptor gain-and-loss-of-function studies in human PASMCs indicated that 
MRS2768 inhibited serum- and PDGF-induced PASMC proliferation and migration, and 
MMP2 activation, in a P2Y2/cAMP/EPAC-dependent manner, counteracting the 
RhoA/ROCK/MLC pathway activated by growth factors. These findings imply that P2Y2 is 
a potential therapeutic target for PAH. 
 
Figure 22. Schematic diagram of the proposed mechanism by which P2Y2 and MRS2768 play a role in 
PAH. Abbreviations: MLC (myosin light chain), MLCK (myosin light-chain kinase), MLCP (myosin light-chain 
phosphatase), RhoA (Ras homolog gene family member A), ROCK (Rho-associated protein kinase), AC 
(adenylyl cyclase), cAMP (cyclic adenosine monophosphate), EPAC (exchange factor directly activated by 
cAMP), ECM (extracellular matrix), MMPs (matrix metalloproteinases), and P2Y2 (purinergic receptor).  
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7 OUTLOOK FOR THE FUTURE 
 
The role of GPCRs in the pathogenesis of PAH has been well recognized [121]. Yet, GPCRs 
are among the most complicated proteins, since they comprise largest protein family in the 
human genome/proteome. In this study, approximately 100 GPCRs were found to be 
differentially expressed in IPAH patients’ pulmonary arteries. Of these GPCRs, only a few 
were known to play a role in PAH pathogenesis. Therefore, further investigation of the 
functions of these differentially expressed GPCRs in PAH in needed.  
 
All types of vascular cells, including endothelial cells, SMCs, fibroblasts, progenitor cells, 
and inflammatory cells, contribute to the pathogenesis of PAH [2]. There is clear evidence 
suggesting that GPCRs regulate various cellular responses depending on the cell type 
[121]. Therefore, it remains critical to study the function of dysregulated GPCRs in other 
vascular cell types to broaden our understanding of GPCR functions in PAH. For example, 
the current study only examined PASMCs to shed light on the cellular functions mediated 
by P2Y2. An obvious follow-up study would be an analysis of the role of P2Y2 in pulmonary 
endothelial cells and intima formation in PAH. Studies on systemic circulation have 
demonstrated that the P2Y2s located in systemic endothelial cells regulate blood pressure 
by transactivating VEGFR/eNOS/NO signaling [210]. It would be interesting to investigate 
whether P2Y2 has a similar effect on pulmonary circulation. 
 
To further explore the therapeutic potential of P2Y2 signaling, in-vivo studies using animal 
PH models are necessary. For example, PH animal models with P2Y2 knockout or 
MRS2768 treatment should be studied regarding their functional (hemodynamics assessed 
by invasive and non-invasive methods) and structural (histomorphometry) relevance. In 
addition, the in-vitro effects on proliferation and migration in PAECs and PASMCs isolated 
from these animal models should be considered.  
 
Finally, the dysregulated orphan GPCRs are also of great interest, even though our lack of 
knowledge of their ligands poses an obstacle. A recently deorphanized example from our 
candidate list is GPR109B [159]. A challenging but not impossible task, deorphanizing such 
receptors via the large-scale screening of agonist/antagonist banks is another important 
goal.   
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8 SUMMARY 
 
Idiopathic pulmonary arterial hypertension is a progressive, chronic, and usually lethal lung 
disease of unknown causes with limited therapeutic options. Pulmonary arterial 
hypertension is characterized by aberrant pulmonary vasoconstriction and abnormal 
pulmonary vascular remodeling. Several lines of evidence suggest that deregulated GPCRs 
may represent a key factor in the progression of PAH.  
 
Specifically, GPCRs are centrally involved in the pathobiology of PAH. Identifying 
dysregulated GPCRs in PAH may pave the way to targeting abnormal pulmonary 
vasoconstriction and remodeling, thereby resulting in options for translational research. 
Therefore, the purpose of the present study was to identify and analyze both known and 
orphan GPCRs potentially involved in the development of PAH. 
 
An analysis of GPCR expression was performed in laser micro-dissected pulmonary 
vessels from donors and IPAH patients using a quantitative GPCR high-throughput 
expression screening system. The quantitative GPCR expression analysis revealed that a 
large number of GPCRs were upregulated in the pulmonary vasculature of PAH patients, 
and these included VIPR1, chemokine receptors (CMKLR1, CXCR7, CXCR6), a leukotriene 
receptor (CYSLTR1), neuropeptide Y receptors (NPY1R, NPY5R), lysophosphatidic acid 
receptors (LPAR1, LPAR2), an endothelin receptor (EDNRB), a trace amine receptor 
(TAAR8), a leucine-rich repeat (LGR7), a niacin receptor (GPR109B), and 5 orphan 
receptors (GPR18, GPR21, GPR97 GPR112, and GPR115). The purinergic receptor 
(P2Y2) and dopamine receptor (DRD1) were downregulated. 
 
Further, the mRNA expression of relevant GPCR hits was analyzed in human PASMCs 
derived from donors and PAH patients. The qPCR results revealed the upregulation of 
VIPR1 and LGR7 in PASMCs from IPAH patients. In contrast, P2Y2 and DRD1 were 
downregulated in the PASMCs of IPAH patients. 
 
The potential role of candidate GPCRs in PASMCs was previously determined by siRNA 
knockdown or ligand stimulation. The proliferation of PASMCs determined using BrdU 
incorporation assay indicated that the knockdown of GPR115, LGR7, and PTAFR 
significantly reduced serum-induced PASMC proliferation. On the other hand, the 
knockdown of P2Y2 did not result in any significant changes in PASMC proliferation. 
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Furthermore, the P2Y2 ligand MRS2768 reduced both PDGF- and serum-induced PASMC 
proliferation. In addition, MRS2768 limited both serum- and PDGF-induced PASMC 
migration. The knockdown of P2Y2 by siRNA resulted in a spontaneous increase in PASMC 
migration under serum-starved conditions. MRS2768 also decreased MMP2 activation in 
PASMCs. Therefore, MRS2768 and its receptor P2Y2 play significant role in migration.  
 
Moreover, upon MRS2768 stimulation, P2Y2 promoted cAMP (a potent vasodilator) 
production in PASMCs. In addition, MRS2768 activated the cAMP/EPAC-mediated 
inhibition of RhoA/ROCK1 and reduced the MLC phosphorylation. Due to its role in 
decreasing MLC phosphorylation, MRS2768 might thereby reduce PASMC 
vasoconstriction. 
 
overall, this study implies that more GPCRs are differentially expressed in the pulmonary 
vasculatures of PAH patients than in those of donors. Most interestingly, P2Y2 might play 
a key role in pulmonary vascular remodeling by regulating PASMC proliferation and 
migration.
  ZUSAMMENFASSUNG 
 
85 
 
9 ZUSAMMENFASSUNG 
 
Die Pulmonal Arterielle Hypertonie (PAH) ist eine fortschreitende, chronische und meist 
tödliche Lungenerkrankung mit unbekannten Ursachen und limitierten therapeutischen 
Optionen. Die Erkrankung ist durch eine erhöhte pulmonale Vasokonstriktion und einen 
abnormalen pulmonalen Gefäßwandumbau charakterisiert. Es gibt Hinweise, dass 
fehlregulierte G-Protein-gekoppelte Rezeptoren (GPCRs: G-protein-coupled receptors) 
eine Rolle bei der Krankheitsentstehung und dem Verlauf spielen. 
 
GPCRs sind maßgeblich an der Pathobiologie der PAH beteiligt. Die Identifikation von 
deregulierten GPCRs in der PAH könnte helfen, diese abnormale pulmonale 
Vasokonstriktion und pulmonalen Gefäßumbau (Remodeling) besser zu verstehen und eine 
neue zielgerichtete Therapie zu ermöglichen. Auf Grund dessen liegt das Ziel heutiger 
Studien in der Identifikation und Analyse von bekannten, sowie seltenen GPCRs, die 
potentiell in der Entwicklung der PAH involviert sind. 
 
Die Analyse der GPCR-Expression erfolgte in dieser Doktorarbeit mittels eines 
quantitativen Hochdurchsatzverfahrens in Laser-mikrodissektierten pulmonalen Gefäßen 
von Donoren und PAH-Patienten. Die quantitative GPCR mRNA Expressionsanalyse zeigte 
eine Vielzahl von hochregulierten GPCRs in den pulmonalen Blutgefäßen von IPAH-
Patienten im Vergleich zu den pulmonalen Blutgefäßen der Donoren. Zu diesen 
hochregulierten GPCRs zählen: VIPR1 (Vasoactive intestinal peptide receptor), 
Chemokinrezeptoren (CMKLR1, CXCR7, CXCR6), CYSLTR1 (Cysteinyl Leukotriene 
receptor 1), Neuropeptid Y Rezeptoren (NPY1R, NPY5R), Lysophosphatidsäure 
Rezeptoren (LPAR1, LPAR2), EDNRB (Endothelin receptor type B), TAAR8 (Trace amine-
associated receptor 8), LGR7 (Leucine-rich repeat-containing G-protein coupled receptor), 
GPR109B (Niacin receptor 2) und fünf seltene (orphane) Rezeptoren (GPR18, GPR21, 
GPR97 GPR112, and GPR115). Im Gegensatz dazu fanden wir P2Y2 (purinergic receptor 
P2Y2) und DRD1 (dopamine receptor D1) herunterreguliert. 
 
Im nächsten Schritt wurde die mRNA-Expression von dysregulierten GPCRs in humanen 
glatten pulmonalarteriellen Muskelzellen (PASMCs: pulmonary arterial smooth muscle 
cells) von Donoren und PAH-Patienten verifiziert. Die Resultate der qPCR zeigten eine 
erhöhte Expression von VIPR1 und LGR7, sowie eine verminderte Expression von P2Y2 
und DRD1 in PASMCs von PAH-Patienten. 
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Die potentielle Rolle verschiedener GPCRs in glatten Muskelzellen wurden über einen 
siRNA knockdown oder eine Liganden-Stimulation untersucht. Die siRNA mediierte 
Ausschaltung (knockdown) von GPR115, LGR7 und PTAFR führte zu einer signifikanten 
Reduktion der Serum-induzierten Proliferation von PASMCs. Im Gegensatz dazu führte der 
knockdown von P2Y2 zu keiner signifikanten Veränderung der PASMC-Proliferation. Eine 
Stimulation mit dem P2Y2 Liganden MRS2768 zeigte hingegen eine Reduktion der Serum-
induzierten PASMC-Proliferation. Der siRNA-vermittelte knockdown von P2Y2 in PASMCs 
erhöhte die Migration, während die Stimulation mit MRS2768 die Migration reduzierte. Eine 
Erklärung dafür kann die durch MRS2768 reduzierte Matrixmetalloproteinase (MMP) 2 
Aktivität sein. 
 
Zusätzlich erhöhte die MRS2768-vermittelte P2Y2-Stimulation die cAMP-Produktion und 
führte über eine EPAC-vermittelte Inhibierung der RhoA/ROCK1 Aktivierung zu einer 
verringerten MLC-Phosphorylierung.  
 
Zusammengefasst lässt sich eine veränderte Expression von mehreren GPCRs in den 
pulmonalen Gefäßen von PAH-Patienten im Vergleich zu Donoren feststellen. Dabei 
scheint insbesondere P2Y2 über die Regulation von Proliferation und Migration von 
PASMCs eine wichtige Rolle für den pulmonalen Gefäßumbau zu spielen. 
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10 APPENDIX 
 
Table 23 App. Primers sequence and respective probes used for High-throughput 
screening of 408 non-olfactory GPCRs 
Human gene Probe Forward primer Reverse primer 
Rho 60 atggcagttctccatgctg tgacgtagagcgtgaggaag 
OPN1SW 69 gcccctcaactacattctgg cagggaagacagagaagatgc 
OPN1MW 53 gaactggatcctggtgaacct cctggttcacaacgctgata 
OPN1LW 49 tggtcactgcatccgtctt caccaggatccagttcagc 
OPN4 18 cgctacctggtaatcacacg ccagggcatagagccaaac 
OPN3 79 ctccgcactcccactcac gaccccgaagagggacac 
RRH 74 ggggtcagtagcattggctat cgtatccaaatttccaacttcc 
RGR 87 tgaccatcttctctttctgcaa tcaggctgatcccactgtc 
OPN5 35 gtagggggccaggttttc aacacgatcacagccgttg 
ADRA1A 16 tatccattggacccctgttc ggcagatggtctcgtcctc 
ADRA1B 34 gccaagagaaccaccaagaa gctccttggagttggacatc 
ADRA1D 3 cctggtggtgtccgtagg cggtgataccgcagaagc 
ADRA2A 49 ccaaaacctcttcctggtgt ccagcgagaaagggatgac 
ADRA2B 28 tggtcatcctggctgtgtt agcgacaccaggaacaggt 
ADRA2C 49 cacagaacctcttcctggtgt cgagaagggcatgaccag 
ADRB1 20 gaccgcctcttcgtcttct gcagtagatgatggggttgaa 
ADRB2 62 caggaagccatcaactgcta ggcttggttcgtgaagaagt 
ADRB3 56 gcctccaacatgccctac cgaagagcatcacgagaaga 
HRH1 62 cctgagcactatctgcttggt ctcactccgtacggcataca 
HRH2 64 agctttggcaaggtcttctg aggctgtgcagagcatcac 
HRH3 58 cctgagctgggagtacctgt agaactcggcatagcagtgg 
HRH4 7 gcaatacaattgcttccaaaatg tgttccctttggtgaagagc 
DRD1 86 gggtggcctttgacatcat cacgctgatcacacagaggt 
DRD2 67 caggagctggagatggagat ggctgtaccgggtcctct 
DRD3 76 cctgcagactaccaccaactact gtggccaccagcaagtct 
DRD4 28 ccttcttcgtggtgcacat agggcgctgttgacgtag 
DRD5 80 gaacctgtgcgtcatcagc gagtcatcttgcgcttgtagc 
CHRM1 23 tagctgggcagtgctacatc atggctgtgccaaaggtg 
CHRM2 83 tccttataagacatttgaagtggtgt cccgataatggtcaccaaac 
CHRM3 22 caagcttccgggtcacag aggttgtccgatgagggtaa 
CHRM4 62 acgccacctttaaaaagacct agtgccgatgttccgatact 
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CHRM5 2 aaagcagcccagacactgag tatacggggtccatgtgatg 
HTR1A 71 atcatcatgggcaccttca gcagaagggcagaacaagag 
HTR1B 9 ggtcaccgacctgcttgt gtgacagtgtacatggtgctga 
HTR1D 79 actgaaccagtcagcagaagg gtggcattcagggatctgtt 
HTR1E 2 cccccttcgacaatgatcta cgttccctggtgctagagat 
HTR1F 5 tttgttcccttgcagtcaca caatgctgaagggcatcac 
HTR2A 51 cagcggtcgatccatagg ttgctcattgctgatggact 
HTR2B 8 tttggcgatttcatgctctt caatcataattgcaagaggtgtg 
HTR2C 47 gcaagttgagaatttagagttaccag tcacacactgctaatcctttcg 
HTR4 49 ttcatggtcaacaagcccta ccatgaggagaaatgggatg 
HTR5A 1 tggtgctcttcgtgtactgg cttcggatatgggtgagacg 
HTR6 4 ctgccttttgtccttgtgg gatcctgcagtaggtgaagcata 
HTR7 59 tcagccaggactttggctat catgacggacatggggata 
TAAR1 50 gttggagtgtccctgctgtt tcttcagcgcctttgaagtt 
TAAR2 79 tctccatggccatcactg ttctccaccgatctgatcatacta 
TAAR9 49 caatgtcgccatggtgttta gcttggctggctgtactttc 
TAAR6 9 ctggctgtgtttggaaacct gagtgcagctgcttgaaatg 
TAAR8 34 tgtgtcgggaatttgcatc aacacagcaccgctgtacg 
TAAR2 79 tctccatggccatcactg ttctccaccgatctgatcatacta 
TAAR5 71 gctgtgggcatatacctcttg gctgtcgaccatcgtgtcta 
MTNR1A 49 agcttagcggtggcagac atcgacatcagcaccaacg 
MTNR1B 49 tcttggtgagtctggcattg aggattagcgggtaggggta 
GPR50 13 ccaccctaagccccattc tggtgggtagaggcagattt 
ADORA1 89 actgcatcaccctcttctgc ggcatagacaatggggttca 
ADORA2A 72 tgctcatgctgggtgtctat catctgcttcagctgtcgtc 
ADORA2B 80 ccgagacttccgctacactt tgacatctgcttggcagaga 
ADORA3 29 caagagaagctttgtgctgga tagcctcggcaccagtattt 
MC1R 85 acacctggaggggaagaact aggaagcaggaaggagtcgt 
MC2R 9 gtcatctggacgttctgcac ggcacatgatgggagaagat 
MC3R 9 actcggagagcaaaatggtc aggagcatcatggcgaag 
MC4R 44 cgggttgggatcatcataag tgatgaacaaaatgcctgaaa 
MC5R 86 ggcatccatgtgcagctta ggcgtagaagatggtgacgta 
CNR1 20 catggacatagagtgtttcatgg gtgagggacaggactgcaa 
CNR2 72 ctgttcattggcagcttgg agctgcatgcaaagaccac 
GPR55 69 cctggctgtcttcgtggt caggaactgcaggaagaacc 
PTGFR 17 aggcagatctcatcatttgga tgggctccaacaaatacagg 
TBXA2R 3 gatcttcttcggcctgtcc ccaggtagcgctctgagg 
PTGDR 7 tctaccgacggcacatcac aaaggtagcgcgcagaaag 
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PTGIR 27 cgtccatgctcatcctcttt cagctgcgcgtagaggtag 
PTGER1 28 cgctatgagctgcagtaccc agaggccagcaagcagtg 
PTGER2 41 tgcacctacttcgctttcg cgaagagcatgagcatcgt 
PTGER3 45 aaccttttcttcgcctctgc ggttgcaggaaaaggtgact 
PTGER4 68 gtggtgctgtgcaagtcg cccacataccagcgtgtaga 
GPR26 4 gtcttcactggcgccttc cttgaggtacgtgcagcaga 
GPR78 79 tgctatccaacgcactggt ggtggcccagagacagatt 
S1PR1 42 accgctcttcatcctgctc aggatgtcacaggtcttcacc 
S1PR2 61 ccactcggcaatgtacctgt acgcctgccagtagatcg 
S1PR3 69 cttacgacgccaacaagagg aaggcaatgagccagcac 
S1PR4 19 tttgctgggctggaactg aagaggatgtagcgcttgga 
S1PR5 44 cttccacgctcccatgtt gccccgacagtaggatgtt 
LPAR1 9 cttgccacagaatggaacac ggccaacatgatgaagatacaa 
LPAR2 45 cccaaggatgtggtcgtg gcagattggtcagcagcac 
LPAR3 13 ctggaattgcctctgcaac tccagaaaacaaggtaactcctg 
LPAR4 31 gtcctcagtggcggtatttc gtggtggttgcattgttgac 
LPAR5 4 cctgctggctaacctcgtc gccagcgtgctgttgtag 
GPR3 39 tctactgcctgctgggtgat ggcagggagcaaggtaagat 
GPR6 18 gggtctctggagctgtcct cacgtcccacggattcac 
GPR12 52 ggagaacatctcggctgct gagctcaggctctggctcta 
GPR21 60 cgcttcagcagccagagt gcatagcgcttatcaggaca 
GPR22 29 tcgaataggcacaagattttca gcctcatgttgtgtggttagag 
GPR52 51 gtggcattgtgaatgtgtcc accacactgtagtggccaaa 
GPR119 76 tctactgcgacatgctcaaga gcatgttccatctttcgaatc 
GPR148 6 acctacacctccattctgtgc gaaacagttggcaatgagagc 
GPR153 46 accagcgagcgcttctac aggaagcagacgccaaag 
GPR162 4 cttctctacccctcgggaac atgtcatcagaggatgaccactt 
GPR27 74 ggagctgagggactgcttc tttcaggtcgcagggatg 
GPR85 27 ggacttttcatggtcctggag tccaaatcctgctagccaat 
GPR173 15 ccgtcaacccaattgtctg tgagtcctcaggcacttcttg 
GPR61 73 ctgctgttgactttcgaatcc ctgctccaggaactcagagg 
GPR62 3 gatcctggcagctgtcgt caggtgcgccaggtagag 
GPR161 27 tctggcttcactcgctcat aaactccacggatgaccaac 
PSP24 49 cgcctacgtggtcacctt cacagcatgacgccaaag 
PSP24B 24 gcctggacatgatgcctaa tatccgtcgctttgtgtgac 
GPR101 82 ccagtcgtcgtaacagcaac cagctttgcactggtagcac 
AVPR1A 61 gtgctggcggtgactttc tgcagagccagcagtacg 
AVPR1B 66 cgctacctggctgtctgtc gatgagcaggtaggtggactg 
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AVPR2 43 ccgtggctctgttccaag tacttcacggcccgacac 
OXTR 77 gtgccgcctggtcaagta cagcagcaggtaggtggag 
EDNRA 56 acaacacagaccggagcag ggagtgcttctaagggtggtc 
EDNRB 14 gcgaaacggtcccaatatc gatgtcaatgacgatgtgcag 
GPR37 36 ccaggagcagagtgtgaagac gctctccttggccagtaaaa 
GPR37L1 37 tctcctctctgggagtcacg cacgtggaagcggtcaat 
HCRTR1 27 caggctgcagtcatggaat actgagaagagccgtgtgc 
HCRTR2 8 tttctctggctgatgtgctc cagtgatatccacgaccagtg 
GPR103, QRFPR 50 tcagtgacctgctcatcacc ccagccagttgtcggaaa 
NPFF1 (GPR147) 71 atggtggcgctgttcttc agctgcccgtagtcgatg 
NPFF2 (GPR74) 53 ggtttccaagaagctttcca aagcttccataggctttgctc 
NPSR1 1 aagcaagccagggtcctc cctcttcccaaatatgatcagg 
TACR1 44 caatcagttcgtgcaaccag caccacaatgaccgtgtagg 
TACR2 88 taatgccatcgtcatctgga cgatgaagtagttggtgactgtg 
TACR3 59 ctggcgtatggtgtggtg caggatgatccagatgacga 
NTSR1 44 cagagcacggtgcattacc cagcagggtgagcaggtc 
NTSR2 62 ttcctgaatggggtcacagt gaagtggacggcacttgg 
NMBR 9 gcaacatcatgctggtgaag gccgccaggttagagatg 
GRPR 63 ttccaaacctgttcatttcca atccactggagcacacgtta 
BRS3 58 caagctctgtggtttctaacga tgcttctattcctggagagttgt 
CCKAR 88 tctcaggaacccccatttc cagtagatgatggggttgacg 
CCKBR 74 aggcctgcctggaaactt agggtcctcatcgggaag 
NPY1R 15 tgctacctgcaaccacaatc atggggttgacacaagtgg 
NPY2R 76 tgcgcacagtaaccaacttt gacacagagtgttcaccaaaaga 
PPYR1 9 catgaagcaggtcaatgtgg cagccagagcacagcaaag 
NPY5R 48 actgctgccactcggaat tcatctacactgcttttatagtcatcc 
GPR178 75 gcgacacaaagggtggag agggtactcggcgtccat 
GPR38 77 tgaccgtgatgctgatcg catgctgcccaggtacaag 
GHSR 6 ggccttctccgatctgct ggtactgccagaggcgaac 
GPR39 19 ccgagacctccaatatgtcc gatgctggactggaacacg 
GNRHR 59 ccaacctgttggagactctga ccagcataccattggactgtaa 
GNRHRII 55 gcctcctcaatgctccttt gttcttggtgccctcttcg 
GPR150 70 caggcaacaccacagtgc caccagcaggaagtccatc 
PRPR 88 ctgctgctggtcacctacct ctgacacccggacgtaaga 
NMUR1 83 tgtggcacaactaccccttc aaacagtagcgtgcggaaat 
NMUR2 15 ggcggtctctgacctcct ttgcgccacatctcatagac 
GPR73 85 ggcttcttacaatggcggta ggcatcccaattgtcttga 
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GPR73L1 12 ccacggatgaattatcaaacg gaatggacaccatccagacc 
GPR83 5 catcatctctgtggcctacg tggtcacatcgccaatcata 
GPR19 15 gaccttctcatcagcgttgc tccaccttccagtggtgaac 
GPR75 41 aatgacttagtgcaggaatatgacag taaacggaggggactggaat 
OPRM1 36 cttgcgcctcaagagtgtc tccttcgaagattcctgtcct 
OPRK1 58 gggacttctgctttccactg tttcggactctgctagtgctc 
OPRD1 45 gtgtgcatgctccagttcc gaacacgcagatcttggtca 
OPRL1 38 gcctcaaccccatcctcta gcagatgcacagcagaactt 
SSTR1 42 gatgatggtggtgatggtgt accagctgcaccacgtaga 
SSTR2 76 cctgacagtcatgagcatcg ccacttggccgacttgat 
SSTR3 72 cgacgagctcttcatgctg ccagtaggacagggcgttc 
SSTR4 13 gacaacttccgccgattct tccagcaccttccaggag 
SSTR5 29 gcgtcaaccagttcaccag gtgcaccactgccaggta 
GPR7 4 ggtgctgcccatcaacat cacatgagctccccgaag 
GPR8 9 ccccactggtcatcagtatgt aggcacgagttggcgtag 
GALR1 62 aagaaggcctacgtggtgtg ggcatagcagaagcagatga 
GALR2 38 atggacatctgcaccttcgt gtaggtcaggccgagaacc 
GALR3 41 atcctgtgcttctggtacgg gaggcaggagttggcgtag 
GPR54 3 ctcgtgccgctcttcttc acgtagatgaccagcgagttc 
MCHR1 26 cttggtcctgtcggtgaag tctgtcctctcctcgtcagc 
MCHR2 18 tgtctcagctatgccagcag ggatttgaggcagacgtttc 
CCR1 76 tcacccatgagtgtgagca gcgatcacctccgtcact 
CCR2 76 ggggtggtgacaagtgtgat aaagatgattcctgggacagaa 
CCR3 58 tgagaagctggaaagaaccag aatagagagttccggctctgc 
CCR4 84 ttcgtgttttccctcccttt acctagcccaaaaacccact 
CCR5 7 tgcatcaaccccatcatcta agaagcgtttggcaatgtg 
CCR6 68 aaaggcatctatgccatcaact gtaccggtccatgctaatgc 
CCR7 25 gtcttcctgtcggcacatc ggagaaggtggtggtggtc 
CCR8 64 tgcctcctgtttgtattcagtct cagaccacaaggaccaggat 
CCR9 31 gccatgttcatctccaactg ggtgacctggaagcagatgt 
CCR10 41 ctttgctacaaggccgatg gtcagggagacactgggttg 
CXCR1 3 gcgtcacttggtcaagtttgt gggcagggacagattcatag 
CXCR2 59 aaactggcggatgctgtta gggtgaatccgtagcagaac 
CXCR3 86 tgctggtgctgacactgc agccaaagacccactggac 
CXCR4 79 attgggatcagcatcgactc caaactcacacccttgcttg 
CXCR5 6 gccatcctggtgacaagc tccaggaagatgacgatgtg 
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CXCR6 63 tgggttcagcagtttcaatg ttgctgaactgcaggaagtct 
CXCR7 54 gagcacagcatcaaggagtg agaagggaacggcaaagc 
CX3CR1 35 ccttctggtggtcatcgtgt aagcgtctccaggaaaatca 
XCR1 89 ctggtgaccatggctgtgt gaagatggtgtcgaggatgg 
ADMR 89 acctgggcattgtcctgtc aggtgtagtccagcgtgacc 
BDKRB1 24 gccaacttctttgccttcac cggcccacaaagacataaat 
BDKRB2 4 acatgctcctgaatgtcgtg catcgtgcagaaggtgatga 
AGTR1 66 gtagccaaagtcacctgcatc cgatggattatagctggcaaa 
AGTR2 5 ggtttctagcatatacatcttcaacct gcccatagaggaagagtagcc 
AGTRL1 40 cacctggtgaagacgctgta aggaagaggtcaaagtcacagg 
FPR 62 tctctccccacgaacatctc ccaggaagagatagccagca 
FPRL1 81 gcacagtcaccaccatctgt gtggccgtgaaagaaaagtc 
FPRL2 42 attgctctggaccgctgtat actcatggtgcgatggttct 
C3AR 4 gtcctcaacatgtttgccagt aagacagcgatccaggctaa 
GPR77 72 gctctcagtgccgacctct gctgaaccgtagaccaccag 
C5R1 12 ttggggtttagccctgct aagtactcctcccggaccac 
BLTR 71 gctcatcatcctgaccttcg cctcagccaggttcacca 
BLTR2 74 ggccttggccttcttcag gtgaggaaacggggacct 
GPR44 21 catcctggagcagatgagc gtcgatgtagcggatgctg 
GPR14 24 gcaaccctcaacagctcct cagcagagtcccaatggtg 
GPR31 38 tgctgtttgctctgtgcttt tggaagatgtgcatcaggac 
GPR25 3 ctctacctggcggccttc cagcagccacaccacaaa 
GPR15 51 ctgtgccagcatctggttt tccctggacagaagagtaggc 
GPR32 73 gggcctgcaaactctacatc ggaggcagttactggcaaag 
CMKLR 1 69 gcagtggcagatttcctgtt catggcggcataggtgata 
GPR1 64 tgaacatgtttgccagtgttt aagacaggatggatcaagtgg 
CCRL1 13 cctgaatttggctgtagcaga ccacccatgaactgcattaac 
CCRL2 32 tgcaaatgagaaaaacactaaggt tggcaaaaacaagcttgaaa 
MAS1 62 ttcgctatgcccatgagact tcccaaaggtcgaccaatac 
MAS1L 3 actctactcattagattcctgtgctg tctgcaccaccgcataga 
MRGPRD 3 aggcaacagcatggtgatct atgcagaaggggttcctgt 
MRGPRE 35 catcctcctcaccgtcctc acagccagtagatgccgaag 
MRGPRF 45 gcacgtttgccgactacat cacgccggtaaggaacat 
MRGPRG 62 gcgtggtcctctttgtctg ccaggacgatgccgtaga 
MRGPRX1 87 cctgtggcccatctggta gacacacaccaccgctga 
MRGPRX2 37 tgatcccggtcttcctgat gagcacaaacccgtttccta 
MRGPRX3 70 cctgtggcccatctggta gagcaggacacacatgactgat 
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MRGPRX4 1 ggacaagcctgaggtggata atggccccaatctgcttc 
LHR 84 tgcaatctctcctttgcagac ggtttgggaatcaactgagg 
TSHR 63 tggggtgttcgtctccac tgcgttgaatatccttgcag 
FSHR 29 gactcaggctaggggtcaga cgtcatgtcaaatcctctgc 
LGR4 43 tgggaatctatactggcatccta ccaccaaatgccaaattca 
LGR5 20 gtcatcgcagcagtgaaca tgccaaaagtgaacgcatc 
LGR6 24 tcagggcccctagcctat gcctgggtagaatcacagga 
LGR7 58 tttcgtggagaatacaataagcat tggccaaagatcctacaagc 
LGR8, GPR106 56 gatggagagcgtgcagtg gtcagtagcagaacagagacttcg 
SALPR 17 ttttctccaccacggtcaa agcaacttgtccgggaaac 
GPR100R 6 ctctgtccgcatcctggt agagagtgaccacatggttgg 
P2Y1 26 atgttctgtgtccccttggt aaatcaaagctctcacaattaatcc 
P2Y2 41 taacctgccacgacacctc ctgagctgtaggccacgaa 
P2Y4 64 catcacccgcaccatttact ttcagtactcggcagtcagc 
P2Y6 42 ctgcccacagccatcttc gctgaggtcatagcagacagtg 
P2Y11 17 gttggtggccagtggtgt ccgcatgatgtggtaggg 
P2Y12 48 catgattctgacttttccattca tgacacacaaaagttctcagtgg 
P2Y13 21 ttttcttgaccggcatcc agctggggatgtgaacaaac 
P2Y14 84 cttgcggtatatgaaagaattcac aagaaataaataatagggtccaagca 
F2R 68 atctgggctttggccatc acctggatggtttgctcct 
F2RL1 13 gagccatgtctatgccctgt cgatgcagctgttaagggtag 
F2RL2 46 ccatttgtgcttatcatctactgc ctatgatcgtatgcattaagtgtcc 
F2RL3 64 aacctctatggtgcctacgtg gatccacgcagctgttgag 
P2RY8 89 gtggccttttacgcaaacat ctccacgctgatacaggtca 
OXGR1 40 ggtaacctgttactatatgtggtggtc ttgcatctcactgttgagca 
SUCNR1 38 tcatgcggaatgtgaggat gttgatgacgacctgagtgc 
GPBAR1 23 tgcagctcccaggctatc cagcaggagcccatagactt 
CYSLT1 71 tgcagaagtccgtggtcata ggagagggtcaaagcaacaa 
CYSLT2 21 tcatggcttcctcaataatgc tgatgtgacactgccgttct 
PTAFR 22 gtgggagctgcatcctactt agcactgtcgggcactgt 
GPR109B 38 ggtggccatcgtctttgt gtgcaggagccagaagatgt 
GPR109A 50 gagcgtcgagctcacagg accggagttggccattaac 
GPR81 83 gggagcatcgtgttccttac ggggtggaccactttgaa 
TG1019 27 atgagacctggcgctttg ttggtggacagcatgaagag 
GPR68 77 gccccggtggtctatgtta gtagagggacaggcagttgg 
GPR4 44 ccgccatccctctacatct ccacagagccaggcagtt 
GPR132 13 aggtactgcagggcaacg tgtacagcagctcgcagagt 
 APPENDIX 
 
94 
 
GPR65 51 atacctggaataaagacaactggact gaaaagcactccctttgcac 
GPR18 29 accctttcgaatgttttattatgc ttgggtaaaacactgtgagagc 
GPR35 86 cgctctgggtgttctgct cgccaggttggtcatgtag 
GPR40 20 gtgtcacctgggtctggtct ccagggaggtgttgctgt 
GPR120 13 gctcatctggggctattcg gggacgactcggaagaaga 
GPR41 43 cacccactgtggtacaagacc ggccacactcaccagacc 
GPR43 19 ttcaccgataaccagttggac gggatgaagaagagcaccag 
GPR84 46 tgcatcaaccctgtgctct aaatggagccatatgcttgg 
GPR30 71 gtggtgctggtcttcttcgt gaggtgcacgctgatgaa 
TRHR 41 gagacagtcagtgaactgaacca attctaaggccaccactgctc 
EBI2 84 ttccacttataatcattctcatctgc tgggttttgtttggcagttc 
P2RY5 74 cacaaacatttgttaattgctcagt cagagagtgattgggtacattgtc 
P2RY10 34 atggctttccaagggatca gactgcagcacacatgaaca 
GPR17 81 gtctacgtgctgcactaccg tgaggcaggaggtgatgc 
GPR20 18 tctttgcgctgactgtcct ccggtaaacacgctgatga 
GPR34 16 gccattgcagacctcctact tgtccacttgttttggttaatatgat 
GPR55 71 agcagaaagcctgcatctaca ggaaggagaccacgaagaca 
GPR82 88 cttccatggctttaccaatca tgtttccaaaaacaccaacaat 
GPR87 40 gccatatccaggtacatccac gctttcggcttgactgactt 
GPR92 4 cctgctggctaacctcgtc gccagcgtgctgttgtag 
GPR171 76 tcaaagccaaagaggctacac ggataggatcaaagcacaggtt 
GPR174 89 gacggctttcaagacaagattt tcacaaaggattttgcatgg 
GPR182 89 acctgggcattgtcctgtc aggtgtagtccagcgtgacc 
SCTR 31 gcatcatggccaactactcc gcgaggagtgtgtgaaggtag 
GHRHR 29 gccaccatgaccaacttca ccaggaggcagttcaggtag 
GIPR 22 cccagatcgtgacccagta aggagactgtgcaggtagacg 
PTHR1 30 acacaagtgtgaccaatgtcg ggtggcagtgggcagtag 
PTHR2 15 tcactttacctggctatgtctgg tggtctcctcgtggaaagag 
CALCR 17 ctggcgacatcccaatttac ggttgttggctggttcattc 
CALCRL 82 tggcgacctgaaggaaag agtgcataaggatgtgcatga 
CRHR1 10 ggtggcaggacaagcact gcttgatgctgtgaaagctg 
CRHR2 9 cggaatgtgattcactggaa cagcaggaaccacatgaca 
GCGR 49 gtggcagccaggattcat ggggctctcagccaatcta 
GLPR1 56 ttgagcacttgcacatcca tgctggtgggacacttga 
GLPR2 46 cattactttgtgggtgccaat agcagcgtgtggaggtaga 
VIPR1 16 gggctggaaccccaaata catggaaacctgcgtgct 
VIPR2 7 gattacagggtctgcggttc ggtctccgtttgcaggaag 
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PACAP 11 gcggagatcaagcgaaaat gaagtccacagcgaagtaacg 
CASR 26 cacagcagcaacgatctca cgctgccaaagatgacct 
GABBR1 63 agacagggtcatcgaccaac cggttctccttctccaacag 
GABBR2 16 cacacggaagccaactcat atccacgccaatgtagcc 
GRM1 49 tctgcaataccagcaacctg tcatgatgaggagtccattgtag 
GRM2 3 gttcccagtgcaccagaag acggtgctcattgacagga 
GRM3 75 ctggttccgggacttctg gcctgtggttgcgtttgt 
GRM4 3 aagtgtgacatctcggacctg ggtgcacgtgaccatgag 
GRM5 20 agaccaaccgtattgcaagg gaatctgggctttttggtaca 
GRM6 57 tacgccatcaccttcctcat gagcagggcagagtagctga 
GRM7 72 cctgggctgtgattcctg tgacaaagatggtggcaatg 
GRM8 80 gtggtgtttgcattgctcag tgtttctagcaggcgtttga 
GPRC6A 48 tgactccttggccatcctac tgccaacaaccagaacaaat 
TAS1R1 37 tgtgtatgccacgctgaga tctccttggagctctatgtggt 
TAS1R2 44 ggtttcagcttcgcctacat gatgaacttggcctcgttgt 
TAS1R3 71 cccaggtgttacctgctcat cccctcccaggaagaactc 
GPR156 20 ggagaccaagtccccatga atctgagccgcctctttct 
GPRC5A 11 ccttcaccttctgtggttcc gcatcgtgaggtagatgtgg 
GPRC5B 15 atgagagctcaccaggtgct agaggccaccgaggtgat 
GPRC5C 3 tttgtgcaggacaccaagaa ccccagaaggaagaatacctg 
GPRC5D 18 gtctgcattgctctggtcac gcagagctcagggacgat 
GPR158 53 cgggtggctggttactctt ttccgggaccaggttagg 
GPR179 43 cctgggagctggatgataac ctctacctgtccccagactca 
CELSR1 76 aatgtggccgtgtacaacct ctaaggggagtgggactgc 
CELSR2 15 tttgagcggggaaatgaac cttcagctcacccgtgga 
CELSR3 7 gggtcagggagcctatcttc gactattccgggcgcttt 
BAI1 12 cgtgcgcacctaccagtt ctctccacgcccaggtag 
BAI2 23 ccacaccctgtccaatgc agtgcaaatcggcctcag 
BAI3 17 tacccctgaatgagcagaca gattgcagacttgggtggtt 
CD97 89 caagaagcaagccgaactg gagaggcgtctgagttggac 
EMR1 77 catctgtgcctttggttatgg gctgcacactggcagagat 
EMR2 42 cagcactgtgtggccagt ccattggaaaggttcttgct 
EMR3 71 gtgtctactggaagagcacagg ttgttcacgtgtatcaggaagc 
ELTD1 65 tgccgacctgtaaaagtgtg gcaagatttggcagacttcat 
GPR97 3 agaaccggaagaaggtgctc caacccccatgtcacacc 
GPR110 18 tctggatgctcatgcttgg tgtgatggaacacgaggatg 
GPR111 55 atttttgaaaagatcagcaagtca agagtgccagccaacacac 
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GPR112 43 cccaactaggcttattgagacc gatgtcaattctgtttcagctgtc 
GPR113 21 cttcgccttcagcttaccc aggaaacgtgggtccaaac 
GPR114 74 gccttggccttcttttcttt ttaagatggtgaagaggaacagc 
GPR115 3 tcagcaaaaatgttgccatc gctattccaaaaccccaggt 
GPR116 46 ggtccactcagaaagccatt tgatgaccgagatggcaag 
GPR123 27 ccacttcctggacatggtct gaagagtcccagggtcacg 
GPR124 75 gtgtgcagctgcttgtacg ggcacagtggtgagtgaaga 
GPR125 65 tgtggtattagagagttctgcacagt ctgaagtcacctttgttgtttacc 
GPR126 69 ccctgctgttcctgaatctc caatgcaaagtccatccaca 
GPR127 33 cacgggcagattcaagaag ttctggggtccaactattgc 
GPR128 7 cttccaaagtgttgatgttgct tggcaatgacctgaggaaa 
GPR133 22 cttcttcctgagtgccttcg ttgatcaccatgctgtagaggt 
GPR144 13 tggtgttcgacgagaggac gtgagtacacgcggtcagc 
GPR64 10 ctatgccccaaacccatgt cacggtgggagaggaaaat 
LPHN1 28 tccgtgtacgtggatgatga gcattggtgttgaaggcata 
LPHN2 10 ctggatcacaggaaggaagc ggtggaattttggttgtagaaact 
LPHN3 8 cgctgccctgttacatttct accccctccaggaacatc 
GPR56 18 aaggtgcacatgaacctgct gctgagcaggaagctcgt 
GPR98 18 cagcacagcctttttcacg ctgggtggacttgctgattt 
GPR157 17 ctgtccaccttcgccaac ggtacaagtagagcgcaatgg 
FZD1 69 cggcaagaccctcaactc ccttgtttgctgttggtgag 
FZD2 1 ggtgtcggtggcctacat gagaagcgctcgttgcac 
FZD3 78 gccatatcctcgacttgtgg actggggctccttcagttg 
FZD4 64 gaagccattgaaatgcacag gttttcactgcggggatg 
FZD5 49 tcttcacgctgctctacacg ggtagtgctgctcgtacaggt 
FZD6 14 cgtctatgagcaagtgaacagg tggtactgacgacaatgatcaga 
FZD7 3 ggacatcgcctacaaccag gcgtcctcttggttcgtg 
FZD8 39 ctctgcttcgtgtccacctt gaagcgctccatgtcgat 
FZD9 27 ccacggcagctatttcca ggatgacgatggtcttgagc 
FZD10 74 ttggacctccaagactctgc tccggctcttcttctttaacc 
SMOH 24 cattcctcgactgcctcag tccctgtcggcaagagtc 
TAS2R1 7 tcctgtccttcctgatcctc aaagatgaaccttctgatgtgaaa 
TAS2R3 49 agctctattctgtctttaggggaat cctcttctttctgaagtgttcagtc 
TAS2R4 35 caattgcaaaacttgggtca cccaggctgaacagaatcc 
TAS2R5 88 cagtccaaattggcttaacattc agggataccgaatgctgct 
TAS2R7 10 ttgcctactatttgtcctttctca gctaattccgtctctggcata 
TAS2R8 41 gccagttcctctcatccact tccagtgcaccaccatatca 
TAS2R9 63 gggccataaaggcagtgat caagaaagactgggtagtacacga 
 APPENDIX 
 
97 
 
TAS2R10 76 tgcgagaaaacaaactgctg aatgagtgaccccagggata 
TAS2R13 20 tgctaggaaccttggtcttctt ccaagttgtgtttctttcatatcg 
TAS2R14 5 acaggcctctctgtcagtgc tgagggctccccatcttt 
TAS2R16 46 gcagcctaattgttgcagtg acaggcatcagccttctgac 
TAS2R19 73 tgactgggttaacacacgaaag ctggagaccaccagagcag 
TAS2R20 73 atttcattgcctgggtcaag gagactgccagagcagcaat 
TAS2R38 64 tgaaggtctataccagaaactctcg agacttgagggctttaatgtgg 
TAS2R39 27 attcttaaatttttgtagcctgtgg attggcaatcttcacaaagtagaa 
TAS2R40 67 tttccaggctcttgctacaga caattcggaatagcagactgaa 
TAS2R41 40 ggccttcttcgtgttgctc agcacaatgaagccattcg 
TAS2R42 30 cttcccccactcccttttc agcataacaatcattccgttca 
TAS2R43 12 cagcaccaaggtccacataa ttccagacttccaaaactcca 
TAS2R44 9 ctccaaccttatttttcttcacttaaa gttgacaagccaaaaatagtaaagg 
TAS2R45 41 gccaagctattggattcagc cttgtttccccaaatcagga 
TAS2R46 12 gatctcaagatcccagcatga tggacagaaagtaaatggcaca 
TAS2R47 75 tctgtccatgatcatatcagtttgt tggcagaacatgaagacagg 
TAS2R48 73 tgactgggttaacacacgaaag ctggagaccaccagagcag 
TAS2R49 73 atttcattgcctgggtcaag cagagcaaaccaactctgga 
TAS2R50 75 cctaatcgtttcggtttgga cagccttgctaaccatgaca 
TAS2R60 87 tctagctttccagtgggacttc ctgagccaggtagaggacca 
VN1R1 21 gcaacagactctcctgcagac gagctcaccaggaccatga 
VN1R2 2 tgtaggaacaatctctaccccaac ctcaccaatgcaaggatgc 
VN1R4 2 atccaggtgggcaaaactta taccaacatgcacacgatcc 
DARC 68 cctggcaattttgcactgt gcctggtggcagaatagg 
GPR88 3 gcagctaccgcctgctac agaggagggacaccgtgag 
GPR135 3 cgtcctcatcatgatcgtctt gcagcaccaggaagcagta 
GPR137 74 cttgcccttctggcttctc ggttcataagcgtcaaggtga 
GPR139 86 cctctgtgcatcacgtcct agcagggcaccaggtagac 
GPR141 85 cgttgctgtgattctgttgg cgtagcttctgcaccatcaa 
GPR142 52 gaagaaaagcctgggcaag ggtgacctcgaaggatcg 
GPR146 3 gctctggacgccacactatc ttccctcgcgagatgatg 
GPR152 83 gcacagagcttgatgatgagg ccaccaggaagaccgtgt 
GPR160 9 gcattcagagttactggctgtc cccaacaggttatgaaagctaca 
GPR151 49 cagccaagagcctgacaatc ctgggtcacttgcatacatga 
GPR149 13 ccccggttacttccaatttc gaggccctggcataaataca 
GPR143 64 ttgtctttggccttctacgg tccttcctgggagactgaaa 
GPR172A 8 cactgactgcccttctggtc ggcaacagcagcagaagac 
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GPR172B 3 gcccatcagctgttctcag attggtcacggcactggt 
GPR137B 38 ccttcgtcttctggctgct cagcgtgagggtgaaaaact 
GPR137C 38 ctgcacttcttcccccact gcgtggagaactggagaca 
TM7SF3 68 gagaggctctatggccgatt gcaaaggcgttctctctcc 
GPR175 36 tcctacaaatgccaagtggac cgtagggctggggtaggt 
GAPDH 82 gcatcctgggctacactga ccagcgtcaaaggtggag 
GPR133 29 ccagctctgcataccaaaca acctctcagggtttccgagt 
 
 
Table 24 App. Primer sequence and probes used for GPCR array validation 
Human gene Probe Forward primer Reverse primer 
VIPR1 25 atgtgcagatgatcgaggtg tgctgcagcctattgtctcat 
GPR137B 38 ccttcgtcttctggctgct cagcgtgagggtgaaaaact 
ADRA2C 64 gtgctgttttgcacctcgt ctgcgtcaccgaccagtag 
CMKLR1 76 ttgagttccccatctctcgt agcaggatattttcccatgc 
CYSLT1 34 agcagtagcagatctactttgtgtg agccaaatgcctttgtgaac 
ADRB1 71 gcagaaggcgctcaagac cacgttggccaggaagaa 
GPR18 29 accctttcgaatgttttattatgc ttgggtaaaacactgtgagagc 
NPY1R 53 tgctacctgcaaccacaatc atggggttgacacaagtgg 
LGR4 75 ttggggttgtgactcttatgc ctttctcctgtgccacactg 
LPAR1 69 ccccacagaaggctcagac ggtcattgctgtgaactcca 
AGTR1 23 gctttccattatgagtcccaaa aaaggaaacaggaaacccagta 
TAS2R4 64 tcctgctgaagcggaatatc ggtgaaagcagaaatcagca 
ADORA2A 90 atcatctggcccagggtag tcaggaaggggcaaactct 
GPR21 8 ttcctgatttggctatactcgac tatccaggtttgccccagt 
GPR4 45 cacaacctgctccgcttt ttcctcttggaggtgagtgg 
GPR112 58 ttcctaagcccacactggac ccccagtggatatgagtgga 
PTAFR 37 cctgccactttggattgtct gcacaggaatttggggagta 
GPR109B 4 gaatggcactgcaaatgtgt tgagcagaacaggatgatgc 
CXCR3 63 agactggcggggacagtt tgtgattgagtctgatttagtctgtg 
TAAR8 83 tgatgggctggaggaattag aacacccagccttgacttaca 
LGR7 50 ttccccttgattcagtggtc accgatggaacagctcgtaa 
GPR115 71 gcgaaggaccttgtatttcttct tccatgaaagtccttagcacag 
DRD1 8 ccttggctgtgtcagatctctt gccagaagccagcaatct 
P2Y12 27 tttgcctaacatgattctgacc ggaaagagcatttcttcacattct 
CXCR6 49 tgcatcactgtggatcgttt cttggcttgctggttgtagg 
LPAR2 24 tcggcttcttctataacaacagtg ccacgaccacatccttgg 
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NPY5R 21 tctcaagagaaccactccagaa gggacccctggtatgaactt 
EDNRB 53 gcacatcgtcattgacatcc attcccacggaggctttc 
GPR110 19 ccccagaactgctaccttca tggctgaggttgttgagatg 
GPR20 58 cgtcctcggttacttcctca gtccacgcagatgcaggt 
CXCR7 4 cccttctccattatcgctgt gcttctcctggtcactggac 
PACAP 13 agagctgtggcttaccagatg cccccagagtttgaggtatg 
CCR7 58 tgtgggcatctggatactagc gctcctctggaggtcactgt 
HCRTR1 1 actggtgcggaactggaa gcttcacttcagccaggaag 
ADRA1A 84 cccgggtgagaagtaaaagc tggttggaacttgatggttct 
GPR97 63 cccaagtcagagcaccaca attcttgagatgcggagtgg 
PTGER4 44 gtccaacgtgctcttttgc accaggtgtctgggtactgc 
FZD1 2 accagcaaccctcagcac ggtaggagggcaccttgag 
HTR2B 31 tgggcagctcttctgatactc tgaaacagccagaataacaagg 
S1PR2 34 gctcatctcgctggtcct gcacagcacataatgcttgg 
S1PR1 3 ccgcctcttcctgctaatc gcagttccagcccatgatag 
P2RY5 69 ctggcgtgtggttaactgtg ccctgagagtgggtagactga 
P2Y2 27 ctacaggtgccgcttcaac cgttcagacacagcccaag 
EDNRA 78 aaaggaaagagaaaacagatggaa gcatgtctgaaacgtgttgttt 
S1PR3 66 tcctctacgcacgcatctac tccgagttgttgtggttgg 
  
Table 25 App. ON-TARGETplus siRNA pools for Human GPCRs 
Catalog Number Human GPCR siRNA - 
SMARTpool 
Target sequences 
L-005556 GPR21 (2844)  ucgaaucacuaguguauuu 
agacuacgccuguguauuu 
cguggucccuucuuuauca 
ccucuuaauggaugucaua 
L-005533 GPR112 (139378)  gcacauuccucuacacuau 
ugacaaagauccuuacugu  
gcaaacaucuacauuggau  
aggcacaccuucagaaaaua  
L-005536 GPR115 (221393) gcucaaggaauccguaaga 
gauccaagauucacuaaa 
ccaaaucgaugaccgacaa 
uggcuuaacugggacaaua 
L-005467 CMKLR1 (1240)  ugagaggacuucuaugaau  
cagccaaccugcaugggaa 
cggcaugcuuugauccuca 
cauagaagcuuuaccaaga  
L-005475 CYSLTR1 (10800)  ggucuugcauuauguguca 
uaugucaaccucuauugua  
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ucuaugaucucuguuguag  
agucagccuuccaaguaua  
L-005649 RXFP1 (59350) caacgagacucaauuccua  
caacugaaauacggaauca 
guauuaauuuggccgcauu 
ggauggagaguacucauug  
L-005552 GPR18 (2841)  ggugcuacuuggucauuau 
gucaugcuauaccguaauu 
gaaccacgguaaccaucua  
gugggagucuggauaauga 
L-005709 PTAFR (5724) gcuuugagcauuacgagaa  
uagcaccaacugugucuua  
gauacacucucuucccgau  
gacaugcucuucuugauca  
L-005570 GPR4 (2828)  ccugcaagcucuuuggguu  
ggaugaaccucuaucgggu  
uaccacagcucacuggcuu  
cgagaccgcuacaaccaca  
L-005474 CXCR6 (10663) ggucucacaucaauggaaa 
cugggcaucuacacuauua  
ggucauauccaucuucuac 
ggcaaugucuuuaaucucg 
L-006688 HCAR3 (338442) ucaaauaaccauuccaaga  
agaaguugcugauccagaa 
cguucgugauggacuacua  
cgccagggcagcaucauau  
L-003688 P2RY2 (5029)  cgagaacacuaaggacauu  
cgacagaacugacaugcag 
gga augcguccaccacaua 
ugccgcu gcuggucuauua  
D-001810 Non-targeting Control ugguuuacaugucgacuaa 
ugguuuacauguuguguga 
ugguuuacauguuuucuga 
ugguuuacauguuuuccua  
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11 LIST OF ABBREVIATIONS 
5-HT = 5 hydroxytryptamine 
AC = adenylate cyclase 
ACE = angiotensin converting enzyme  
Akt = Protein kinase B (PKB) 
AT1R = Angiotensin receptor 1  
AT2R = Angiotensin receptor 2  
BALF = bronchoalveolar lavage fluid 
BMPR- bone morphogenic protein receptor type II 
cAMP = cyclic AMP 
cAMP = cyclic AMP  
CAV1 = caveolin-1 
CCL19 and CCL21 = CC-chemokine ligand 19 and 21  
CCR7 = CC-chemokine receptor  
cGMP = cyclic GMP 
CHF = congestive heart failure, 
CMKLR1 = Chemokine receptor-like 1  
CXCR6 = Chemokine (C-X-C motif) receptor 6  
CXCR7 = Atypical chemokine receptor 3  
CYSTLR1, CysLTs = Cysteinyl leukotriene receptor 1  
DAG = diacyl glycerol  
DCs = dendritic cells  
DRD1 = Dopamine receptor D1  
ECE-1 = endothelin converting enzyme 1  
ECL = enhanced chemiluminescence 
EDNRB = Endothelin receptor type B  
EETs = epoxyeicosatrienoic acids  
EETs = Epoxyeicosatrienoic acids  
EGF = epidermal growth factor  
EIA = enzyme immunoassay  
ENG = endoglin 
eNOS = endothelial nitric oxide synthase  
EPAC = exchange protein directly activated by cAMP 
ERA = endothelin receptor antagonists 
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ERK = mitogen-activated protein kinase 1  
ETA = endothelin receptor type A 
ETB = endothelin receptor type B  
FRET = Fluorescence Resonance Energy Transfer  
FGF = fibroblast growth factor  
GDP = guanosine diphosphate 
GMP = guanosine monophosphate  
GPCRs = G protein-coupled receptors  
GPR109B = Hydroxycarboxylic acid receptor 3  
GPR112 = G protein-coupled receptor 112  
GPR115 = G protein-coupled receptor 115  
GPR18 = G protein-coupled receptor 18  
GPR21 = G protein-coupled receptor 21  
GPR4 = G protein-coupled receptor 4  
GPR97 = G protein-coupled receptor 97 
GRK = G protein-coupled receptor kinase  
GTP = guanosine triphosphate 
HBSS = Hank´s buffered saline solution 
HETEs = hydroxyecosatetraenoic acids  
HIV = human immunodeficiency virus 
HRP = horse radish peroxidase  
IP = prostaglandin I2 
IP = prostaglandin I2 (prostacyclin) receptor  
IP3 = inositol-1,4,5-triphosphate  
JNK = c-Jun N-terminal kinases 
LAS AF = Leica Application Suite Advanced Fluorescence  
LGR7 = Relaxin/insulin-like family peptide receptor1  
LIM = Lin-11, Isl-1, and Mec-3 protein 
LO = lipoxygenase  
LPAR1 = Lysophosphatidic acid receptor 1  
LPAR2 = Lysophosphatidic acid receptor 2  
LTB4, LTC4, and LTE4 = Leukotrienes B4, C4 and E4 
LTD4 = Leukotriene D4  
MAPK = Mitogen-activated protein kinases 
Mins = minutes 
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mPAP = mean pulmonary artery pressure  
mTOR1 = mammalian target of rapamycin complex 1 
NF-κB = Nuclear factor-κB 
NPY1R = Neuropeptide Y receptor Y1  
NPY5R = Neuropeptide Y receptor Y5  
P2Y2 = Purinergic receptor P2Y 
PAF = Platelet-activating Factor  
PAH = pulmonary arterial hypertension 
PAP = pulmonary artery pressure 
PCNA = proliferating cell nuclear antigen  
PCP = pulmonary capillary pressure 
PDE-5 = phosphodiesterase type 5 
PDGF = platelet derived growth factor  
PDGF-R TKI = PDGF receptor tyrosine kinase inhibitors  
PFA = Paraformaldehyde  
PGIS = prostaglandin I synthase  
PI3 kinase = Phosphoinositide 3-kinase 
PKC = protein kinase C  
PLC = phospholipase C  
PPARs = peroxisome proliferator-activated receptors  
PTAFR = Platelet-activating factor receptor  
PTGER4 = Prostaglandin E receptor 4 (subtype EP4)  
PVR = pulmonary vascular resistance 
qPCR = quantitative realtime polymerase chain reaction 
RAS = Renin–angiotensin system  
RGS = regulators of G protein signaling 
RhoA = Ras homolog gene family, member A 
ROCK1 = Rho kinase 1 
R-SMAD = receptor-regulated Smads  
scr = scrambled 
SDS-PAGE = sodium dodecyl sulfate polyacrylamide gel electrophoresis  
Sec = seconds 
sGC = soluble guanylate cyclase 
siRNA = small interfering RNA  
SMCs = smooth muscle cells  
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TAAR8 = Trace amine associated receptor 8  
TBS = tris-buffered saline 
TBST = tris-buffered saline with tween 20 
TGF-β = transforming growth factor beta 
TKR = tyrosine kinase receptor 
TM = transmembrane  
TP = thromboxane receptor 
VEGF = vascular endothelial growth factor  
VIPR1  = Vasoactive intestinal polypeptide receptor 1  
VPAC = vasointestinal peptide receptor 
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